0001213900-22-009569.txt : 20220228 0001213900-22-009569.hdr.sgml : 20220228 20220228070612 ACCESSION NUMBER: 0001213900-22-009569 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220228 DATE AS OF CHANGE: 20220228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALTERITY THERAPEUTICS LTD CENTRAL INDEX KEY: 0001131343 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-49843 FILM NUMBER: 22683885 BUSINESS ADDRESS: STREET 1: LEVEL 3, 460 BOURKE STREET CITY: MELBOURNE STATE: C3 ZIP: VIC 3000 BUSINESS PHONE: 61 3 9349 4906 MAIL ADDRESS: STREET 1: LEVEL 3, 460 BOURKE STREET CITY: MELBOURNE STATE: C3 ZIP: VIC 3000 FORMER COMPANY: FORMER CONFORMED NAME: PRANA BIOTECHNOLOGY LTD DATE OF NAME CHANGE: 20010105 6-K 1 ea156195-6k_alterity.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of February 2022

Commission File Number 000-49843

ALTERITY THERAPEUTICS LIMITED

(Name of Registrant)

LEVEL 3, 460 BOURKE STREET, MELBOURNE, VIC 3000, AUSTRALIA

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

This Form 6-K is not being incorporated by reference into the Registrant’s Registration Statements on Form S-8 (Files No. 333-228671, 333-248980 and 333-251073) and our Registration Statements on Form F-3 (Files No. 333-231417, 333-249311, 333-250076 and 333-251647).

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1	Condensed Consolidated Financial Statements of Alterity Therapeutics Limited and Subsidiaries (a development stage enterprise) as of December 31, 2021
99.2	Operating and Financial Review and Prospects for the Six Months ended December 31, 2021
99.3	Auditor’s Independence Declaration
99.4	Independent auditor’s report to the members of Alterity Therapeutics Limited

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited

	/s/ Dr. David Stamler
	By:	Dr. David Stamler
	Chief Executive Officer

Date: February 28, 2022

EX-99.1 2 ea156195ex99-1_alterity.htm CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF ALTERITY THERAPEUTICS LIMITED AND SUBSIDIARIES (A DEVELOPMENT STAGE ENTERPRISE) AS OF DECEMBER 31, 2021

Exhibit 99.1

Alterity Therapeutics Limited

Appendix 4D

Half-year ended 31 December 2021

Name of entity:	Alterity Therapeutics Limited
ABN:	37 080 699 065
Half-year ended:	31 December 2021
Previous period:	31 December 2020

Results for announcement to the market

		A$
Revenue from ordinary activities	Down	79.4% to 1,350
Net loss after tax (from ordinary activities) for the period attributable to members	Down	(23.1)% to 6,583,559
Net loss after tax for the period attributable to members	Down	(23.1)% to 6,583,559

Net tangible assets per security

	31 December		31 December
	2021		2020
	cents		cents

Net tangible asset backing (cents per share)		1.71		1.69

Explanation of results

Alterity Therapeutics Limited recorded income of $1,350 for the half-year ended 31 December 2021 (2020: $6,553) which is interest received on the Group’s bank accounts. Alterity Therapeutics Limited has incurred a loss of $6,583,559 for the half-year ended 31 December 2021 (2020: $8,561,862).

An explanation of the key financial elements contributing to the revenue and result above can be found in the review of operations included within the directors’ report.

Distributions

No dividends have been paid or declared by the Group for the current financial period. No dividends were paid for the previous financial period.

Changes in controlled entities

There have been no changes in controlled entities during the period ended 31 December 2021.

Other information required by Listing Rule 4.2A

N/A

Interim review

The interim financial statements have been reviewed by the Group’s independent auditor without any modified opinion, disclaimer or emphasis of matters.

Alterity Therapeutics Limited

ABN 37 080 699 065

Interim financial report for the

half-year ended 31 December 2021

Contents

		Page
Corporate directory		1
Directors’ report		2
Consolidated statement of profit or loss and other comprehensive income		7
Consolidated statement of financial position		8
Consolidated statement of changes in equity		9
Consolidated statement of cash flows		10
Notes to the consolidated financial statements		11
Directors’ declaration		20
Independent auditor’s report to the members		22

Alterity Therapeutics Limited

Corporate directory

Directors		Mr. Geoffrey Kempler
		Chairman

		Mr. Brian Meltzer
		Independent Non-Executive Director

		Mr. Peter Marks
		Independent Non-Executive Director

		Mr. Lawrence Gozlan
		Non-Executive Director

		Dr. David Sinclair (resigned 4 January 2022)
		Non-Executive Director

		Mr. Tristan Edwards (resigned 4 January 2022)
		Non-Executive Director

Secretary		Mr. Phillip Hains

Principal registered office in Australia		Level 3, 62 Lygon Street
		Carlton Victoria 3053
		Australia
		+61 3 9824 5254

Share register		Computershare Investor Services Pty Ltd Yarra Falls, 452 Johnston Street Abbotsford Victoria 3067
		1300 85 05 05 (within Australia) & +61 3 9414 4000 (overseas)

Auditor		PricewaterhouseCoopers
		2 Riverside Quay
		Southbank Victoria 3006

Solicitors		Quinert Rodda & Associates Pty Ltd Level 6/400 Collins St
		Melbourne Victoria 3000

Website		www.alteritytherapeutics.com

Alterity Therapeutics Limited

Directors’ report

31 December 2021

Your directors present their report on the Consolidated Entity (referred to hereafter as the group) consisting of Alterity Therapeutics Limited and the entities it controlled at the end of, or during, the half-year ended 31 December 2021.

Directors

The following persons held office as directors of Alterity Therapeutics Limited during the financial period:

Mr. Geoffrey Kempler

Mr. Brian Meltzer

Mr. Peter Marks

Mr. Lawrence Gozlan

Dr. David Sinclair (resigned 4 January 2022)

Mr. Tristan Edwards (resigned 4 January 2022)

Review of operations - 31 December 2021

Operations

Detailed below is an update on the status of the Group’s research and development projects and overall operations for the half-year ended 31 December 2021.

The Group’s 30 June 2021 Annual Report contains detailed background information relating to its operations including its research and development projects and collaboration partners and should be read in conjunction with this report.

Product Development Lead compound - ATH434

Alterity Therapeutics’ lead compound ATH434 is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain. In this way, it has excellent potential to treat Parkinson’s disease as well as various forms of atypical Parkinsonism. ATH434 is orally bioavailable, brain penetrant, and is being developed for Multiple System Atrophy (MSA), a Parkinsonian disorder.

MSA is a rare neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement and can include rigidity, autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes to falls. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability. Current treatment includes medications and lifestyle changes to help manage symptoms, but there is no treatment to slow disease progression and there is no cure.

The Company’s Phase 1 Clinical trial reported in 2019 found ATH434 was considered safe and well-tolerated in adult and older adult (≥ 65 years) human subjects, with an adverse event profile comparable to placebo. The safety profile was similar for adult and older adult volunteers. The results also indicated that ATH434 crosses the blood brain barrier in humans and that well-tolerated doses achieved concentrations in the brain that exceed those associated with robust efficacy in animal models.

ATH434 has Orphan drug designation both with the US FDA and European Commission for the treatment of MSA.

Alterity Therapeutics Limited

Directors’ report

31 December 2021

(continued)

Review of operations - 31 December 2021 (continued)

Phase 2 clinical trial for patients with MSA

Alterity is in the advanced stages of planning for the commencement of its Phase 2 clinical trial for patients with early-stage MSA.

The trial is a randomized, double-blind, placebo-controlled investigation that will explore the effect of ATH434 treatment on imaging and protein biomarkers such as aggregating α-synuclein and excess iron, which are important contributors to MSA pathology. Clinical endpoints and other biomarkers will permit comprehensive assessment of ATH434 efficacy along with characterization of safety and pharmacokinetics. Patients will receive treatment for 12 months which will provide an opportunity to detect changes in efficacy endpoints in order to optimize design of a definitive Phase 3 study.

The company announced its first clinical location in December with the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) authorizing Alterity to commence recruitment in that country. This is the first jurisdiction to authorize the trial with further countries to follow in 2022. The trial expected to open for enrollment in the first quarter of CY 2022.

bioMUSE natural history study for MSA patients

Biomarkers of progression in Multiple Systems Atrophy (bioMUSE) is a natural history study tracking the progression of patients with early MSA. The study is being conducted in collaboration with Vanderbilt University Medical Center in the US under the direction of Daniel Claassen, MD, Associate Professor of Neurology and Principal Investigator. Natural history studies are important for characterizing disease progression in target patient populations.

bioMUSE has met its initial enrollment goal and has been expanded to 20 patients. It continues to provide longitudinal biomarker and clinical data to characterize disease progression in a patient population that mirrors those to be enrolled in the Phase 2 study. The data generated thus far have been invaluable in informing and reducing risk in the Phase 2 trial design.

Key data from bioMUSE were presented at the International Parkinson and Movement Disorder Society Congress and reported that advanced MRI methods employed in the study, referred to as quantitative susceptibility mapping (QSM), demonstrated pathological iron accumulation in multiple areas of the brain in patients with early MSA.

The study investigators concluded that advanced MRI methods for measuring iron may improve patient selection in clinical trials of disease modifying therapy and have potential to serve as a biomarker for assessing treatment induced changes.

Growing scientific validation

Scientific interest and validation in ATH434 continue to grow with data from the Phase 1 trial presented at several global scientific and clinical conferences.

This included the American Autonomic Society 32nd Annual International Symposium. The poster, entitled “Cardiovascular safety and pharmacokinetics of ATH434, a novel small molecule inhibitor of α-synuclein aggregation, in adults and older adults”, described results from the Company’s Phase 1 clinical trial conducted in healthy volunteers. In this trial, ATH434 was well tolerated in adult and ≥ 65-year-old volunteers and demonstrated no cardiac adverse event signal and no clinically significant changes in blood pressure or heart rate at any dose. ATH434 also demonstrated dose dependent pharmacokinetics (PK) after single and multiple oral doses and a half-life that supports twice-daily dosing.

Alterity Therapeutics Limited

Directors’ report

31 December 2021

(continued)

Review of operations - 31 December 2021 (continued)

In addition, three preclinical studies demonstrating the potential of ATH434 to treat Parkinsonian disorders were published.

Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society, published results from a study demonstrating that ATH434 reduces α-synuclein related neurodegeneration in a widely accepted murine model of MSA. The study was performed at the Laboratory for Translational Neurodegeneration Research, Department of Neurology, Medical University of Innsbruck in Austria, a leading laboratory of animal research in MSA, under the direction of Professor Nadia Stefanova. The pre-clinical study showed that treatment with ATH434 was neuroprotective and improved motor function.

The Journal of Parkinson’s Disease published the results from a preclinical study investigating the effect of ATH434 on gastrointestinal complications titled “ATH434 Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson’s Disease”. Non-motor symptoms are common in patients with Parkinsonian disorders, such as Parkinson’s disease and MSA. Parkinson’s disease patients experience gastrointestinal complications, cognitive deficits, autonomic dysfunction, and mood disturbance and these non-motor manifestations are an important source of morbidity and reduced quality of life.

Plos ONE published an in vitro study concluding that the novel mechanism of action of ATH434 provides a compelling case for its continued development as a therapeutic agent in neurodegenerative diseases associated with iron accumulation.

Post the reporting period, Alterity advised that data in an animal model of MSA was published in the Journal of Parkinson’s Disease. The publication, entitled, “The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy” described a study evaluating the efficacy of ATH434 in genetically altered mice that develop manifestations of MSA. The investigation demonstrated that in the studied brain region, ATH434 treatment reduced both the toxic oligomeric and aggregated forms of α-synuclein, a central nervous system protein important for normal function of nerve cells. At the same time, ATH434 treatment reduced the cardinal pathology of MSA (glial cell inclusions), reduced brain iron, preserved neurons, and improved motor performance. The results independently confirmed the previous findings from the laboratory of Dr. Stefanova. The publication concluded that ATH434 is a promising small molecule drug candidate that has potential for treating MSA. The study was led by David I. Finkelstein, Ph.D., Head of Parkinson’s Disease Laboratory at the Florey Institute of Neuroscience and Mental Health and the University of Melbourne.

Next generation compounds to treat neurodegenerative diseases

Alterity’s clinical development strategy is based on the hypothesis that its therapeutics can reduce α-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain, thereby disrupting the underlying pathology of neurodegenerative conditions. This includes Parkinsonian disorders such as Parkinson’s disease and Multiple System Atrophy, as well as Alzheimer’s disease.

During the period, significant progress was made on two important new patents that place Alterity in a strong position with respect to its iron chaperone technology. These new patent families support the expansion of Alterity’s drug development portfolio. These novel molecules are designed to redistribute the excess iron implicated in many neurodegenerative diseases. In July, the Company announced that the United States Patent and Trademark Office (USPTO) granted US patent No. 10,941,143 relating to claims on a group of 150 novel compounds that act as iron chaperones. This was followed, in August, by a second composition of matter patent, which was allowed by the USPTO securing exclusivity for a new group of iron chaperones that covers more than 80 novel compounds. This patent No. US 11,155,547 has subsequently been granted.

Significant changes in the state of affairs

In July 2021, the Group raised A$17,176,040 by issuing 322,857,900 shares at $0.0532 per share through the use of its “at-the-market” (ATM) facility to fund working capital and progress its research and development activities.

There have been no other significant changes in the state of affairs of the Company during the period.

Alterity Therapeutics Limited

Directors’ report

31 December 2021

(continued)

Events since the end of the financial year

Resignation of Non-Executive Directors

On 4 January 2022 Dr. David Sinclair and Mr. Tristan Edwards resigned as Non-Executive Directors of the Group.

Options issued under the ESOP Plan to Dr. Sinclair (7,000,000) and Mr. Edwards (7,000,000) as approved in September 2020 were forfeited and cancelled upon resignation.

No other matters or circumstances have arisen since 31 December 2021 that have significantly affected the Group’s operations, results or state of affairs, or may do so in future periods.

Auditor’s independence declaration

A copy of the auditor’s independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 6.

Rounding of amounts

The company is of a kind referred to ASIC Legislative Instrument 2016/191, relating to the ‘rounding off’ of amounts in the directors’ report and financial report. Amounts in the directors’ report and financial report have been rounded off to the nearest dollar in accordance with the instrument.

This report is made in accordance with a resolution of directors.

Mr. Geoffrey Kempler

Chairman

Melbourne

28 February 2022

This page is intentionally left blank.

Alterity Therapeutics Limited

Consolidated statement of profit or loss and other comprehensive income

(Unaudited)

For the half-year ended 31 December 2021

		31 December			31 December
		2021			2020
	Notes	A$			A$

Income
Interest income	6		1,350			6,553
Other income	6		2,359,198			1,924,389

Expenses
Intellectual property expenses			(205,896	)		(160,304	)
General and administration expenses	7		(3,194,790	)		(3,673,407	)
Research and development expenses	7		(6,761,542	)		(5,806,841	)
Other operating expenses			(624	)		(20	)
Other gains/(losses)	7		1,218,745			(852,232	)
Loss for the period			(6,583,559	)		(8,561,862	)

Loss before income tax			(6,583,559	)		(8,561,862	)

Income tax expense			-			-

Other comprehensive loss
Other comprehensive income for the period, net of tax			-			-

Total comprehensive loss for the period			(6,583,559	)		(8,561,862	)

		Cents			Cents
Loss per share for profit attributable to the ordinary equity holders of the Group:
Basic loss per share	5		(0.27	)		(0.65	)
Diluted loss per share	5		(0.27	)		(0.65	)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

Alterity Therapeutics Limited

Consolidated statement of financial position

(Unaudited)

As at 31 December 2021

		31 December			30 June
		2021			2021
	Notes	A$			A$

ASSETS
Current assets
Cash and cash equivalents			37,002,201			28,115,516
Trade and other receivables	8(a)		6,260,577			4,277,677
Other current assets			1,599,963			1,095,753
Total current assets			44,862,741			33,488,946

Non-current assets
Property, plant and equipment			27,270			31,313
Right-of-use assets			41,039			65,495
Total non-current assets			68,309			96,808

Total assets			44,931,050			33,585,754

LIABILITIES
Current liabilities
Trade and other payables			3,134,160			2,502,509
Provisions			613,098			537,368
Other current liabilities			15,167			27,746
Total current liabilities			3,762,425			3,067,623

Non-current liabilities
Provisions			12,907			9,768
Other non-current liabilities			26,727			37,903
Total non-current liabilities			39,634			47,671

Total liabilities			3,802,059			3,115,294

Net assets			41,128,991			30,470,460

EQUITY
Contributed equity	9(a)		213,814,776			197,447,990
Reserves	9(c)		3,626,188			2,750,884
Accumulated losses	9(b)		(176,311,973	)		(169,728,414	)

Total equity			41,128,991			30,470,460

The above consolidated statement of financial position should be read in conjunction with the accompanying notes.

Alterity Therapeutics Limited

Consolidated statement of changes in equity

(Unaudited)

For the half-year ended 31 December 2021

		Attributable to owners of
		Alterity Therapeutics Limited
		Contributed					Accumulated
		equity			Reserves		losses			Total
	Notes	A$			A$		A$			A$

Balance at 1 July 2020			160,703,754			866,121		(154,419,061	)		7,150,814

Loss for the period			-			-		(8,561,862	)		(8,561,862	)
Total comprehensive income for the period			-			-		(8,561,862	)		(8,561,862	)

Transactions with owners in their capacity as owners:
Issue of ordinary shares			36,562,055			-		-			36,562,055
Share-based payment expenses			-			1,577,720		-			1,577,720
Transaction costs			(2,372,505	)		-		-			(2,372,505	)
			34,189,550			1,577,720		-			35,767,270

Balance at 31 December 2020			194,893,304			2,443,841		(162,980,923	)		34,356,222

Balance at 1 July 2021			197,447,990			2,750,884		(169,728,414	)		30,470,460

Loss for the period			-			-		(6,583,559	)		(6,583,559	)
Total comprehensive income for the period			-			-		(6,583,559	)		(6,583,559	)

Transactions with owners in their capacity as owners:
Issue of ordinary shares	9(a)		17,176,040			-		-			17,176,040
Share-based payment expenses	9(c)(i)		-			875,304		-			875,304
Transaction costs	9(a)		(809,254	)		-		-			(809,254	)
			16,366,786			875,304		-			17,242,090

Balance at 31 December 2021			213,814,776			3,626,188		(176,311,973	)		41,128,991

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Alterity Therapeutics Limited

Consolidated statement of cash flows

(Unaudited)

For the half-year ended 31 December 2021

		31 December			31 December
		2021			2020
	Notes	A$			A$

Cash flows from operating activities
Payments to suppliers and employees			(9,002,490	)		(7,385,267	)
COVID-19 government relief			103,338			53,564
Other grant received			225,746			-
Interest received			1,352			1,397
Net cash (outflow) from operating activities	10		(8,672,054	)		(7,330,306	)

Cash flows from investing activities
Payments for property, plant and equipment			(2,559	)		(2,494	)
Net cash (outflow) from investing activities			(2,559	)		(2,494	)

Cash flows from financing activities
Proceeds from issues of shares and other equity securities			17,176,040			36,562,055
Transaction costs relating to issue of equity			(809,254	)		(2,372,505	)
Principle elements of lease payments			(23,755	)		(24,249	)
Net cash inflow from financing activities			16,343,031			34,165,301

Net increase in cash and cash equivalents			7,668,418			26,832,501
Cash and cash equivalents at the beginning of the financial year			28,115,516			9,196,892
Effects of exchange rate changes on cash and cash equivalents			1,218,267			(987,215	)
Cash and cash equivalents at end of period			37,002,201			35,042,178

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.

Alterity Therapeutics Limited

Notes to the consolidated financial statements

(Unaudited)

31 December 2021

Basis of preparation of half-year report

This condensed consolidated interim report for the half-year reporting period ended 31 December 2021 has been prepared in accordance with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Act 2001. These financial statements also comply with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), as applicable to interim financial reporting.

This condensed consolidated interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2021 and any public announcements made by Alterity Therapeutics Limited (the “Group”) during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period except as discussed below.

(a)

New and amended standards adopted by the Group

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ‘AASB’ that are mandatory for the current reporting period.

The adoption of these standards has not had any impact on the disclosures or amounts reported in these financial statements.

Significant changes in the current reporting period

There have been no other significant changes in the state of affairs of the Company during the period.

Segment information

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer of Alterity Therapeutics Limited. For the current and previous reporting periods, the Group operated in one segment, being research and development in the field of Parkinsonian and other neurodegenerative disorders.

Dividends

The Group has not declared any dividends in the period ended 31 December 2021 (2020: nil)

Alterity Therapeutics Limited

Notes to the consolidated financial statements

(Unaudited)

31 December 2021

(continued)

5	Loss per share

(a)

Basic and diluted loss per share

	31 December			31 December
	2021 Cents			2020 Cents
Loss per share for profit attributable to the ordinary equity holders of the Group:
Basic loss per share		(0.27	)		(0.65	)
Diluted loss per share		(0.27	)		(0.65	)

(b)

Reconciliation of loss used in calculating loss per share

	31 December			31 December
	2021 A$			2020 A$
Basic loss per share
Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share:		(6,583,559	)		(8,561,862	)

Diluted loss per share
Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share:		(6,583,559	)		(8,561,862	)

Alterity Therapeutics Limited

Notes to the consolidated financial statements

(Unaudited)

31 December 2021

(continued)

5	Loss per share (continued)

(c)	Weighted average number of shares used as the denominator

	31 December 2021 Number		31 December 2020 Number

Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share		2,405,110,327		1,323,432,372

Options that are considered to be potential ordinary shares are excluded from the weighted average number of ordinary shares used in the calculation of basic loss per share. Where dilutive, potential ordinary shares are included in the calculation of diluted loss per share. All the options on issue do not have the effect to dilute the loss per share. Therefore, they have been excluded from the calculation of diluted loss per share.

6	Interest and other income

	31 December		31 December
	2021 A$		2020 A$
Interest and other income
Interest income		1,350		6,553
		1,350		6,553
Other Income
R&D tax incentive		2,133,452		1,883,325
COVID-19 relief		-		41,064
Other grant ⁽¹⁾		225,746		-
		2,359,198		1,924,389

¹	Other grants relates to the receipt of grant funding awarded by Michael J. Fox Foundation during the period ended 31 December 2021.

Alterity Therapeutics Limited

Notes to the consolidated financial statements

(Unaudited)

31 December 2021

(continued)

7	Loss for the period

	31 December			31 December
	2021 A$			2020 A$
Loss before income tax has been determined after:

General and administration expenses
Depreciation on fixed assets		6,602			12,417
Depreciation on leased assets		24,934			23,215
Employee expenses (non R&D related)		370,564			376,220
Consultant and director expenses		242,563			387,310
Audit, internal control and other assurance expenses		109,398			115,798
Corporate compliance expenses		217,776			372,697
Office rental		30,458			66,664
Other administrative and office expenses		503,885			332,784
Insurance expenses		324,798			258,582
Share-based payment expenses		875,304			1,577,720
Corporate advisory		488,508			150,000
		3,194,790			3,673,407
Research and development expenses
Employee expenses		1,192,238			1,072,468
Other research and development expenses¹		5,569,304			4,734,373
		6,761,542			5,806,841
Other gains and losses
Foreign exchange (gain)/ loss		(1,218,745	)		852,232
		(1,218,745	)		852,232

⁽¹⁾	Other research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.

Alterity Therapeutics Limited

Notes to the consolidated financial statements

(Unaudited)

31 December 2021

(continued)

8	Financial assets and financial liabilities

(a)

Trade and other receivables

	31 December 2021						30 June 2021
	Current		Non- current		Total		Current		Non- current		Total
	A$		A$		A$		A$		A$		A$

R&D tax incentive receivable		6,259,819		-		6,259,819		4,126,364		-		4,126,364
Accrued interest income		267		-		267		269		-		269
Goods and services tax receivable		491		-		491		47,706		-		47,706
Other receivable		-		-		-		103,338		-		103,338
		6,260,577		-		6,260,577		4,277,677		-		4,277,677

R&D tax incentive receivable represents the amount of R&D tax incentive the Group expects to recover. For further details, see note 13(a).

A 43.5% R&D Tax incentive refundable tax offset is available to eligible small companies with an annual aggregate turnover of less than $20 million. For the year ended 30 June 2021 and half-year ended 31 December 2021, the Group recorded $4,126,364 and $2,133,722 respectively in other income and receivables.

(i) Classification as trade and other receivables

Trade receivables and other receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. If collection of the amounts is expected in one year or less they are classified as current assets. If not, they are presented as non-current assets. Trade and other receivables are generally due for settlement within one year and therefore are all classified as current.

(b)

Recognised fair value measurements

The financial instruments recognised at fair value in the statement of financial position have been analysed and classified using a fair value hierarchy reflecting the significance of the inputs used in making the measurements.

The fair value hierarchy consists of the following levels:

●	quoted prices in active markets for identical assets or liabilities (Level 1);

●	inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices) (Level 2); and

●	inputs for the asset or liability that are not based on observable market data (unobservable inputs) (Level3).

During the period, none of the Group’s assets and liabilities had their fair value determined using the fair value hierarchy. No transfers between the levels of the fair value hierarchy occurred during the current or previous periods.

Alterity Therapeutics Limited

Notes to the consolidated financial statements

(Unaudited)

31 December 2021

(continued)

9	Equity

(a)

Contributed equity

31 December
2021
Shares

30 June
2021
Shares

31 December
2021
A$

30 June
2021
A$

Ordinary shares - fully paid

2,406,874,578

2,084,016,678

213,814,776

197,447,990

Movements in ordinary share:

Details	Number of shares		A$
Opening balance 1 July 2021		2,084,016,678		197,447,990
Shares issued during the year		322,857,900		17,176,040
Transaction costs		-		(809,254	)
Balance 31 December 2021		2,406,874,578		213,814,776

Details of shares issued during the current period:

Issue price

Amount

Details

Number

2-Jul-2021

Issue of shares under ATM facility

322,857,900

0.0532

17,176,040

322,857,900

17,176,040

(b)

Accumulated losses

Movements in accumulated losses were as follows:

	31 December 2021 A$		31 December 2020 A$

Balance at the beginning of the period		169,728,414		154,419,061
Net loss for the period		6,583,559		8,561,862
Balance at the end of the period		176,311,973		162,980,923

(c)

Reserves

(i)

Options

31 December
2021
Options

30 June
2021
Options

31 December
2021
A$

30 June
2021
A$

Options over fully paid ordinary shares

205,692,720

160,542,720

3,626,188

2,750,884

Alterity Therapeutics Limited

Notes to the consolidated financial statements

(Unaudited)

31 December 2021

(continued)

9	Equity (continued)

(c)	Reserves (continued)

(i)

Options (continued)

The table below presents the movements in options granted and issued during the half-year ended 31 December 2021.

Details		Number		Amount A$
8-Dec-2021	Unlisted options issued to consultant		12,000,000		326,544
8-Dec-2021	Unlisted options issued to employees		13,900,000		13,326
8-Dec-2021	Unlisted options issued to employees		19,250,000		18,816
			45,150,000		358,686

							Fair value at grant
Date issued	Quantity		Grant Date	Expiry Date	Exercise price ($)		date per option ($) *
08-Dec-2021		12,000,000	31-Jul-2021	31-Jul-2024	$	0.0700	$	0.0272
08-Dec-2021		13,900,000	29-Nov-2021	29-Nov-2026	$	0.0238	$	0.0210
08-Dec-2021		19,250,000	29-Nov-2021	29-Nov-2026	$	0.0375	$	0.0214
		45,150,000

*	Rounded to the nearest four decimal points.

(ii)

Free-attaching options

	31 December 2021 Options		30 June 2021 Options		31 December 2021 A$		30 June 2021 A$

Free-attaching options		674,694,939		674,694,939		-		-

There was no movement during the half-year ended 31 December 2021.

There have been no other options over fully paid ordinary shares issued, exercised or forfeited during the current period.

(iii)

Nature and purpose of reserves

The share-based payments reserve is used to recognise the fair value of options issued to employees and consultants but not exercised.

Alterity Therapeutics Limited

Notes to the consolidated financial statements

(Unaudited)

31 December 2021

(continued)

10	Reconciliation of profit after income tax to net cash flow from operating activities

	31 December 2021 A$			31 December 2020 A$
Loss for the period		6,583,559			8,561,862
Depreciation on fixed assets		(6,602	)		(12,417	)
Depreciation on leased assets		(24,934	)		(23,215	)
Non-cash employee benefits expense - share-based payments		(875,304	)		(1,577,720	)
Net foreign exchange differences		1,218,745			(987,215	)
(Increase)/decrease in provisions		(78,869	)		(62,547	)
Increase/(decrease) in trade and other receivables		1,982,900			1,916,120
Increase/(decrease) in other current assets		504,210			(229,445	)
(Increase)/decrease in trade and other payables		(631,651	)		(255,505	)
(Increase)/decrease in other current liabilities		-			388
		8,672,054			7,330,306

11	Related party transactions

During the half-year ended 31 December 2021 the Group paid a total of A$37,500 (excl. GST) in corporate advisory fees to Montoya Pty Ltd, an associated entity of Mr. Lawrence Gozlan, a director of the Group and A$101,400 (excl. GST) in corporate advisory fees to Kemdev Pty Ltd, an associated entity of Mr. Geoffrey Kempler. A$75,000 (excl. GST) is payable to Kemdev Pty Ltd at the end of the period.

There were no other related party transactions other than those related to director and key management personnel remuneration and equity and transactions by the Group and its subsidiaries.

12	Events occurring after the reporting period

Resignation of Non-Executive Directors

On 4 January 2022 Dr. David Sinclair and Mr. Tristan Edwards resigned as Non-Executive Directors of the Group.

Options issued under the ESOP Plan to Dr. Sinclair (7,000,000) and Mr. Edwards (7,000,000) as approved in September 2020 were forfeited and cancelled upon resignation.

No other matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group or economic entity in subsequent financial periods.

13	Significant estimates and assumptions

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances.

The Company and its two wholly-owned subsidiaries (the “Group”) makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial period are discussed below.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period.

Alterity Therapeutics Limited

Notes to the consolidated financial statements

(Unaudited)

31 December 2021

(continued)

13	Significant estimates and assumptions (continued)

(a)

R&D tax incentives

The Australian Government replaced the research and development tax concession with the research and development tax incentive from 1 July 2011. The provisions provide refundable or non-refundable tax offsets. The research and development tax incentive applies to expenditure incurred and the use of depreciating assets in an income year commencing on or after 1 July 2011. A 43.5% refundable tax offset will be available to eligible small companies with an annual aggregate turnover of less than $20 million. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. For the period to 31 December 2021 the Group has recorded an item in other income of $A2,133,452 (31 Dec 2020:

$1,883,325) to recognise this amount which relates to this period.

On 7 October 2020, the Treasury Laws Amendment (A Tax Plan for the Covid-19 Economic Recovery Bill 2020) was introduced to the Parliament. This legislation supersedes the Treasury Laws Amendment (Research and Development Incentive) Bill 2019. Under the amendments, commencing 1 July 2021, the refundable tax offset rate for companies with aggregated turnover below $20 million would become 18.5% above the companies tax rate and the R&D expenditure threshold would be increased from $100 million to $150 million.

Management does not consider the rate reduction or the refund cap has material impact towards the Group’s R&D tax incentive claim for the next financial year going forward. The rate reduction has no material impact on the R&D tax incentive estimate reported in financial statements for the half-year ended 31 December 2021.

14	COVID-19 impact on business

The COVID-19 pandemic has caused uncertainty in global markets and its impact is unable to be reliably measured. However, COVID-19 has had limited effect thus far on the Group’s operation. Development activities have continued with minimal disruption.

Alterity Therapeutics Limited

Directors’ declaration

31 December 2021

In the directors’ opinion:

(a)

the interim financial statements and notes set out on pages 2 to 19 are in accordance with the Corporations Act 2001, including:

(i)

complying with Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements, and

(ii)

giving a true and fair view of the consolidated entity’s financial position as at 31 December 2021 and of its performance for the half-year ended on that date, and

(b)

there are reasonable grounds to believe that Alterity Therapeutics Limited will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of directors.

Mr. Geoffrey Kempler

Chairman

Melbourne

28 February 2022

Preparation of interim financial statements for users in multiple jurisdictions

The Group has prepared the interim financial statements to conform to the requirements and needs of users of the financial statements located in both Australia and the U.S.

For U.S users, the Group has prepared the interim financial statements to conform to the requirements of IAS 34 Interim Financial Reporting. Consistent with U.S. domestic registrants, the Group has labelled the interim financial information “unaudited” because the interim financial information is not subject to an audit by our independent registered public accounting firm. The auditor’s independence declaration and independent auditor’s review report are included within this filing to meet the requirements of Australian laws and regulations and are furnished, not filed, for the purposes of incorporation of the related financial statements in any U.S. registration document.

For Australian users, the Group has prepared the interim financial statements to conform to the requirements of the Corporations Act 2001 and AASB 134 Interim Financial Reporting. A review of the interim financial information has been performed by the Group’s independent auditors to meet the requirements of Australian Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity and users should refer to the auditor’s independence declaration and independent auditor’s review report included within this filing.

This page is intentionally left blank.

EX-99.2 3 ea156195ex99-2_alterity.htm OPERATING AND FINANCIAL REVIEW AND PROSPECTS FOR THE SIX MONTHS ENDED DECEMBER 31, 2021

Exhibit 99.2

OPERATING AND FINANCIAL REVIEW AND PROSPECTS

The following discussion and analysis includes certain forward-looking statements with respect to the business, financial condition and results of operations of our company. The words “estimate,” “project,” “potential”, “plan”, “should”, “expect”, variations of such words and similar expressions are intended to identify forward-looking statements within the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by such forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by us herein are discussed in filings we make with the United States Securities and Exchange Commission, or the SEC, including our Annual Report on Form 20-F. This discussion and analysis should be read in conjunction with our consolidated financial statements and notes thereto included in Exhibit 99.1.

Background

Alterity Therapeutics Limited, or the Company (or together with its subsidiaries, the Group), is a development stage enterprise incorporated under the laws of the Commonwealth of Australia on November 11, 1997. Our mission is to develop therapeutic drugs designed to treat the underlying cause of neurodegenerative diseases, currently focusing on Parkinsonian and other movement disorders. The principal listing of our ordinary shares and listed options to purchase our ordinary shares is on the Australian Securities Exchange, or ASX. Since September 5, 2002, our American Depository Shares, or ADSs, have traded on the NASDAQ Capital Market under the symbol “PRAN.” On April 8, 2019, we changed our name to Alterity Therapeutics Limited and our ADSs have traded under the symbol “ATHE” since that date. The Bank of New York, acting as depositary, issues American Depository Receipts, or ADRs, each of which evidences an ADS, which in turn represents sixty of our ordinary shares. As used in this annual report, the terms “we,” “us,” “our” and “Alterity” mean Alterity Therapeutics Limited and its subsidiaries, unless otherwise indicated.

Our interim consolidated financial statements appearing in Exhibit 99.1 are prepared in Australian dollars and in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, and comply with both IFRS as issued by the IASB and Australian equivalents to International Financial Reporting Standards, or A-IFRS. In this report, all references to “U.S. dollars” or “US$” are to the currency of the United States of America, and all references to “Australian dollars” or “A$” are to the currency of Australia.

All of our current revenues are generated in Australian dollars, except for interest earned on foreign currency bank accounts, and the majority of our expenses are incurred in Australian dollars.

Overview

We are a development stage enterprise at an early to mid-stage in the development of our pharmaceutical products that are designed to treat the underlying causes of neurodegeneration of the brain. We have incurred net losses since inception and expect to incur substantial and increasing losses for the next several years as we expand our research and development activities and move our product candidates into later stages of development. All of our product candidates are in early to mid-stage of development and we face the risks of failure inherent in developing drugs based on new technologies. The process of carrying out the development of our products to later stages of development may require significant additional research and development expenditures, including pre-clinical testing, manufacturing and clinical trials, as well as for obtaining regulatory approval. For additional details about our risks see Item 3.D., “Key Information – Risk Factors,” of our Form 20-F for the year ended June 30, 2021.

To date, we have funded our operations primarily through the sale of equity securities, proceeds from the exercise of options, government grants, tax incentive payments, licensing and research collaborations and interest income.

Since completing our initial public offering and listing process on the ASX on March 28, 2000, we have concentrated our resources toward the pursuit of our disease targets. We have developed a diversified library of chemical compounds, which may yield future product candidates across various neurodegenerative indications. For additional details regarding our clinical trials see Item 4.A., “Information on the Company - History and Development of the Company,” of our Form 20-F for the year ended June 30, 2021.

Highlights For The Six Months Ended December 31, 2021

Operations

Detailed below is an update on the status of the Group’s research and development projects and overall operations for the half-year ended 31 December 2021.

PRODUCT DEVELOPMENT

Lead compound – ATH434

ATH434 has Orphan drug designation both with the US FDA and European Commission for the treatment of MSA.

Phase 2 clinical trial for patients with MSA

Alterity is in the advanced stages of planning for the commencement of its Phase 2 clinical trial for patients with early-stage MSA.

bioMUSE natural history study for MSA patients

Key data from bioMUSE were presented at the International Parkinson and Movement Disorder Society Congress and reported that advanced MRI methods employed in the study, referred to as quantitative susceptibility mapping (QSM), demonstrated pathological iron accumulation in multiple areas of the brain in patients with early MSA. 

The study investigators concluded that advanced MRI methods for measuring iron may improve patient selection in clinical trials of disease modifying therapy and have potential to serve as a biomarker for assessing treatment induced changes. 

Growing scientific validation

Scientific interest and validation in ATH434 continue to grow with data from the Phase 1 trial presented at several global scientific and clinical conferences.

In addition, three preclinical studies demonstrating the potential of ATH434 to treat Parkinsonian disorders were published.

Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society, published results from a study demonstrating that ATH434 reduces α-synuclein related neurodegeneration in a widely accepted murine model of MSA. The study was performed at the Laboratory for Translational Neurodegeneration Research, Department of Neurology, Medical University of Innsbruck in Austria, a leading laboratory of animal research in MSA, under the direction of Professor Nadia Stefanova. The pre-clinical study showed that treatment with ATH434 was neuroprotective and improved motor function.

The Journal of Parkinson’s Disease published the results from a preclinical study investigating the effect of ATH434 on gastrointestinal complications titled “ATH434 Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson’s Disease”. Non-motor symptoms are common in patients with Parkinsonian disorders, such as Parkinson’s disease and MSA. Parkinson’s disease patients experience gastrointestinal complications, cognitive deficits, autonomic dysfunction, and mood disturbance and these non-motor manifestations are an important source of morbidity and reduced quality of life.

Plos ONE published an in vitro study concluding that the novel mechanism of action of ATH434 provides a compelling case for its continued development as a therapeutic agent in neurodegenerative diseases associated with iron accumulation.

Post the reporting period, Alterity advised that data in an animal model of MSA was published in the Journal of Parkinson’s Disease. The publication, entitled, “The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy” described a study evaluating the efficacy of ATH434 in genetically altered mice that develop manifestations of MSA. The investigation demonstrated that in the studied brain region, ATH434 treatment reduced both the toxic oligomeric and aggregated forms of α-synuclein, a central nervous system protein important for normal function of nerve cells. At the same time, ATH434 treatment reduced the cardinal pathology of MSA (glial cell inclusions), reduced brain iron, preserved neurons, and improved motor performance. The results independently confirmed the previous findings from the laboratory of Dr. Stefanova. The publication concluded that ATH434 is a promising small molecule drug candidate that has potential for treating MSA. The study was led by David I. Finkelstein, Ph.D., Head of Parkinson’s Disease Laboratory at the Florey Institute of Neuroscience and Mental Health and the University of Melbourne.

Next generation compounds to treat neurodegenerative diseases

During the period, significant progress was made on two important new patents that place Alterity in a strong position with respect to its iron chaperone technology. These new patent families support the expansion of Alterity’s drug development portfolio. These novel molecules are designed to redistribute the excess iron implicated in many neurodegenerative diseases.  In July, the Company announced that the United States Patent and Trademark Office (USPTO) granted US patent No. 10,941,143 relating to claims on a group of 150 novel compounds that act as iron chaperones. This was followed, in August, by a second composition of matter patent, which was allowed by the USPTO securing exclusivity for a new group of iron chaperones that covers more than 80 novel compounds. This patent No. US 11,155,547 has subsequently been granted.

Cash

The Group’s cash on hand as at December 31, 2021 totaled A$37 million. In addition, the Group has recorded a trade receivable at December 31, 2021 of A$6.3 million from the Australian Tax Office. This amount is in respect of the estimated 2022 R&D tax incentive claim of A$2.13 million and for the financial year ended June 30, 2021 of A$4.13 million.

Six Months Ended December 31, 2021 Compared to Six Months Ended December 31, 2020

Income from ordinary activities

Income from ordinary activities, consisting of interest income, decreased to A$1,350 for the six months ended December 31, 2021 from A$6,553 for the six months ended December 31, 2020, a decrease of A$5,203, or 79.4%. The decrease in interest income is primarily attributable to the lower interest rates, lower Australian dollar cash balances and lower utilization of longer-term interest-bearing deposits during the period.

Other income

Other income of A$2,359,198 for the six months ended December 31, 2021 includes the Group’s estimate of R&D tax incentive claimable of A$2,133,452 from the Australian Tax Office. This amount was calculated based on the tax incentive policy introduced by the Australian Government on July 1, 2011. The Group is entitled to 43.5% of tax incentives based on the total eligible research and development expenditure incurred during the period. This amount increased by A$250,127, or 13.3% from A$1,883,325 for the six months ended December 31, 2020. This increase in total R&D expenditures is primarily caused by the increase in the period attributable to preparation for the Phase II study of the Group’s lead product candidate ATH434.

In addition, other income of A$225,746 was recognized in relation to the receipt of grant funding awarded by Michael J. Fox Foundation during the half-year ended December 31, 2021.

General and administration expenses

General and administration expenses reduced to A$3,194,790 for the six months ended December 31, 2021 from A$3,673,407 for the six months ended December 31, 2020, which represented a decrease of A$478,617, or 13.03%. The decrease in general and administration expenses was mainly due to share-based expense from the issuance of unlisted options to Directors of the Group in the prior period.

Research and development expenses

Research and development expenses increased to A$6,761,542 for the six months ended December 31, 2021 from A$5,806,841 for the six months ended December 31, 2020, which represented an increase of A$954,701, or 16.4%. The increase in research and development expenses in the six months ending December 31, 2021 was primarily due to the increase in research and development activities attributable to preparation ofr the Phase II study of the Group’s lead product candidate ATH434.

Other gains and losses

Other gains and losses consist of gains and losses from foreign exchange for the periods. This increased to a gain of A$1,218,745 for the six months ended December 31, 2020 from a loss of A$852,232 for the six months ended December 31, 2020, an increase of A$2,070,977, or 243%. In the 6 months ended December 31 2021, the Australian dollar depreciated against the US dollar by 3.03%, while in the 2020 period the Australian dollar appreciated by 10.37%. Furthermore, the Company holds more cash in USD in current period as compared to last period end.

Inflation and Seasonality

Management believes that inflation has had no material impact on the Group’s operations or financial condition and that our operations are not currently subject to seasonal influences.

Liquidity and Capital Resources

We are a development stage company and have had no sales income to date, and as of December 31, 2021 our accumulated deficit totaled A$176,311,973. From inception until our initial public offering in March 2000 we financed our operations primarily through borrowings from two of our then directors, which were repaid from the proceeds of such offering. Since our initial public offering, we have financed our operations primarily through sales of equity securities, proceeds from the exercise of options, government grants, tax incentive payments, licensing and research collaborations and interest earned on investments. Please see our Annual Report on Form 20-F for the year ended June 30, 2021 for a discussion of our financing efforts prior to June 30, 2021.

We had A$37,002,201 of cash and cash equivalents at December 31, 2021 compared to A$28,115,516 at June 30, 2021.

Capital expenditures for the six months ended December 31, 2021 were A$2,559 and capital expenditures for the six months ended December 31, 2020 were A$2,494. These expenditures were principally for computer equipment. We currently do not have significant capital spending or purchase commitments, but we expect to continue to engage in capital spending consistent with the level of our operations.

We believe that the Australian Government tax incentive scheme relating to eligible research and development activities, introduced on July 1, 2011, will provide us with significant benefits in future years. Such eligible R&D activities include but are not limited to:

	●	Core activities, which are experimental activities whose outcome cannot be known or determined in advance, but can only be determined by applying a systematic progression of work;

	●	Core activities conducted for the purpose of generating new knowledge (including new knowledge in the form of new or improved processes and materials); or

●

Supporting activities that are directly related and designed to support the above.

Under the research and development incentive scheme, entities with an aggregated turnover for the income year of less than A$20 million will be entitled to a 43.5% refundable tax offset. In the half-year ended December 31, 2021, we recorded A$2,133,452 in other income with respect to funds we will receive in relation to the 2022 financial year under the research and development incentive scheme. In the half-year ended December 31, 2020, we recorded A$1,883,325 in other income with respect to funds we will receive in relation to the 2021 financial year under the research and development incentive scheme.

Cash Flows

Net cash used in operating activities increased to A$8,672,054 for the six months ended December 31, 2021 from A$7,330,306 for the six months ended December 31, 2020. Net cash used in operating activities consists of payments to suppliers and employees. The increase in net cash used in the 2022 period was due receipt of the R&D tax incentive refund for the 2021 financial year not being received within the current period.

Net cash used by investing activities increased to A$2,559 for the six months ended December 31, 2021 from A$2,494 for the six months ended December 31, 2020. Cash flows used for investing activities was primarily attributable to payments for the purchase of computer and office equipment in both periods.

Net cash generated from financing activities decreased to A$16,343,031 for the six months ended December 31, 2021 from A$34,165,301 used for the six months ended December 31, 2020. The decrease is attributable to the two tranche A$35 million private placement in the prior period.

We have an unrealized foreign exchange gain of A$1,218,267 for the six months ended December 31, 2021 compared to a loss of A$987,215 for the six months ended December 31, 2020. In the 6 months ended December 31, 2021, the Australian dollar depreciated against the US dollar by 3.03%, while in the 2020 period the Australian dollar appreciated by 10.37%. The current period gain is primarily attributable to a larger US dollar cash balance which was favorably impacted by this depreciation in AUD.

Off-Balance Sheet Arrangements

We are not a party to any material off-balance sheet arrangements. In addition, we have no unconsolidated special purpose financing or partnership entities that are likely to create material contingent obligations.

Conditions in Australia

We are incorporated under the laws of, and our principal offices and research and development facilities are located in, the Commonwealth of Australia. Therefore, we are directly affected by political and economic conditions in Australia.

Risk Factors

There have been no material changes in our risk factors reported in our Annual Report on Form 20-F for the year ended June 30, 2021.

EX-99.3 4 ea156195ex99-3_alterity.htm AUDITOR'S INDEPENDENCE DECLARATION

Exhibit 99.3

Auditor’s Independence Declaration

As lead auditor for the review of Alterity Therapeutics Limited for the half-year ended 31 December 2021, I declare that to the best of my knowledge and belief, there have been:

(a)

no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and

(b)

no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Alterity Therapeutics Limited and the entities it controlled during the period.


Jon Roberts	Melbourne
Partner	28 February 2022
PricewaterhouseCoopers

PricewaterhouseCoopers, ABN 52 780 433 757

2 Riverside Quay, SOUTHBANK VIC 3006, GPO Box 1331, MELBOURNE VIC 3001

T: 61 3 8603 1000, F: 61 3 8603 1999, www.pwc.com.au

Liability limited by a scheme approved under Professional Standards Legislation.

EX-99.4 5 ea156195ex99-4_alterity.htm INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ALTERITY THERAPEUTICS LIMITED

Exhibit 99.4

Independent auditor's review report to the members of Alterity Therapeutics Limited

Report on the half-year financial report

Conclusion

We have reviewed the half-year financial report of Alterity Therapeutics Limited (the Company) and the entities it controlled during the half-year (together the Group), which comprises the consolidated statement of financial position as at 31 December 2021, the consolidated statement of changes in equity, consolidated statement of cash flows and consolidated statement of profit or loss and other comprehensive income for the half-year ended on that date, significant accounting policies and explanatory notes and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Alterity Therapeutics Limited does not comply with the Corporations Act 2001 including:

giving a true and fair view of the Group's financial position as at 31 December 2021 and of its performance for the half-year ended on that date

complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity (ASRE 2410). Our responsibilities are further described in the Auditor’s responsibilities for the review of the half-year financial report section of our report.

We are independent of the Group in accordance with the auditor independence requirements of the Corporations Act 2001 and the ethical requirements of the Accounting Professional & Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Responsibilities of the directors for the half-year financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement whether due to fraud or error.

Auditor's responsibilities for the review of the half-year financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including giving a true and fair view of the Group's financial position as at 31 December 2021 and of its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

PricewaterhouseCoopers, ABN 52 780 433 757

2 Riverside Quay, SOUTHBANK VIC 3006, GPO Box 1331, MELBOURNE VIC 3001

T: 61 3 8603 1000, F: 61 3 8603 1999

Liability limited by a scheme approved under Professional Standards Legislation.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


PricewaterhouseCoopers


Jon Roberts	Melbourne
Partner	28 February 2022

GRAPHIC 6 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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ex99-3_001.jpg GRAPHIC begin 644 ex99-3_001.jpg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end GRAPHIC 8 ex99-3_002.jpg GRAPHIC begin 644 ex99-3_002.jpg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ex99-4_001.jpg GRAPHIC begin 644 ex99-4_001.jpg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end GRAPHIC 10 ex99-4_002.jpg GRAPHIC begin 644 ex99-4_002.jpg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end GRAPHIC 11 ex99-4_003.jpg GRAPHIC begin 644 ex99-4_003.jpg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athe-20211231.xsd XBRL SCHEMA FILE 001 - Statement - Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Statement of Financial Position (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statement of Changes in Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Disclosure - Basis of Preparation of Half-Year Report link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Significant Changes in The Current Reporting Period link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Segment Information link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Dividends link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Loss Per Share link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Interest and Other Income link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Loss for the Period link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Financial Assets and Financial Liabilities link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Equity link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Events Occurring After the Reporting Period link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Significant Estimates and Assumptions link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Covid-19 Impact on Business link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Interest and Other Income (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Loss for the Period (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Financial Assets and Financial Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Significant Changes in The Current Reporting Period (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Dividends (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Loss Per Share (Details) - Schedule of earning loss per share link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Interest and Other Income (Details) - Schedule of interest and other income link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Loss for the Period (Details) - Schedule of loss for the period link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Financial Assets and Financial Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Financial Assets and Financial Liabilities (Details) - Schedule of trade and other receivables link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Equity (Details) - Schedule of contributed equity link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Equity (Details) - Schedule of movements in ordinary share link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Equity (Details) - Schedule of details of shares issued during the current period link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Equity (Details) - Schedule of movements in accumulated losses link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Equity (Details) - Schedule of options link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Equity (Details) - Schedule of presents the movements in options granted and issued link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Equity (Details) - Schedule of fair value at grant date per option link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Equity (Details) - Schedule of options free-attaching options link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Details) - Schedule of profit after income tax to net cash flow from operating activities link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Events Occurring After the Reporting Period (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Significant Estimates and Assumptions (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 13 athe-20211231_cal.xml XBRL CALCULATION FILE EX-101.DEF 14 athe-20211231_def.xml XBRL DEFINITION FILE EX-101.LAB 15 athe-20211231_lab.xml XBRL LABEL FILE Profit or loss [abstract] Loss for the period Loss before income tax Total comprehensive loss for the period Total comprehensive income for the period Statement of financial position [abstract] Total current assets Total non-current assets Total assets Total current liabilities Total non-current liabilities Total liabilities Net assets Total equity Balance Balance Consolidated Statement of Changes in Equity (Unaudited) [Abstract] Components of equity [axis] Statement of cash flows [abstract] Net cash (outflow) from operating activities Net cash (outflow) from investing activities Net cash inflow from financing activities Net increase in cash and cash equivalents Cash and cash equivalents at the beginning of the financial year Cash and cash equivalents at end of period Cash and cash equivalents Disclosure of basis of preparation of financial statements [text block] [Abstract] Significant Changes In Current Reporting Period [Abstract] Disclosure of entity's operating segments [text block] [Abstract] Dividends [Abstract] Disclosure of earnings per share [text block] [Abstract] Schedule of earning loss per share [Abstract] Disclosure of significant judgements and assumptions made in relation to interests in other entities [text block] [Abstract] Schedule of interest and other income [Abstract] Loss For The Period [Abstract] Schedule of loss for the period [Abstract] Disclosure of financial instruments [text block] [Abstract] Schedule of trade and other receivables [Abstract] Disclosure of investments accounted for using equity method [text block] [Abstract] Schedule of contributed equity [Abstract] Schedule of movements in ordinary share [Abstract] Opening balance, shares Ending balance, shares Opening balance Ending balance Schedule of details of shares issued during the current period [Abstract] Schedule of movements in accumulated losses [Abstract] Balance at the beginning of the period Balance at the end of the period Schedule of options [Abstract] Schedule of presents the movements in options granted and issued [Abstract] Classes of share capital [axis] Schedule of fair value at grant date per option [Abstract] Schedule of options free-attaching options [Abstract] Disclosure of profit (loss) from operating activities [text block] [Abstract] Schedule of profit after income tax to net cash flow from operating activities [Abstract] Disclosure of transactions between related parties [text block] [Abstract] Disclosure of non-adjusting events after reporting period [text block] [Abstract] Disclosure of accounting judgements and estimates [text block] [Abstract] Covid 19 Impact On Business [Abstract] Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Document Type Entity Central Index Key Entity File Number Entity Registrant Name Income Interest income Other income Expenses Other operating expenses Other gains/(losses) Other comprehensive loss Other comprehensive income for the period, net of tax Loss per share for profit attributable to the ordinary equity holders of the Group: Basic loss per share (in Dollars per share) Basic loss per share Diluted loss per share (in Dollars per share) Diluted loss per share ASSETS Current assets Trade and other receivables Trade and other receivables, Current Other current assets Non-current assets Property, plant and equipment Right-of-use assets LIABILITIES Current liabilities Trade and other payables Provisions Other current liabilities Non-current liabilities Provisions Other non-current liabilities EQUITY Contributed equity Reserves Options over fully paid ordinary shares, value Accumulated losses Loss for the period Transactions with owners in their capacity as owners: Issue of ordinary shares Share-based payment expenses Transaction costs Total transactions with owners in their capacity as owners Cash flows from operating activities COVID-19 government relief Other grant received Interest received Cash flows from investing activities Cash flows from financing activities Proceeds from issues of shares and other equity securities Effects of exchange rate changes on cash and cash equivalents Intellectual property expenses General and administration expenses Research and development expenses Income tax expense Payments to suppliers and employees Payments for property, plant and equipment Transaction costs relating to issue of equity Principle elements of lease payments Contributed equity Reserves Accumulated losses Basis of preparation of half-year report Significant changes in the current reporting period Segment information Dividends Loss per share Schedule of earning loss per share Loss per share for profit attributable to the ordinary equity holders of the Group: Basic loss per share Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share: Diluted loss per share Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share: Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share Interest and other income Schedule of interest and other income Interest and other income Total Other Income R&D tax incentive COVID-19 relief Other grant Total Loss for the period Schedule of loss for the period Loss before income tax has been determined after: General and administration expenses Depreciation on fixed assets Depreciation on leased assets Employee expenses (non R&D related) Consultant and director expenses Audit, internal control and other assurance expenses Corporate compliance expenses Office rental Other administrative and office expenses Insurance expenses Share-based payment expenses Corporate advisory Total general and administration expense Research and development expenses Employee expenses Other research and development expenses Total research and development expenses Other gains and losses Foreign exchange (gain)/ loss Loss for the period Financial assets and financial liabilities Schedule of trade and other receivables R&D tax incentive receivable, Current R&D tax incentive receivable, Non-current R&D tax incentive receivable, Total Accrued interest income, Current Accrued interest income, Non-current Accrued interest income, Total Goods and services tax receivable, Current Goods and services tax receivable, Non-current Goods and services tax receivable, Total Other receivable, Current Other receivable, Non-current Other receivable, Total Trade and other receivables, Non-current Trade and other receivables, Total Equity Schedule of contributed equity Ordinary shares - fully paid, shares Ordinary shares - fully paid value Schedule of movements in ordinary share Shares issued during the year, shares Shares issued during the year Transaction costs, shares Transaction costs | $ Schedule of details of shares issued during the current period Number Issue of shares under ATM facility Issue price Issue of shares under ATM facility Amount Issue of shares under ATM facility Total number of shares issued Total value of shares issued Schedule of movements in accumulated losses Net loss for the period Schedule of options Options over fully paid ordinary shares, shares Schedule of presents the movements in options granted and issued Issued Date Number of stock option shares issued Stock option shares issued value Schedule of fair value at grant date per option Date issued Quantity Grant Date Expiry Date Exercise price Fair value at grant date per option Schedule of options free-attaching options Free-attaching options, shares Free-attaching options, value Reconciliation of profit after income tax to net cash flow from operating activities Schedule of profit after income tax to net cash flow from operating activities Loss for the period Depreciation on fixed assets Depreciation on leased assets Non-cash employee benefits expense - share-based payments Net foreign exchange differences (Increase)/decrease in provisions Increase/(decrease) in trade and other receivables Increase/(decrease) in other current assets (Increase)/decrease in trade and other payables (Increase)/decrease in other current liabilities Net cash flows used in operating activities Related party transactions Events occurring after the reporting period Significant estimates and assumptions COVID-19 impact on business Unlisted options issued to consultant [Member] Unlisted options issued to employees [Member] Unlisted options issued to employees [Member[ Date Issued One [Member] Date Issued Two [Member] Date Issued Three [Member] Ownership [Axis] Business combinations [axis] Range [axis] Company issued amount Number Of Shares Issued Price per share Dividends R&D tax incentive percentage Company annual aggregate turnover Other income Other receivables Advisory fees paid Forfeited and cancelled Research and development, description Description of other income Other income recognise amount Refundable tax offset rate value Refundable tax offset rate Research and development expenditure Lawrence Gozlan [Member] Geoffrey Kempler [Member] Dr Sinclair [Member] Mr Edwards [Member] Bottom of range [member] Top of range [member] Equity [member] Basis of Preparation of Half-Year Report [Table] Disclosure Of background and significant accounting policies [Abstract] Segment Information [Table] Segment Reporting [Abstract] Loss Per Share [Table] Earnings per share [abstract] Interest and Other Income [Abstract] Loss for the Period [Abstract] Financial Assets and Financial Liabilities [Abstract] Equity [Abstract] Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities [Table] Reconciliation of profit after income tax to net cash flow from operating activities [Abstract] Related Party Transactions [Table] Related party transactions [Abstract] Events Occurring After the Reporting Period [Table] Events Occurring after the Reporting Period [Abstract] Significant Estimates and Assumptions [Table] Significant Estimates and Assumptions [Abstract] Covid-19 Impact on Business [Table] Covid-19 Impact on Business [Abstract] Share capital [member] Equity (Details) - Schedule of presents the movements in options granted and issued [Table] Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items] Equity (Details) - Schedule of fair value at grant date per option [Table] Equity (Details) - Schedule of fair value at grant date per option [Line Items] Ownership [Domain] Related Party Transactions (Details) [Table] Related Party Transactions (Details) [Line Items] Entity's total for business combinations [member] Events Occurring After the Reporting Period (Details) [Table] Events Occurring After the Reporting Period (Details) [Line Items] Ranges [member] Significant Estimates and Assumptions (Details) [Table] Significant Estimates and Assumptions (Details) [Line Items] Opening balance. Represents the amount of expenses related to audit internal control and other assurance. COVID-19 government relief. COVID-19 relief. The amount of company annual aggregate turnover. Company issued amount. Consultant and director expenses. Corporate advisory. Represents the amount of corporate compliance expenses. Amount of fixed assets lose value as they age because they provide long-term income, these assets are expensed differently than other items. Depreciation on leased assets. Amount of capital leases can have an impact on companies' financial statements, influencing interest expense, depreciation expense, assets, and liabilities. Description of research and development. Discription of other income. Represents the amount of employee benefit expense under research and development. Exercise price. Expiry Date. Fair value at grant date per option. Free-attaching options shares. Free-attaching options value. Intellectual property expenses. Issuance of shares net of costs value. Issue of shares under ATM facility. Issue price of shares under ATM facility. Issued Date. Stock option shares issued date. Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share. Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share. Loss for the period. The amount of net cash flows used in operating activities. Amount of non-cash employee benefits expense share-based payments. Number Issue of shares under ATM facility. Number Of Shares Issued. Opening balance, shares. Number of shares quantity. Number of stock option shares issued. Ordinary shares - fully paid. Ordinary shares - fully paid, shares. The Amount of Other receivable Total. The cash inflow from the exercise of options and issue of securities. R&D Tax incentive Percentage. Refundable tax offset rate value. Research and development expenditure. Represents the amount of research and development that the entity does not separately disclose in the same statement or note. Research and development tax incentive. The amount of research and development tax incentive receivable. The amount of research and development tax incentive receivable current. The amount of research and development tax incentive receivable non-current. Retained Earnings. Share-based payment expenses. Shares issued during the year. Shares issued during the year, shares. Stock option shares issued value. Total value of shares issued. Transaction costs. Transaction costs, shares. OtherGainsAndLossesAbstract CashFlowsFromInvestingActivitiesAbstract IssuedDated LossAttributableToOrdinaryEquityHoldersOfGroupUsedInCalculatingDilutedLoss SignificantChangesInCurrentReportingPeriod ScheduleOfLossForThePeriodTableTextBlock ResearchAndDevelopmentTaxIncentiveReceivableNoncurrent OrdinarySharesFullyPaidShares DateIssuedThreeMember TotalResearchAndDevelopmentExpenses ScheduleOfMovementsInAccumulatedLossesTableTextBlock ScheduleOfDetailsOfSharesIssuedDuringTheCurrentPeriodTableTextBlock IssuedDates ProceedsFromIssuesOfSharesAndOtherEquitySecurities NumberOfStockOptionShareIssued RetainedEarning SharebasedPaymentExpenses EarningsPerSharesTableTextBlock ResearchAndDevelopmentExpenseOther TotalGeneralAndAdministrationExpense CompanyIssuedAmount DiscriptionOfOtherIncome SharesIssuedDuringPeriod ResearchAndDevelopmentTaxIncentiveReceivableCurrent OtherGrant1 UnlistedOptionsIssuedToEmployeesOneMember ScheduleOfProfitLossFromOperatingActivitiesExplanatoryTableTextBlock ScheduleOfContributedEquityTableTextBlock DisclosureOfOtherOperatingIncomeExpenseExplanatoryTableTextBlock IssuanceOfSharesNetOfCostsValue IssueOfSharesUnderATMFacility DrSinclairMember OrdinarySharesFullyPaid NetCashFlowUsedInOperatingActivities ResearchAndDevelopmentTaxIncentive LossPerShareForProfitAttributableToTheOrdinaryEquityHoldersOfTheGroupAbstract ScheduleOfFairValueAtGrantDatePerOptionTableTextBlock LossAttributableToOrdinaryEquityHoldersOfGroupUsedInCalculatingBasicLoss OtherReceivableTotal EmployeeBenefitsExpenseUnderResearchAndDevelopment TransactionCostsShares LossBeforeIncomeTaxHasBeenDeterminedAfterAbstract ResearchAndDevelopmentExpenditure GeoffreyKemplerMember NumberIssueOfSharesUnderATMFacility AuditInternalControlAndOtherAssuranceExpenses NumberOfShareIssued COVID19GovernmentRelief IntellectualPropertyExpenses CashFlowsFromFinancingActivitiesAbstract CashFlowsFromOperatingActivitiesAbstract GeneralAndAdministrationExpensesAbstract ResearchAndDevelopmentExpensesAbstract CompanyAnnualAggregateTurnover ExpensesAbstract ScheduleOfOptionsTableTextBlock FreeattachingOptionsValues DisclosureOfTradeAndOtherReceivablesTableTextBlock TransactionCostsRelatingToShareIssues AmountOfIssuedAndFullyPaid IssuePriceOfShareUnderATMFacility DateIssuedTwoMember StockOptionSharesIssuedValue MrEdwardsMember ConsultantAndDirectorExpenses ScheduleOfMovementsInOrdinaryShareTableTextBlock ExercisePrice FairValueAtGrantDatePerOption LossPerShareForProfitAttributableToTheOrdinaryEquityHoldersOfTheGroupAbstract0 ExpiryDate ResearchAndDevelopmentTaxIncentiveReceivable DateIssuedOneMember CorporateComplianceExpenses NumberOfSharesQuantity Covid19ImpactOnBusinessTextBlock RDTaxIncentivePercentage DepreciatonOnLeasedAssets RefundableTaxOffsetRateValue SharesIssuedDuringTheYearShares ScheduleOfPresentsTheMovementsInOptionsGrantedAndIssuedTableTextBlock DescriptionOfResearchAndDevelopment NumberOfShareIssuedAndFullyPaid NoncashEmployeeBenefitsExpenseSharebasedPayments UnlistedOptionsIssuedToConsultantMember DepreciationOnFixedAssets DepreciationOnLeasedAssets FreeattachingOptionsShares LossForThePeriod COVID19Relief OtherComprehensiveLossAbstract UnlistedOptionsIssuedToEmployeesMember IncomeAbstract CorporateAdvisory DividendsTextBlock LossForThePeriodTextBlock LawrenceGozlanMember TotalValueOfSharesIssued ScheduleOfOptionsFreeattachingOptionsTableTextBlock Assets Purchase of property, plant and equipment, classified as investing activities Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Trade and other non-current receivables Depreciation, right-of-use assets Profit (loss) Non-current accrued income including non-current contract assets Disclosure of basis of preparation of financial statements [text block] Accrued Income Taxes Rental expense Other operating income (expense) Other current receivables Equity Component of Operating Income [Abstract] Entity File Number Trade and other current payables Other comprehensive income Current liabilities Non-current assets [abstract] Profit (loss) before tax Tax rate effect of tax losses Dividends paid, other shares per share Top of range [member] Income from government grants Non-current receivables from taxes other than income tax Adjustments for decrease (increase) in trade and other receivables General and Administrative Expense Trade and other receivables Dividends recognised as distributions to owners Retained earnings [member] Payments of lease liabilities, classified as financing activities Disclosure of entity's operating segments [text block] Disclosure of non-adjusting events after reporting period [text block] Reserve of share-based payments Liabilities Research and development expense Other non-current receivables Issued capital Receivables from taxes other than income tax Disclosure of significant judgements and assumptions made in relation to interests in other entities [text block] Liabilities [abstract] Other Income Interest income Current Fiscal Year End Date Assets (liabilities) Payments to suppliers for goods and services and to and on behalf of employees Number of shares issued and fully paid Disclosure of transactions between related parties [text block] Basic earnings (loss) per share Retained earnings Non-current provisions Interest and Other Income [Abstract] [Standard Label] Employee benefits expense Assets [abstract] Interest received, classified as operating activities Issued capital [member] Professional fees expense Comprehensive income Right-of-use assets Increase (decrease) through share-based payment transactions, equity Disclosure of accounting judgements and estimates [text block] Current assets Reserve of exchange differences on translation [member] Foreign exchange gain (loss) Other Noncash Income Name of subsidiary Current provisions Gains (losses) on exchange differences on translation of foreign operations, net of tax Tax expense (income) Other revenue Current receivables from taxes other than income tax Trade and other current receivables Non-current liabilities Profit (loss), attributable to owners of parent Bottom of range [member] Document Fiscal Year Focus Weighted average number of ordinary shares used in calculating basic earnings per share Current accrued income including current contract assets Cash flows from (used in) operating activities Document Type Disclosure of investments accounted for using equity method [text block] Profit (loss) from operating activities Document Fiscal Period Focus Disclosure of financial instruments [text block] Effect of exchange rate changes on cash and cash equivalents Cash flows from (used in) financing activities Non-current liabilities [abstract] Property, plant and equipment Disclosure of profit (loss) from operating activities [text block] Diluted earnings (loss) per share Administrative expenses Research and Development Expense, Software (Excluding Acquired in Process Cost) Adjustments for decrease (increase) in other current assets Other current assets Number of shares issued General and administrative expense Non-current assets Other Receivables Increase (decrease) in cash and cash equivalents after effect of exchange rate changes Cash flows from (used in) investing activities Insurance expense Increase (decrease) in other provisions Entity Registrant Name Adjustments for increase (decrease) in trade and other payables Current liabilities [abstract] Adjustments for increase (decrease) in other current liabilities Diluted earnings per share [abstract] Disclosure of earnings per share [text block] Document Period End Date Other non-current liabilities Changes in equity [abstract] Amendment Flag Revenue Cash and cash equivalents Increase (decrease) through transactions with owners, equity Payments for share issue costs Entity Central Index Key Other gains (losses) Current assets [abstract] Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other current liabilities Statement of changes in equity [table] Statement of changes in equity [line items] Segments [axis] EX-101.PRE 16 athe-20211231_pre.xml XBRL PRESENTATION FILE XML 17 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1

Document And Entity Information
6 Months Ended

Dec. 31, 2021

Document Information Line Items

Entity Registrant Name ALTERITY THERAPEUTICS LTD

Document Type 6-K

Current Fiscal Year End Date --06-30

Amendment Flag false

Entity Central Index Key 0001131343

Document Period End Date Dec. 31, 2021

Document Fiscal Year Focus 2022

Document Fiscal Period Focus Q2

Entity File Number 000-49843

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 18 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited) - AUD ($)
6 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Income

Interest income $ 1,350 $ 6,553

Other income 2,359,198 1,924,389

Expenses

Intellectual property expenses (205,896) (160,304)

General and administration expenses (3,194,790) (3,673,407)

Research and development expenses (6,761,542) (5,806,841)

Other operating expenses (624) (20)

Other gains/(losses) 1,218,745 (852,232)

Loss for the period (6,583,559) (8,561,862)

Loss before income tax (6,583,559) (8,561,862)

Income tax expense

Other comprehensive loss

Other comprehensive income for the period, net of tax

Total comprehensive loss for the period $ (6,583,559) $ (8,561,862)

Loss per share for profit attributable to the ordinary equity holders of the Group:

Basic loss per share (in Dollars per share) $ (0.27) $ (0.65)

Diluted loss per share (in Dollars per share) $ (0.27) $ (0.65)

X

- References
No definition available.
+ Details

Name: athe_ExpensesAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_IncomeAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Intellectual property expenses.
+ References
No definition available.
+ Details

Name: athe_IntellectualPropertyExpenses

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_LossPerShareForProfitAttributableToTheOrdinaryEquityHoldersOfTheGroupAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_OtherComprehensiveLossAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2021-01-01
-Paragraph 66
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2021-01-01
-Paragraph 67
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_BasicEarningsLossPerShare

Namespace Prefix: ifrs-full_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B12
-Subparagraph b
-Clause ix
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 106
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 81A
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_ComprehensiveIncome

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2021-01-01
-Paragraph 66
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2021-01-01
-Paragraph 67
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DilutedEarningsLossPerShare

Namespace Prefix: ifrs-full_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of expense relating to general and administrative activities of the entity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 112
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_GeneralAndAdministrativeExpense

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 26
-IssueDate 2021-01-01
-Paragraph 35
-Subparagraph b
-Clause viii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-Subparagraph h
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 12
-IssueDate 2021-01-01
-Paragraph 79
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 12
-IssueDate 2021-01-01
-Paragraph 81
-Subparagraph c
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 82
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 12
-IssueDate 2021-01-01
-Paragraph 81
-Subparagraph c
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard
-URIDate 2021-03-24

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B13
-Subparagraph g
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B
-URIDate 2021-03-24
+ Details

Name: ifrs-full_IncomeTaxExpenseContinuingOperations

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 106
-Subparagraph d
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_ii&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B12
-Subparagraph b
-Clause viii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 81A
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_b&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 91
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_OtherComprehensiveIncome

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The gains (losses) that the entity does not separately disclose in the same statement or note.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_OtherGainsLosses

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 85
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_OtherOperatingIncomeExpense

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The profit (loss) before tax expense or income. [Refer: Profit (loss)]
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2021-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_ProfitLossBeforeTax

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 32
-IssueDate 2021-01-01
-Paragraph IE33
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 85
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_ProfitLossFromOperatingActivities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 38
-IssueDate 2021-01-01
-Paragraph 126
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_ResearchAndDevelopmentExpense

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of income arising from interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_c&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B13
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 112
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_RevenueFromInterest

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue and income classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.4)
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 19 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1

Consolidated Statement of Financial Position (Unaudited) - AUD ($)

Dec. 31, 2021

Jun. 30, 2021

Current assets

Cash and cash equivalents $ 37,002,201 $ 28,115,516

Trade and other receivables 6,260,577 4,277,677

Other current assets 1,599,963 1,095,753

Total current assets 44,862,741 33,488,946

Non-current assets

Property, plant and equipment 27,270 31,313

Right-of-use assets 41,039 65,495

Total non-current assets 68,309 96,808

Total assets 44,931,050 33,585,754

Current liabilities

Trade and other payables 3,134,160 2,502,509

Provisions 613,098 537,368

Other current liabilities 15,167 27,746

Total current liabilities 3,762,425 3,067,623

Non-current liabilities

Provisions 12,907 9,768

Other non-current liabilities 26,727 37,903

Total non-current liabilities 39,634 47,671

Total liabilities 3,802,059 3,115,294

Net assets 41,128,991 30,470,460

EQUITY

Contributed equity 213,814,776 197,447,990

Reserves 3,626,188 2,750,884

Accumulated losses (176,311,973) (169,728,414)

Total equity $ 41,128,991 $ 30,470,460

X

- Definition
The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 13
-IssueDate 2021-01-01
-Paragraph 93
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 13
-IssueDate 2021-01-01
-Paragraph 93
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 13
-IssueDate 2021-01-01
-Paragraph 93
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 55
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_Assets

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 45
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B13
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 54
-Subparagraph i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_CashAndCashEquivalents

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B12
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 66
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24
+ Details

Name: ifrs-full_CurrentAssets

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: ifrs-full_CurrentAssetsAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period. Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B12
-Subparagraph b
-Clause iii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 69
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24
+ Details

Name: ifrs-full_CurrentLiabilities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: ifrs-full_CurrentLiabilitiesAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 54
-Subparagraph l
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_l&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_CurrentProvisions

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of residual interest in the assets of the entity after deducting all its liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 24
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 32
-Subparagraph a
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 13
-IssueDate 2021-01-01
-Paragraph 93
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 13
-IssueDate 2021-01-01
-Paragraph 93
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 13
-IssueDate 2021-01-01
-Paragraph 93
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 55
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard
-URIDate 2021-03-24

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_Equity

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: ifrs-full_EquityAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The nominal value of capital issued.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_IssuedCapital

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 13
-IssueDate 2021-01-01
-Paragraph 93
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 13
-IssueDate 2021-01-01
-Paragraph 93
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 13
-IssueDate 2021-01-01
-Paragraph 93
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 55
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_Liabilities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of assets less the amount of liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph IG63
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG63&doctype=Implementation%20Guidance
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 112
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_NetAssetsLiabilities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of assets that do not meet the definition of current assets. [Refer: Current assets]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 66
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B12
-Subparagraph b
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24
+ Details

Name: ifrs-full_NoncurrentAssets

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: ifrs-full_NoncurrentAssetsAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B12
-Subparagraph b
-Clause iv
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 69
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24
+ Details

Name: ifrs-full_NoncurrentLiabilities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: ifrs-full_NoncurrentLiabilitiesAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 54
-Subparagraph l
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_l&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_NoncurrentProvisions

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 55
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_OtherCurrentAssets

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 55
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_OtherCurrentLiabilities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 55
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_OtherNoncurrentLiabilities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 16
-IssueDate 2021-01-01
-Paragraph 73
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 54
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_PropertyPlantAndEquipment

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
A component of equity resulting from share-based payments.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_ReserveOfSharebasedPayments

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
A component of equity representing the entity's cumulative undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph IG6
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance
-URIDate 2021-03-24
+ Details

Name: ifrs-full_RetainedEarnings

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 16
-IssueDate 2021-01-01
-Paragraph 53
-Subparagraph j
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_RightofuseAssets

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 54
-Subparagraph k
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_TradeAndOtherCurrentPayables

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 54
-Subparagraph h
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_TradeAndOtherCurrentReceivables

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 20 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1

Consolidated Statement of Changes in Equity (Unaudited) - AUD ($)

Contributed equity

Reserves

Accumulated losses

Total

Balance at Jun. 30, 2020 $ 160,703,754 $ 866,121 $ (154,419,061) $ 7,150,814

Loss for the period (8,561,862) (8,561,862)

Total comprehensive income for the period (8,561,862) (8,561,862)

Transactions with owners in their capacity as owners:

Issue of ordinary shares 36,562,055 36,562,055

Share-based payment expenses 1,577,720 1,577,720

Transaction costs (2,372,505) (2,372,505)

Total transactions with owners in their capacity as owners 34,189,550 1,577,720 35,767,270

Balance at Dec. 30, 2020 194,893,304 2,443,841 (162,980,923) 34,356,222

Balance at Jun. 30, 2021 197,447,990 2,750,884 (169,728,414) 30,470,460

Total comprehensive income for the period (6,583,559)

Balance at Dec. 31, 2021 41,128,991

Balance at Jun. 30, 2021 197,447,990 2,750,884 (169,728,414) 30,470,460

Loss for the period (6,583,559) (6,583,559)

Total comprehensive income for the period (6,583,559) (6,583,559)

Transactions with owners in their capacity as owners:

Issue of ordinary shares 17,176,040 17,176,040

Share-based payment expenses 875,304 875,304

Transaction costs (809,254) (809,254)

Total transactions with owners in their capacity as owners 16,366,786 875,304 17,242,090

Balance at Dec. 30, 2021 $ 213,814,776 $ 3,626,188 $ (176,311,973) $ 41,128,991

X

- Definition
Issuance of shares net of costs value.
+ References
No definition available.
+ Details

Name: athe_IssuanceOfSharesNetOfCostsValue

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Share-based payment expenses.
+ References
No definition available.
+ Details

Name: athe_SharebasedPaymentExpenses

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: ifrs-full_ChangesInEquityAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B12
-Subparagraph b
-Clause ix
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 106
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 81A
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_ComprehensiveIncome

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of residual interest in the assets of the entity after deducting all its liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 24
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 32
-Subparagraph a
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 13
-IssueDate 2021-01-01
-Paragraph 93
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 13
-IssueDate 2021-01-01
-Paragraph 93
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 13
-IssueDate 2021-01-01
-Paragraph 93
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 55
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard
-URIDate 2021-03-24

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_Equity

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 106
-Subparagraph d
-Clause iii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) in equity resulting from transactions with owners.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 106
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2021-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2021-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard
-URIDate 2021-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2023-01-01
-Name IFRS
-Number 17
-IssueDate 2021-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2021-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2021-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_ProfitLoss

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 21 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1

Consolidated Statement of Cash Flows (Unaudited) - AUD ($)
6 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Cash flows from operating activities

Payments to suppliers and employees $ (9,002,490) $ (7,385,267)

COVID-19 government relief 103,338 53,564

Other grant received 225,746

Interest received 1,352 1,397

Net cash (outflow) from operating activities (8,672,054) (7,330,306)

Cash flows from investing activities

Payments for property, plant and equipment (2,559) (2,494)

Net cash (outflow) from investing activities (2,559) (2,494)

Cash flows from financing activities

Proceeds from issues of shares and other equity securities 17,176,040 36,562,055

Transaction costs relating to issue of equity (809,254) (2,372,505)

Principle elements of lease payments (23,755) (24,249)

Net cash inflow from financing activities 16,343,031 34,165,301

Net increase in cash and cash equivalents 7,668,418 26,832,501

Cash and cash equivalents at the beginning of the financial year 28,115,516 9,196,892

Effects of exchange rate changes on cash and cash equivalents 1,218,267 (987,215)

Cash and cash equivalents at end of period $ 37,002,201 $ 35,042,178

X

- Definition
COVID-19 government relief.
+ References
No definition available.
+ Details

Name: athe_COVID19GovernmentRelief

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_CashFlowsFromFinancingActivitiesAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_CashFlowsFromInvestingActivitiesAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_CashFlowsFromOperatingActivitiesAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from the exercise of options and issue of securities.
+ References
No definition available.
+ Details

Name: athe_ProceedsFromIssuesOfSharesAndOtherEquitySecurities

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 45
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B13
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 54
-Subparagraph i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_CashAndCashEquivalents

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 10
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 50
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_CashFlowsFromUsedInFinancingActivities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 10
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 50
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_CashFlowsFromUsedInInvestingActivities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 10
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 50
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_CashFlowsFromUsedInOperatingActivities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 25
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 28
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 45
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_IncreaseDecreaseInCashAndCashEquivalents

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from interest received, classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 31
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_InterestReceivedClassifiedAsOperatingActivities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for share issue costs.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 17
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_PaymentsForShareIssueCosts

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 17
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for payments to suppliers for goods and services and to, and on behalf of, employees.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 14
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_14&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 16
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of income recognised in relation to government grants. [Refer: Government grants]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 20
-IssueDate 2021-01-01
-Paragraph 39
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_b&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_RevenueFromGovernmentGrants

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 22 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1

Basis of Preparation of Half-Year Report
6 Months Ended

Dec. 31, 2021

Disclosure Of background and significant accounting policies [Abstract]

Basis of preparation of half-year report
1 Basis of preparation of half-year report

This condensed consolidated interim report for the half-year reporting period ended 31 December 2021 has been prepared in accordance with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Act 2001. These financial statements also comply with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), as applicable to interim financial reporting.

This condensed consolidated interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2021 and any public announcements made by Alterity Therapeutics Limited (the “Group”) during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period except as discussed below.

(a) New and amended standards adopted by the Group

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ‘AASB’ that are mandatory for the current reporting period.

The adoption of these standards has not had any impact on the disclosures or amounts reported in these financial statements.

X

- References
No definition available.
+ Details

Name: athe_BasisofPreparationofHalfYearReportLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The disclosure of the basis used for the preparation of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 10
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory

Namespace Prefix: ifrs-full_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1

Significant Changes in The Current Reporting Period
6 Months Ended

Dec. 31, 2021

Significant Changes In Current Reporting Period [Abstract]

Significant changes in the current reporting period
2 Significant changes in the current reporting period

In July 2021, the Group raised A$17,176,040 by issuing 322,857,900 shares at $0.0532 per share through the use of its “at-the-market” (ATM) facility to fund working capital and progress its research and development activities.

There have been no other significant changes in the state of affairs of the Company during the period.

X

- References
No definition available.
+ Details

Name: athe_SignificantChangesInCurrentReportingPeriod

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_SignificantChangesInCurrentReportingPeriodAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1

Segment Information
6 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Segment information
3 Segment information

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer of Alterity Therapeutics Limited. For the current and previous reporting periods, the Group operated in one segment, being research and development in the field of Parkinsonian and other neurodegenerative disorders.

X

- References
No definition available.
+ Details

Name: athe_SegmentInformationLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Section Disclosure
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory

Namespace Prefix: ifrs-full_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1

Dividends
6 Months Ended

Dec. 31, 2021

Dividends [Abstract]

Dividends
4 Dividends

The Group has not declared any dividends in the period ended 31 December 2021 (2020: nil)

X

- References
No definition available.
+ Details

Name: athe_DividendsTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DividendsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1

Loss Per Share
6 Months Ended

Dec. 31, 2021

Earnings per share [abstract]

Loss per share
5 Loss per share

(a) Basic and diluted loss per share

31 December 31 December

2021
Cents
2020
Cents

Loss per share for profit attributable to the ordinary equity holders of the Group:

Basic loss per share (0.27 ) (0.65 )

Diluted loss per share (0.27 ) (0.65 )

(b) Reconciliation of loss used in calculating loss per share

31 December 31 December

2021
A$ 2020
A$

Basic loss per share

Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share: (6,583,559 ) (8,561,862 )

Diluted loss per share

Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share: (6,583,559 ) (8,561,862 )

(c) Weighted average number of shares used as the denominator

31 December
2021
Number 31 December
2020
Number

Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share 2,405,110,327 1,323,432,372

Options that are considered to be potential ordinary shares are excluded from the weighted average number of ordinary shares used in the calculation of basic loss per share. Where dilutive, potential ordinary shares are included in the calculation of diluted loss per share. All the options on issue do not have the effect to dilute the loss per share. Therefore, they have been excluded from the calculation of diluted loss per share.

X

- References
No definition available.
+ Details

Name: athe_LossPerShareLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2021-01-01
-Section Disclosure
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DisclosureOfEarningsPerShareExplanatory

Namespace Prefix: ifrs-full_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1

Interest and Other Income
6 Months Ended

Dec. 31, 2021

Interest and Other Income [Abstract]

Interest and other income
6 Interest and other income

31 December 31 December

2021
A$ 2020
A$

Interest and other income

Interest income 1,350 6,553

1,350 6,553

Other Income

R&D tax incentive 2,133,452 1,883,325

COVID-19 relief
-
41,064

Other grant ⁽¹⁾ 225,746
-

2,359,198 1,924,389

¹ Other grants relates to the receipt of grant funding awarded by Michael J. Fox Foundation during the period ended 31 December 2021.

X

- References
No definition available.
+ Details

Name: ifrs-full_ClassesOfCashPaymentsAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The disclosure of significant judgements and assumptions made in relation to interests in other entities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph 7
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory

Namespace Prefix: ifrs-full_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1

Loss for the Period
6 Months Ended

Dec. 31, 2021

Loss for the Period [Abstract]

Loss for the period
7 Loss for the period

31 December 31 December

2021
A$ 2020
A$

Loss before income tax has been determined after:

General and administration expenses

Depreciation on fixed assets 6,602 12,417

Depreciation on leased assets 24,934 23,215

Employee expenses (non R&D related) 370,564 376,220

Consultant and director expenses 242,563 387,310

Audit, internal control and other assurance expenses 109,398 115,798

Corporate compliance expenses 217,776 372,697

Office rental 30,458 66,664

Other administrative and office expenses 503,885 332,784

Insurance expenses 324,798 258,582

Share-based payment expenses 875,304 1,577,720

Corporate advisory 488,508 150,000

3,194,790 3,673,407

Research and development expenses

Employee expenses 1,192,238 1,072,468

Other research and development expenses¹ 5,569,304 4,734,373

6,761,542 5,806,841

Other gains and losses

Foreign exchange (gain)/ loss (1,218,745 ) 852,232

(1,218,745 ) 852,232

⁽¹⁾ Other research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.

X

- References
No definition available.
+ Details

Name: athe_LossForThePeriodTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: ifrs-full_BasicEarningsPerShareAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1

Financial Assets and Financial Liabilities
6 Months Ended

Dec. 31, 2021

Financial Assets and Financial Liabilities [Abstract]

Financial assets and financial liabilities
8 Financial assets and financial liabilities

(a) Trade and other receivables

31 December
2021 30 June
2021

Current Non-
current Total Current Non-
current Total

A$ A$ A$ A$ A$ A$

R&D tax incentive receivable 6,259,819
 -
6,259,819 4,126,364
 -
4,126,364

Accrued interest income 267
-
267 269
-
269

Goods and services tax receivable 491
-
491 47,706
-
47,706

Other receivable
-

-

-
103,338
-
103,338

6,260,577
-
6,260,577 4,277,677
-
4,277,677

R&D tax incentive receivable represents the amount of R&D tax incentive the Group expects to recover. For further details, see note 13(a).

A 43.5% R&D Tax incentive refundable tax offset is available to eligible small companies with an annual aggregate turnover of less than $20 million. For the year ended 30 June 2021 and half-year ended 31 December 2021, the Group recorded $4,126,364 and $2,133,722 respectively in other income and receivables.

(i) Classification as trade and other receivables

Trade receivables and other receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. If collection of the amounts is expected in one year or less they are classified as current assets. If not, they are presented as non-current assets. Trade and other receivables are generally due for settlement within one year and therefore are all classified as current.

(b) Recognised fair value measurements

The financial instruments recognised at fair value in the statement of financial position have been analysed and classified using a fair value hierarchy reflecting the significance of the inputs used in making the measurements.

The fair value hierarchy consists of the following levels:

● quoted prices in active markets for identical assets or liabilities (Level 1);

● inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices) (Level 2); and

● inputs for the asset or liability that are not based on observable market data (unobservable inputs) (Level3).

During the period, none of the Group’s assets and liabilities had their fair value determined using the fair value hierarchy. No transfers between the levels of the fair value hierarchy occurred during the current or previous periods.

X

- Definition
The entire disclosure for financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 7
-IssueDate 2021-01-01
-Section Scope
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DisclosureOfFinancialInstrumentsExplanatory

Namespace Prefix: ifrs-full_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1

Equity
6 Months Ended

Dec. 31, 2021

Equity [Abstract]

Equity
9 Equity

(a) Contributed equity

31 December
2021
Shares 30 June
2021
Shares 31 December
2021
A$ 30 June
2021
A$

Ordinary shares - fully paid 2,406,874,578 2,084,016,678 213,814,776 197,447,990

Movements in ordinary share:

Details Number of shares A$

Opening balance 1 July 2021 2,084,016,678 197,447,990

Shares issued during the year 322,857,900 17,176,040

Transaction costs
-
(809,254 )

Balance 31 December 2021 2,406,874,578 213,814,776

Details of shares issued during the current period:

Issue price Amount

Details Number A$ A$

2-Jul-2021 Issue of shares under ATM facility 322,857,900 0.0532 17,176,040

322,857,900 17,176,040

(b) Accumulated losses

Movements in accumulated losses were as follows:

31 December
2021
A$ 31 December
2020
A$

Balance at the beginning of the period 169,728,414 154,419,061

Net loss for the period 6,583,559 8,561,862

Balance at the end of the period 176,311,973 162,980,923

(c) Reserves

(i) Options

31 December
2021
Options 30 June
2021
Options 31 December
2021
A$ 30 June
2021
A$

Options over fully paid ordinary shares 205,692,720 160,542,720 3,626,188 2,750,884

The table below presents the movements in options granted and issued during the half-year ended 31 December 2021.

Details Number Amount
A$

8-Dec-2021 Unlisted options issued to consultant 12,000,000 326,544

8-Dec-2021 Unlisted options issued to employees 13,900,000 13,326

8-Dec-2021 Unlisted options issued to employees 19,250,000 18,816

45,150,000 358,686

Fair value at grant

Date issued Quantity Grant Date Expiry Date Exercise price ($) date per option ($) *

08-Dec-2021 12,000,000 31-Jul-2021 31-Jul-2024 $ 0.0700 $ 0.0272

08-Dec-2021 13,900,000 29-Nov-2021 29-Nov-2026 $ 0.0238 $ 0.0210

08-Dec-2021 19,250,000 29-Nov-2021 29-Nov-2026 $ 0.0375 $ 0.0214

45,150,000

* Rounded to the nearest four decimal points.

(ii) Free-attaching options

31 December
2021
Options 30 June
2021
Options 31 December
2021
A$ 30 June
2021
A$

Free-attaching options 674,694,939 674,694,939
 -

 -

There was no movement during the half-year ended 31 December 2021.

There have been no other options over fully paid ordinary shares issued, exercised or forfeited during the current period.

(iii) Nature and purpose of reserves

The share-based payments reserve is used to recognise the fair value of options issued to employees and consultants but not exercised.

X

- Definition
The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 10
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory

Namespace Prefix: ifrs-full_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: ifrs-full_EquityAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1

Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities
6 Months Ended

Dec. 31, 2021

Reconciliation of profit after income tax to net cash flow from operating activities [Abstract]

Reconciliation of profit after income tax to net cash flow from operating activities
10 Reconciliation of profit after income tax to net cash flow from operating activities

31 December
2021
A$ 31 December
2020
A$

Loss for the period 6,583,559 8,561,862

Depreciation on fixed assets (6,602 ) (12,417 )

Depreciation on leased assets (24,934 ) (23,215 )

Non-cash employee benefits expense - share-based payments (875,304 ) (1,577,720 )

Net foreign exchange differences 1,218,745 (987,215 )

(Increase)/decrease in provisions (78,869 ) (62,547 )

Increase/(decrease) in trade and other receivables 1,982,900 1,916,120

Increase/(decrease) in other current assets 504,210 (229,445 )

(Increase)/decrease in trade and other payables (631,651 ) (255,505 )

(Increase)/decrease in other current liabilities
-
388

8,672,054 7,330,306

X

- References
No definition available.
+ Details

Name: athe_ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivitiesLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The disclosure of profit (loss) from operating activities. [Refer: Profit (loss) from operating activities]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 10
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory

Namespace Prefix: ifrs-full_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1

Related Party Transactions
6 Months Ended

Dec. 31, 2021

Related party transactions [Abstract]

Related party transactions
11 Related party transactions

During the half-year ended 31 December 2021 the Group paid a total of A$37,500 (excl. GST) in corporate advisory fees to Montoya Pty Ltd, an associated entity of Mr. Lawrence Gozlan, a director of the Group and A$101,400 (excl. GST) in corporate advisory fees to Kemdev Pty Ltd, an associated entity of Mr. Geoffrey Kempler. A$75,000 (excl. GST) is payable to Kemdev Pty Ltd at the end of the period.

There were no other related party transactions other than those related to director and key management personnel remuneration and equity and transactions by the Group and its subsidiaries.

X

- References
No definition available.
+ Details

Name: athe_RelatedPartyTransactionsLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 24
-IssueDate 2021-01-01
-Paragraph 18
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory

Namespace Prefix: ifrs-full_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1

Events Occurring After the Reporting Period
6 Months Ended

Dec. 31, 2021

Events Occurring after the Reporting Period [Abstract]

Events occurring after the reporting period
12 Events occurring after the reporting period

Resignation of Non-Executive Directors

On 4 January 2022 Dr. David Sinclair and Mr. Tristan Edwards resigned as Non-Executive Directors of the Group.

Options issued under the ESOP Plan to Dr. Sinclair (7,000,000) and Mr. Edwards (7,000,000) as approved in September 2020 were forfeited and cancelled upon resignation.

No other matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group or economic entity in subsequent financial periods.

X

- References
No definition available.
+ Details

Name: athe_EventsOccurringAftertheReportingPeriodLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [member]]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 10
-IssueDate 2021-01-01
-Paragraph 21
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory

Namespace Prefix: ifrs-full_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1

Significant Estimates and Assumptions
6 Months Ended

Dec. 31, 2021

Significant Estimates and Assumptions [Abstract]

Significant estimates and assumptions
13 Significant estimates and assumptions

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances.

The Company and its two wholly-owned subsidiaries (the “Group”) makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial period are discussed below.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period.

(a) R&D tax incentives

The Australian Government replaced the research and development tax concession with the research and development tax incentive from 1 July 2011. The provisions provide refundable or non-refundable tax offsets. The research and development tax incentive applies to expenditure incurred and the use of depreciating assets in an income year commencing on or after 1 July 2011. A 43.5% refundable tax offset will be available to eligible small companies with an annual aggregate turnover of less than $20 million. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. For the period to 31 December 2021 the Group has recorded an item in other income of $A2,133,452 (31 Dec 2020:
$1,883,325) to recognise this amount which relates to this period.

On 7 October 2020, the Treasury Laws Amendment (A Tax Plan for the Covid-19 Economic Recovery Bill 2020) was introduced to the Parliament. This legislation supersedes the Treasury Laws Amendment (Research and Development Incentive) Bill 2019. Under the amendments, commencing 1 July 2021, the refundable tax offset rate for companies with aggregated turnover below $20 million would become 18.5% above the companies tax rate and the R&D expenditure threshold would be increased from $100 million to $150 million.

Management does not consider the rate reduction or the refund cap has material impact towards the Group’s R&D tax incentive claim for the next financial year going forward. The rate reduction has no material impact on the R&D tax incentive estimate reported in financial statements for the half-year ended 31 December 2021.

X

- References
No definition available.
+ Details

Name: athe_SignificantEstimatesandAssumptionsLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 10
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory

Namespace Prefix: ifrs-full_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1

Covid-19 Impact on Business
6 Months Ended

Dec. 31, 2021

Covid-19 Impact on Business [Abstract]

COVID-19 impact on business
14 COVID-19 impact on business

The COVID-19 pandemic has caused uncertainty in global markets and its impact is unable to be reliably measured. However, COVID-19 has had limited effect thus far on the Group’s operation. Development activities have continued with minimal disruption.

X

- References
No definition available.
+ Details

Name: athe_Covid19ImpactOnBusinessTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_Covid19ImpactonBusinessLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1

Loss Per Share (Tables)
6 Months Ended

Dec. 31, 2021

Disclosure of earnings per share [text block] [Abstract]

Schedule of earning loss per share

31 December 31 December

2021
Cents
2020
Cents

Loss per share for profit attributable to the ordinary equity holders of the Group:

Basic loss per share (0.27 ) (0.65 )

Diluted loss per share (0.27 ) (0.65 )

31 December 31 December

2021
A$ 2020
A$

Basic loss per share

Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share: (6,583,559 ) (8,561,862 )

Diluted loss per share

Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share: (6,583,559 ) (8,561,862 )

31 December
2021
Number 31 December
2020
Number

Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share 2,405,110,327 1,323,432,372

X

- References
No definition available.
+ Details

Name: athe_DisclosureOfEarningsPerShareTextBlockAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_EarningsPerSharesTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1

Interest and Other Income (Tables)
6 Months Ended

Dec. 31, 2021

Interest and Other Income [Abstract]

Schedule of interest and other income

31 December 31 December

2021
A$ 2020
A$

Interest and other income

Interest income 1,350 6,553

1,350 6,553

Other Income

R&D tax incentive 2,133,452 1,883,325

COVID-19 relief
-
41,064

Other grant ⁽¹⁾ 225,746
-

2,359,198 1,924,389

¹ Other grants relates to the receipt of grant funding awarded by Michael J. Fox Foundation during the period ended 31 December 2021.

X

- References
No definition available.
+ Details

Name: athe_DisclosureOfOtherOperatingIncomeExpenseExplanatoryTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: ifrs-full_ClassesOfCashPaymentsAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1

Loss for the Period (Tables)
6 Months Ended

Dec. 31, 2021

Loss for the Period [Abstract]

Schedule of loss for the period

31 December 31 December

2021
A$ 2020
A$

Loss before income tax has been determined after:

General and administration expenses

Depreciation on fixed assets 6,602 12,417

Depreciation on leased assets 24,934 23,215

Employee expenses (non R&D related) 370,564 376,220

Consultant and director expenses 242,563 387,310

Audit, internal control and other assurance expenses 109,398 115,798

Corporate compliance expenses 217,776 372,697

Office rental 30,458 66,664

Other administrative and office expenses 503,885 332,784

Insurance expenses 324,798 258,582

Share-based payment expenses 875,304 1,577,720

Corporate advisory 488,508 150,000

3,194,790 3,673,407

Research and development expenses

Employee expenses 1,192,238 1,072,468

Other research and development expenses¹ 5,569,304 4,734,373

6,761,542 5,806,841

Other gains and losses

Foreign exchange (gain)/ loss (1,218,745 ) 852,232

(1,218,745 ) 852,232

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfLossForThePeriodTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: ifrs-full_BasicEarningsPerShareAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1

Financial Assets and Financial Liabilities (Tables)
6 Months Ended

Dec. 31, 2021

Financial Assets and Financial Liabilities [Abstract]

Schedule of trade and other receivables

31 December
2021 30 June
2021

Current Non-
current Total Current Non-
current Total

A$ A$ A$ A$ A$ A$

R&D tax incentive receivable 6,259,819
 -
6,259,819 4,126,364
 -
4,126,364

Accrued interest income 267
-
267 269
-
269

Goods and services tax receivable 491
-
491 47,706
-
47,706

Other receivable
-

-

-
103,338
-
103,338

6,260,577
-
6,260,577 4,277,677
-
4,277,677

X

- References
No definition available.
+ Details

Name: athe_DisclosureOfTradeAndOtherReceivablesTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1

Equity (Tables)
6 Months Ended

Dec. 31, 2021

Equity [Abstract]

Schedule of contributed equity

31 December
2021
Shares 30 June
2021
Shares 31 December
2021
A$ 30 June
2021
A$

Ordinary shares - fully paid 2,406,874,578 2,084,016,678 213,814,776 197,447,990

Schedule of movements in ordinary share

Details Number of shares A$

Opening balance 1 July 2021 2,084,016,678 197,447,990

Shares issued during the year 322,857,900 17,176,040

Transaction costs
-
(809,254 )

Balance 31 December 2021 2,406,874,578 213,814,776

Schedule of details of shares issued during the current period

Issue price Amount

Details Number A$ A$

2-Jul-2021 Issue of shares under ATM facility 322,857,900 0.0532 17,176,040

322,857,900 17,176,040

Schedule of movements in accumulated losses

31 December
2021
A$ 31 December
2020
A$

Balance at the beginning of the period 169,728,414 154,419,061

Net loss for the period 6,583,559 8,561,862

Balance at the end of the period 176,311,973 162,980,923

Schedule of options

31 December
2021
Options 30 June
2021
Options 31 December
2021
A$ 30 June
2021
A$

Options over fully paid ordinary shares 205,692,720 160,542,720 3,626,188 2,750,884

Schedule of presents the movements in options granted and issued

Details Number Amount
A$

8-Dec-2021 Unlisted options issued to consultant 12,000,000 326,544

8-Dec-2021 Unlisted options issued to employees 13,900,000 13,326

8-Dec-2021 Unlisted options issued to employees 19,250,000 18,816

45,150,000 358,686

Schedule of fair value at grant date per option

Fair value at grant

Date issued Quantity Grant Date Expiry Date Exercise price ($) date per option ($) *

08-Dec-2021 12,000,000 31-Jul-2021 31-Jul-2024 $ 0.0700 $ 0.0272

08-Dec-2021 13,900,000 29-Nov-2021 29-Nov-2026 $ 0.0238 $ 0.0210

08-Dec-2021 19,250,000 29-Nov-2021 29-Nov-2026 $ 0.0375 $ 0.0214

45,150,000

Schedule of options free-attaching options

31 December
2021
Options 30 June
2021
Options 31 December
2021
A$ 30 June
2021
A$

Free-attaching options 674,694,939 674,694,939
 -

 -

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfContributedEquityTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfDetailsOfSharesIssuedDuringTheCurrentPeriodTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfFairValueAtGrantDatePerOptionTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfMovementsInAccumulatedLossesTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfMovementsInOrdinaryShareTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfOptionsFreeattachingOptionsTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfOptionsTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfPresentsTheMovementsInOptionsGrantedAndIssuedTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: ifrs-full_EquityAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1

Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Tables)
6 Months Ended

Dec. 31, 2021

Disclosure of profit (loss) from operating activities [text block] [Abstract]

Schedule of profit after income tax to net cash flow from operating activities

31 December
2021
A$ 31 December
2020
A$

Loss for the period 6,583,559 8,561,862

Depreciation on fixed assets (6,602 ) (12,417 )

Depreciation on leased assets (24,934 ) (23,215 )

Non-cash employee benefits expense - share-based payments (875,304 ) (1,577,720 )

Net foreign exchange differences 1,218,745 (987,215 )

(Increase)/decrease in provisions (78,869 ) (62,547 )

Increase/(decrease) in trade and other receivables 1,982,900 1,916,120

Increase/(decrease) in other current assets 504,210 (229,445 )

(Increase)/decrease in trade and other payables (631,651 ) (255,505 )

(Increase)/decrease in other current liabilities
-
388

8,672,054 7,330,306

X

- References
No definition available.
+ Details

Name: athe_DisclosureOfProfitLossFromOperatingActivitiesTextBlockAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfProfitLossFromOperatingActivitiesExplanatoryTableTextBlock

Namespace Prefix: athe_

Data Type: dtr:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1

Significant Changes in The Current Reporting Period (Details)
1 Months Ended

Jul. 31, 2021

AUD ($)

$ / shares

shares

Significant Changes In Current Reporting Period [Abstract]

Company issued amount | $ $ 17,176,040

Number Of Shares Issued | shares 322,857,900

Price per share | $ / shares $ 0.0532

X

- Definition
Company issued amount.
+ References
No definition available.
+ Details

Name: athe_CompanyIssuedAmount

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number Of Shares Issued.
+ References
No definition available.
+ Details

Name: athe_NumberOfShareIssued

Namespace Prefix: athe_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: athe_SignificantChangesInCurrentReportingPeriodAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of dividends paid per other share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 34
-IssueDate 2021-01-01
-Paragraph 16A
-Subparagraph f
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=34&code=ifrs-tx-2021-en-r&anchor=para_16A_f&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DividendsPaidOtherSharesPerShare

Namespace Prefix: ifrs-full_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 43 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1

Dividends (Details) - USD ($)
6 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Dividends [Abstract]

Dividends

X

- Definition
The amount of dividends recognised as distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 107
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_107&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DividendsPaid

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DividendsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1

Loss Per Share (Details) - Schedule of earning loss per share - AUD ($)
6 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Loss per share for profit attributable to the ordinary equity holders of the Group:

Basic loss per share $ (0.27) $ (0.65)

Diluted loss per share $ (0.27) $ (0.65)

Basic loss per share

Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share: $ (6,583,559) $ (8,561,862)

Diluted loss per share

Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share: $ (6,583,559) $ (8,561,862)

Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share 2,405,110,327 1,323,432,372

X

- Definition
Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share.
+ References
No definition available.
+ Details

Name: athe_LossAttributableToOrdinaryEquityHoldersOfGroupUsedInCalculatingBasicLoss

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share.
+ References
No definition available.
+ Details

Name: athe_LossAttributableToOrdinaryEquityHoldersOfGroupUsedInCalculatingDilutedLoss

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_LossPerShareForProfitAttributableToTheOrdinaryEquityHoldersOfTheGroupAbstract0

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2021-01-01
-Paragraph 66
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2021-01-01
-Paragraph 67
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_BasicEarningsLossPerShare

Namespace Prefix: ifrs-full_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: ifrs-full_BasicEarningsPerShareAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2021-01-01
-Paragraph 66
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2021-01-01
-Paragraph 67
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DilutedEarningsLossPerShare

Namespace Prefix: ifrs-full_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: ifrs-full_DilutedEarningsPerShareAbstract

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2021-01-01
-Paragraph 70
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_WeightedAverageShares

Namespace Prefix: ifrs-full_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 45 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1

Interest and Other Income (Details) - Schedule of interest and other income - AUD ($)
6 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Interest and other income

Interest income $ 1,350 $ 6,553

Total 1,350 6,553

Other Income

R&D tax incentive 2,133,452 1,883,325

COVID-19 relief 41,064

Other grant ^[1] 225,746

Total $ 2,359,198 $ 1,924,389

[1] Other grants relates to the receipt of grant funding awarded by Michael J. Fox Foundation during the period ended 31 December 2021.

X

- Definition
COVID-19 relief.
+ References
No definition available.
+ Details

Name: athe_COVID19Relief

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_OtherGrant1

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 112
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_OtherRevenue

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 32
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 33
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 34
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 82
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2021-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard
-URIDate 2021-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard
-URIDate 2021-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2021-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2021-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24
+ Details

Name: ifrs-full_Revenue

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of income arising from interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_c&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B13
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 112
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_RevenueFromInterest

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InterestAndOtherIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 46 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1

Loss for the Period (Details) - Schedule of loss for the period - AUD ($)
6 Months Ended

Dec. 31, 2021

Dec. 31, 2020

General and administration expenses

Depreciation on fixed assets $ 6,602 $ 12,417

Depreciation on leased assets 24,934 23,215

Employee expenses (non R&D related) 370,564 376,220

Consultant and director expenses 242,563 387,310

Audit, internal control and other assurance expenses 109,398 115,798

Corporate compliance expenses 217,776 372,697

Office rental 30,458 66,664

Other administrative and office expenses 503,885 332,784

Insurance expenses 324,798 258,582

Share-based payment expenses 875,304 1,577,720

Corporate advisory 488,508 150,000

Total general and administration expense 3,194,790 3,673,407

Research and development expenses

Employee expenses 1,192,238 1,072,468

Other research and development expenses ^[1] 5,569,304 4,734,373

Total research and development expenses 6,761,542 5,806,841

Other gains and losses

Foreign exchange (gain)/ loss (1,218,745) 852,232

Loss for the period $ (1,218,745) $ 852,232

[1] Other research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.

X

- Definition
Represents the amount of expenses related to audit internal control and other assurance.
+ References
No definition available.
+ Details

Name: athe_AuditInternalControlAndOtherAssuranceExpenses

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Consultant and director expenses.
+ References
No definition available.
+ Details

Name: athe_ConsultantAndDirectorExpenses

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Corporate advisory.
+ References
No definition available.
+ Details

Name: athe_CorporateAdvisory

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the amount of corporate compliance expenses.
+ References
No definition available.
+ Details

Name: athe_CorporateComplianceExpenses

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Depreciation on leased assets.
+ References
No definition available.
+ Details

Name: athe_DepreciationOnLeasedAssets

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the amount of employee benefit expense under research and development.
+ References
No definition available.
+ Details

Name: athe_EmployeeBenefitsExpenseUnderResearchAndDevelopment

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_GeneralAndAdministrationExpensesAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Loss for the period.
+ References
No definition available.
+ Details

Name: athe_LossForThePeriod

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_OtherGainsAndLossesAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the amount of research and development that the entity does not separately disclose in the same statement or note.
+ References
No definition available.
+ Details

Name: athe_ResearchAndDevelopmentExpenseOther

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_ResearchAndDevelopmentExpensesAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_TotalGeneralAndAdministrationExpense

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_TotalResearchAndDevelopmentExpenses

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expenses that the entity classifies as being administrative.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 26
-IssueDate 2021-01-01
-Paragraph 35
-Subparagraph b
-Clause vi
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_vi&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 99
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_AdministrativeExpense

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 16
-IssueDate 2021-01-01
-Paragraph 53
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_a&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_DepreciationRightofuseAssets

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 99
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 104
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_EmployeeBenefitsExpense

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 21
-IssueDate 2021-01-01
-Paragraph 52
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 35
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of expense arising from purchased insurance.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 112
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_InsuranceExpense

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognised on rental activities.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 85
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_RentalExpense

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 47 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1

Financial Assets and Financial Liabilities (Details)
6 Months Ended

Dec. 31, 2021

AUD ($)

Disclosure of financial instruments [text block] [Abstract]

R&D tax incentive percentage 43.50%

Company annual aggregate turnover $ 20,000,000

Other income 4,126,364

Other receivables $ 2,133,722

X

- Definition
The amount of company annual aggregate turnover.
+ References
No definition available.
+ Details

Name: athe_CompanyAnnualAggregateTurnover

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_DisclosureOfFinancialInstrumentsTextBlockAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
R&D Tax incentive Percentage.
+ References
No definition available.
+ Details

Name: athe_RDTaxIncentivePercentage

Namespace Prefix: athe_

Data Type: dtr:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income or gain included in net income that result in no cash inflow (outflow), classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherNoncashIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount due from parties in nontrade transactions, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 48 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1

Financial Assets and Financial Liabilities (Details) - Schedule of trade and other receivables - AUD ($)

Dec. 31, 2021

Jun. 30, 2021

Schedule of trade and other receivables [Abstract]

R&D tax incentive receivable, Current $ 6,259,819 $ 4,126,364

R&D tax incentive receivable, Non-current

R&D tax incentive receivable, Total 6,259,819 4,126,364

Accrued interest income, Current 267 269

Accrued interest income, Non-current

Accrued interest income, Total 267 269

Goods and services tax receivable, Current 491 47,706

Goods and services tax receivable, Non-current

Goods and services tax receivable, Total 491 47,706

Other receivable, Current 103,338

Other receivable, Non-current

Other receivable, Total 103,338

Trade and other receivables, Current 6,260,577 4,277,677

Trade and other receivables, Non-current

Trade and other receivables, Total $ 6,260,577 $ 4,277,677

X

- Definition
The Amount of Other receivable Total.
+ References
No definition available.
+ Details

Name: athe_OtherReceivableTotal

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of research and development tax incentive receivable.
+ References
No definition available.
+ Details

Name: athe_ResearchAndDevelopmentTaxIncentiveReceivable

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of research and development tax incentive receivable current.
+ References
No definition available.
+ Details

Name: athe_ResearchAndDevelopmentTaxIncentiveReceivableCurrent

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of research and development tax incentive receivable non-current.
+ References
No definition available.
+ Details

Name: athe_ResearchAndDevelopmentTaxIncentiveReceivableNoncurrent

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfTradeAndOtherReceivablesAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 55
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of non-current accrued income including non-current contract assets. [Refer: Accrued income including contract assets]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 55
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_NoncurrentAccruedIncomeIncludingNoncurrentContractAssets

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 54
-Subparagraph h
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_NoncurrentReceivables

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of non-current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_NoncurrentReceivablesFromTaxesOtherThanIncomeTax

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of current other receivables. [Refer: Other receivables]
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_OtherCurrentReceivables

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of non-current other receivables. [Refer: Other receivables]
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_OtherNoncurrentReceivables

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 54
-Subparagraph h
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_TradeAndOtherCurrentReceivables

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 54
-Subparagraph h
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_TradeAndOtherReceivables

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(a))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910
+ Details

Name: us-gaap_AccruedIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 49 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1

Equity (Details) - Schedule of contributed equity - AUD ($)

Dec. 31, 2021

Jun. 30, 2021

Schedule of contributed equity [Abstract]

Ordinary shares - fully paid, shares 2,406,874,578 2,084,016,678

Ordinary shares - fully paid value $ 213,814,776 $ 197,447,990

X

- Definition
Ordinary shares - fully paid.
+ References
No definition available.
+ Details

Name: athe_OrdinarySharesFullyPaid

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Ordinary shares - fully paid, shares.
+ References
No definition available.
+ Details

Name: athe_OrdinarySharesFullyPaidShares

Namespace Prefix: athe_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfContributedEquityAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1

Equity (Details) - Schedule of movements in ordinary share
6 Months Ended

Dec. 31, 2021

AUD ($)

shares

Schedule of movements in ordinary share [Abstract]

Opening balance, shares | shares 2,084,016,678

Opening balance | $ $ 197,447,990

Shares issued during the year, shares | shares 322,857,900

Shares issued during the year | $ $ 17,176,040

Transaction costs, shares | shares

Transaction costs | $ | $ $ (809,254)

Ending balance, shares | shares 2,406,874,578

Ending balance | $ $ 213,814,776

X

- Definition
Opening balance.
+ References
No definition available.
+ Details

Name: athe_AmountOfIssuedAndFullyPaid

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Opening balance, shares.
+ References
No definition available.
+ Details

Name: athe_NumberOfShareIssuedAndFullyPaid

Namespace Prefix: athe_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfMovementsInOrdinaryShareAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Shares issued during the year.
+ References
No definition available.
+ Details

Name: athe_SharesIssuedDuringPeriod

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Shares issued during the year, shares.
+ References
No definition available.
+ Details

Name: athe_SharesIssuedDuringTheYearShares

Namespace Prefix: athe_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Transaction costs.
+ References
No definition available.
+ Details

Name: athe_TransactionCostsRelatingToShareIssues

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Transaction costs, shares.
+ References
No definition available.
+ Details

Name: athe_TransactionCostsShares

Namespace Prefix: athe_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 51 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1

Equity (Details) - Schedule of details of shares issued during the current period

Jul. 02, 2021

AUD ($)

$ / shares

shares

Schedule of details of shares issued during the current period [Abstract]

Number Issue of shares under ATM facility | shares 322,857,900

Issue price Issue of shares under ATM facility | $ / shares $ 0.0532

Amount Issue of shares under ATM facility | $ $ 17,176,040

Total number of shares issued | shares 322,857,900

Total value of shares issued | $ $ 17,176,040

X

- Definition
Issue of shares under ATM facility.
+ References
No definition available.
+ Details

Name: athe_IssueOfSharesUnderATMFacility

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Issue price of shares under ATM facility.
+ References
No definition available.
+ Details

Name: athe_IssuePriceOfShareUnderATMFacility

Namespace Prefix: athe_

Data Type: dtr:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number Issue of shares under ATM facility.
+ References
No definition available.
+ Details

Name: athe_NumberIssueOfSharesUnderATMFacility

Namespace Prefix: athe_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfDetailsOfSharesIssuedDuringTheCurrentPeriodAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total value of shares issued.
+ References
No definition available.
+ Details

Name: athe_TotalValueOfSharesIssued

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued by the entity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 106
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_NumberOfSharesIssued

Namespace Prefix: ifrs-full_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 52 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1

Equity (Details) - Schedule of movements in accumulated losses - AUD ($)
6 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Schedule of movements in accumulated losses [Abstract]

Balance at the beginning of the period $ 169,728,414 $ 154,419,061

Net loss for the period 6,583,559 8,561,862

Balance at the end of the period $ 176,311,973 $ 162,980,923

X

- Definition
Retained Earnings.
+ References
No definition available.
+ Details

Name: athe_RetainedEarning

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfMovementsInAccumulatedLossesAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 53 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1

Equity (Details) - Schedule of options - AUD ($)

Dec. 31, 2021

Jun. 30, 2021

Schedule of options [Abstract]

Options over fully paid ordinary shares, shares 205,692,720 160,542,720

Options over fully paid ordinary shares, value $ 3,626,188 $ 2,750,884

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfOptionsAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares issued by the entity, for which full payment has been received.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 79
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_ii&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_NumberOfSharesIssuedAndFullyPaid

Namespace Prefix: ifrs-full_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A component of equity resulting from share-based payments.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 78
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_ReserveOfSharebasedPayments

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 54 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1

Equity (Details) - Schedule of presents the movements in options granted and issued
6 Months Ended

Dec. 31, 2021

AUD ($)

shares

Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]

Number of stock option shares issued | shares 45,150,000

Stock option shares issued value | $ $ 358,686

Unlisted options issued to consultant [Member]

Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]

Issued Date Dec. 08, 2021

Number of stock option shares issued | shares 12,000,000

Stock option shares issued value | $ $ 326,544

Unlisted options issued to employees [Member]

Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]

Issued Date Dec. 08, 2021

Number of stock option shares issued | shares 13,900,000

Stock option shares issued value | $ $ 13,326

Unlisted options issued to employees [Member[

Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]

Issued Date Dec. 08, 2021

Number of stock option shares issued | shares 19,250,000

Stock option shares issued value | $ $ 18,816

X

- References
No definition available.
+ Details

Name: athe_EquityDetailsScheduleofpresentsthemovementsinoptionsgrantedandissuedLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock option shares issued date.
+ References
No definition available.
+ Details

Name: athe_IssuedDates

Namespace Prefix: athe_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of stock option shares issued.
+ References
No definition available.
+ Details

Name: athe_NumberOfStockOptionShareIssued

Namespace Prefix: athe_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock option shares issued value.
+ References
No definition available.
+ Details

Name: athe_StockOptionSharesIssuedValue

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: ifrs-full_ClassesOfShareCapitalAxis=athe_UnlistedOptionsIssuedToConsultantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ifrs-full_ClassesOfShareCapitalAxis=athe_UnlistedOptionsIssuedToEmployeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ifrs-full_ClassesOfShareCapitalAxis=athe_UnlistedOptionsIssuedToEmployeesOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1

Equity (Details) - Schedule of fair value at grant date per option
6 Months Ended

Dec. 31, 2021

$ / shares

shares

Equity (Details) - Schedule of fair value at grant date per option [Line Items]

Quantity | shares 45,150,000

Date Issued One [Member]

Equity (Details) - Schedule of fair value at grant date per option [Line Items]

Date issued Dec. 08, 2021

Quantity | shares 12,000,000

Grant Date 31-Jul-2021

Expiry Date 31-Jul-2024

Exercise price $ 0.07

Fair value at grant date per option $ 0.0272 ^[1]

Date Issued Two [Member]

Equity (Details) - Schedule of fair value at grant date per option [Line Items]

Date issued Dec. 08, 2021

Quantity | shares 13,900,000

Grant Date 29-Nov-2021

Expiry Date 29-Nov-2026

Exercise price $ 0.0238

Fair value at grant date per option $ 0.021 ^[1]

Date Issued Three [Member]

Equity (Details) - Schedule of fair value at grant date per option [Line Items]

Date issued Dec. 08, 2021

Quantity | shares 19,250,000

Grant Date 29-Nov-2021

Expiry Date 29-Nov-2026

Exercise price $ 0.0375

Fair value at grant date per option $ 0.0214 ^[1]

[1] Rounded to the nearest four decimal points.

X

- References
No definition available.
+ Details

Name: athe_EquityDetailsScheduleoffairvalueatgrantdateperoptionLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price.
+ References
No definition available.
+ Details

Name: athe_ExercisePrice

Namespace Prefix: athe_

Data Type: dtr:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Expiry Date.
+ References
No definition available.
+ Details

Name: athe_ExpiryDate

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value at grant date per option.
+ References
No definition available.
+ Details

Name: athe_FairValueAtGrantDatePerOption

Namespace Prefix: athe_

Data Type: dtr:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Issued Date.
+ References
No definition available.
+ Details

Name: athe_IssuedDated

Namespace Prefix: athe_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares quantity.
+ References
No definition available.
+ Details

Name: athe_NumberOfSharesQuantity

Namespace Prefix: athe_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The name of a subsidiary. [Refer: Subsidiaries [member]]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2021-01-01
-Paragraph 17
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_i&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2021-01-01
-Paragraph 16
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_i&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph 12
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_a&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph 19B
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_a&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_NameOfSubsidiary

Namespace Prefix: ifrs-full_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: ifrs-full_ClassesOfShareCapitalAxis=athe_DateIssuedOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ifrs-full_ClassesOfShareCapitalAxis=athe_DateIssuedTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ifrs-full_ClassesOfShareCapitalAxis=athe_DateIssuedThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1

Equity (Details) - Schedule of options free-attaching options - AUD ($)

Dec. 31, 2021

Jun. 30, 2021

Schedule of options free-attaching options [Abstract]

Free-attaching options, shares 674,694,939 674,694,939

Free-attaching options, value

X

- Definition
Free-attaching options shares.
+ References
No definition available.
+ Details

Name: athe_FreeattachingOptionsShares

Namespace Prefix: athe_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Free-attaching options value.
+ References
No definition available.
+ Details

Name: athe_FreeattachingOptionsValues

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfOptionsFreeAttachingOptionsAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1

Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Details) - Schedule of profit after income tax to net cash flow from operating activities - AUD ($)
6 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Schedule of profit after income tax to net cash flow from operating activities [Abstract]

Loss for the period $ 6,583,559 $ 8,561,862

Depreciation on fixed assets (6,602) (12,417)

Depreciation on leased assets (24,934) (23,215)

Non-cash employee benefits expense - share-based payments (875,304) (1,577,720)

Net foreign exchange differences 1,218,745 (987,215)

(Increase)/decrease in provisions (78,869) (62,547)

Increase/(decrease) in trade and other receivables 1,982,900 1,916,120

Increase/(decrease) in other current assets 504,210 (229,445)

(Increase)/decrease in trade and other payables (631,651) (255,505)

(Increase)/decrease in other current liabilities 388

Net cash flows used in operating activities $ 8,672,054 $ 7,330,306

X

- Definition
Amount of fixed assets lose value as they age because they provide long-term income, these assets are expensed differently than other items.
+ References
No definition available.
+ Details

Name: athe_DepreciationOnFixedAssets

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of capital leases can have an impact on companies' financial statements, influencing interest expense, depreciation expense, assets, and liabilities.
+ References
No definition available.
+ Details

Name: athe_DepreciatonOnLeasedAssets

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net cash flows used in operating activities.
+ References
No definition available.
+ Details

Name: athe_NetCashFlowUsedInOperatingActivities

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of non-cash employee benefits expense share-based payments.
+ References
No definition available.
+ Details

Name: athe_NoncashEmployeeBenefitsExpenseSharebasedPayments

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_ScheduleOfProfitAfterIncomeTaxToNetCashFlowFromOperatingActivitiesAbstract

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 20
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 20
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 20
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 7
-IssueDate 2021-01-01
-Paragraph 20
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) in other provisions. [Refer: Other provisions]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 37
-IssueDate 2021-01-01
-Paragraph 84
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_ChangesInOtherProvisions

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 91
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 81B
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_ii&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_ProfitLossAttributableToOwnersOfParent

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 58 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1

Related Party Transactions (Details)
6 Months Ended

Dec. 31, 2021

AUD ($)

Related Party Transactions (Details) [Line Items]

Advisory fees paid $ 37,500

Lawrence Gozlan [Member]

Related Party Transactions (Details) [Line Items]

Advisory fees paid 101,400

Geoffrey Kempler [Member]

Related Party Transactions (Details) [Line Items]

Advisory fees paid $ 75,000

X

- References
No definition available.
+ Details

Name: athe_RelatedPartyTransactionsDetailsLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of fees paid or payable for professional services.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 112
-Subparagraph c
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_ProfessionalFeesExpense

Namespace Prefix: ifrs-full_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_OwnershipAxis=athe_LawrenceGozlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_OwnershipAxis=athe_GeoffreyKemplerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1

Events Occurring After the Reporting Period (Details)
1 Months Ended

Sep. 30, 2020

shares

Dr Sinclair [Member]

Events Occurring After the Reporting Period (Details) [Line Items]

Forfeited and cancelled (7,000,000)

Mr Edwards [Member]

Events Occurring After the Reporting Period (Details) [Line Items]

Forfeited and cancelled (7,000,000)

X

- References
No definition available.
+ Details

Name: athe_EventsOccurringAftertheReportingPeriodDetailsLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares related to Restricted Stock Award forfeited during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: ifrs-full_BusinessCombinationsAxis=athe_DrSinclairMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ifrs-full_BusinessCombinationsAxis=athe_MrEdwardsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 60 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1

Significant Estimates and Assumptions (Details) - AUD ($)
6 Months Ended

Jul. 02, 2021

Dec. 31, 2021

Dec. 31, 2020

Significant Estimates and Assumptions (Details) [Line Items]

Research and development, description The research and development tax incentive applies to expenditure incurred and the use of depreciating assets in an income year commencing on or after 1 July 2011. A 43.5% refundable tax offset will be available to eligible small companies with an annual aggregate turnover of less than $20 million. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme.

Description of other income the Group has recorded an item in other income of $A2,133,452

Other income recognise amount $ 1,883,325

Refundable tax offset rate value $ 20,000,000

Refundable tax offset rate 18.50%

Bottom of range [member]

Significant Estimates and Assumptions (Details) [Line Items]

Research and development expenditure $ 100,000,000

Top of range [member]

Significant Estimates and Assumptions (Details) [Line Items]

Research and development expenditure $ 150,000,000

X

- Definition
Description of research and development.
+ References
No definition available.
+ Details

Name: athe_DescriptionOfResearchAndDevelopment

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Discription of other income.
+ References
No definition available.
+ Details

Name: athe_DiscriptionOfOtherIncome

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Refundable tax offset rate value.
+ References
No definition available.
+ Details

Name: athe_RefundableTaxOffsetRateValue

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Research and development expenditure.
+ References
No definition available.
+ Details

Name: athe_ResearchAndDevelopmentExpenditure

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Research and development tax incentive.
+ References
No definition available.
+ Details

Name: athe_ResearchAndDevelopmentTaxIncentive

Namespace Prefix: athe_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: athe_SignificantEstimatesandAssumptionsDetailsLineItems

Namespace Prefix: athe_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 12
-IssueDate 2021-01-01
-Paragraph 81
-Subparagraph c
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard
-URIDate 2021-03-24
+ Details

Name: ifrs-full_TaxRateEffectOfTaxLosses

Namespace Prefix: ifrs-full_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 ea156195-6k_alterity_htm.xml IDEA: XBRL DOCUMENT 0001131343 2021-07-01 2021-12-31 0001131343 2020-07-01 2020-12-31 0001131343 2021-12-31 0001131343 2021-06-30 0001131343 ifrs-full:IssuedCapitalMember 2020-06-30 0001131343 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-06-30 0001131343 ifrs-full:RetainedEarningsMember 2020-06-30 0001131343 2020-06-30 0001131343 ifrs-full:IssuedCapitalMember 2020-07-01 2020-12-30 0001131343 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-07-01 2020-12-30 0001131343 ifrs-full:RetainedEarningsMember 2020-07-01 2020-12-30 0001131343 2020-07-01 2020-12-30 0001131343 ifrs-full:IssuedCapitalMember 2020-12-30 0001131343 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-12-30 0001131343 ifrs-full:RetainedEarningsMember 2020-12-30 0001131343 2020-12-30 0001131343 ifrs-full:IssuedCapitalMember 2021-06-30 0001131343 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-06-30 0001131343 ifrs-full:RetainedEarningsMember 2021-06-30 0001131343 ifrs-full:IssuedCapitalMember 2021-07-01 2021-12-30 0001131343 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-07-01 2021-12-30 0001131343 ifrs-full:RetainedEarningsMember 2021-07-01 2021-12-30 0001131343 2021-07-01 2021-12-30 0001131343 ifrs-full:IssuedCapitalMember 2021-12-30 0001131343 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-12-30 0001131343 ifrs-full:RetainedEarningsMember 2021-12-30 0001131343 2021-12-30 0001131343 2020-12-31 0001131343 2021-07-31 0001131343 2021-07-01 2021-07-31 0001131343 2021-07-02 0001131343 2021-07-01 2021-07-02 0001131343 athe:UnlistedOptionsIssuedToConsultantMember 2021-07-01 2021-12-31 0001131343 athe:UnlistedOptionsIssuedToEmployeesMember 2021-07-01 2021-12-31 0001131343 athe:UnlistedOptionsIssuedToEmployeesOneMember 2021-07-01 2021-12-31 0001131343 athe:DateIssuedOneMember 2021-07-01 2021-12-31 0001131343 athe:DateIssuedTwoMember 2021-07-01 2021-12-31 0001131343 athe:DateIssuedThreeMember 2021-07-01 2021-12-31 0001131343 athe:LawrenceGozlanMember 2021-07-01 2021-12-31 0001131343 athe:GeoffreyKemplerMember 2021-07-01 2021-12-31 0001131343 athe:DrSinclairMember 2020-09-01 2020-09-30 0001131343 athe:MrEdwardsMember 2020-09-01 2020-09-30 0001131343 2021-06-22 2021-07-02 0001131343 ifrs-full:BottomOfRangeMember 2021-06-22 2021-07-02 0001131343 ifrs-full:TopOfRangeMember 2021-06-22 2021-07-02 iso4217:AUD iso4217:AUD shares shares iso4217:USD shares iso4217:USD pure 6-K false --06-30 Q2 2022 2021-12-31 0001131343 000-49843 1350 6553 2359198 1924389 205896 160304 3194790 3673407 6761542 5806841 -624 -20 1218745 -852232 -6583559 -8561862 -6583559 -8561862 -6583559 -8561862 -0.27 -0.65 -0.27 -0.65 37002201 28115516 6260577 4277677 1599963 1095753 44862741 33488946 27270 31313 41039 65495 68309 96808 44931050 33585754 3134160 2502509 613098 537368 15167 27746 3762425 3067623 12907 9768 26727 37903 39634 47671 3802059 3115294 41128991 30470460 213814776 197447990 3626188 2750884 -176311973 -169728414 41128991 30470460 160703754 866121 -154419061 7150814 -8561862 -8561862 -8561862 -8561862 36562055 36562055 1577720 1577720 -2372505 -2372505 34189550 1577720 35767270 194893304 2443841 -162980923 34356222 197447990 2750884 -169728414 30470460 -6583559 -6583559 -6583559 -6583559 17176040 17176040 875304 875304 -809254 -809254 16366786 875304 17242090 213814776 3626188 -176311973 41128991 9002490 7385267 103338 53564 225746 1352 1397 -8672054 -7330306 2559 2494 -2559 -2494 17176040 36562055 809254 2372505 23755 24249 16343031 34165301 7668418 26832501 28115516 9196892 1218267 -987215 37002201 35042178 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0in"/><td style="width: 0.25in">1</td><td>Basis of preparation of half-year report</td></tr></table> This condensed consolidated interim report for the half-year reporting period ended 31 December 2021 has been prepared in accordance with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Act 2001. These financial statements also comply with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), as applicable to interim financial reporting. This condensed consolidated interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2021 and any public announcements made by Alterity Therapeutics Limited (the “Group”) during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001. The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period except as discussed below. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0%"/><td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify">New and amended standards adopted by the Group</td> </tr></table> The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ‘AASB’ that are mandatory for the current reporting period. The adoption of these standards has not had any impact on the disclosures or amounts reported in these financial statements. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0%"/><td style="width: 0.25in">2</td><td>Significant changes in the current reporting period</td></tr></table> In July 2021, the Group raised A$17,176,040 by issuing 322,857,900 shares at $0.0532 per share through the use of its “at-the-market” (ATM) facility to fund working capital and progress its research and development activities. There have been no other significant changes in the state of affairs of the Company during the period. 17176040 322857900 0.0532 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0%"/><td style="width: 0.25in">3</td><td>Segment information</td></tr></table> Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer of Alterity Therapeutics Limited. For the current and previous reporting periods, the Group operated in one segment, being research and development in the field of Parkinsonian and other neurodegenerative disorders. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0%"/><td style="width: 0.25in">4</td><td>Dividends</td></tr></table> The Group has not declared any dividends in the period ended 31 December 2021 (2020: nil) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">5</td><td style="text-align: justify">Loss per share</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify">Basic and diluted loss per share</td> </tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">31 December</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: right">31 December</td><td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">2021 Cents</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">2020 Cents</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Loss per share for profit attributable to the ordinary equity holders of the Group: </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Basic loss per share</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">(0.27</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(0.65</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td>Diluted loss per share</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(0.27</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.65</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(b)</td><td style="text-align: justify">Reconciliation of loss used in calculating loss per share</td> </tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; text-align: right; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">31 December</td><td style="white-space: nowrap; text-align: right; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right"> </td> <td colspan="2" style="white-space: nowrap; text-align: right">31 December</td><td style="white-space: nowrap; text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right; font-weight: bold">2021 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">2020 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic">Basic loss per share</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share:</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">(6,583,559</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(8,561,862</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic">Diluted loss per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share:</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,583,559</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,561,862</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(c)</td><td style="text-align: justify">Weighted average number of shares used as the denominator</td> </tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 Number</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">31 December 2020 Number</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,405,110,327</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,323,432,372</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> Options that are considered to be potential ordinary shares are excluded from the weighted average number of ordinary shares used in the calculation of basic loss per share. Where dilutive, potential ordinary shares are included in the calculation of diluted loss per share. All the options on issue do not have the effect to dilute the loss per share. Therefore, they have been excluded from the calculation of diluted loss per share. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">31 December</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: right">31 December</td><td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">2021 Cents</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">2020 Cents</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Loss per share for profit attributable to the ordinary equity holders of the Group: </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Basic loss per share</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">(0.27</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(0.65</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td>Diluted loss per share</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(0.27</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.65</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; text-align: right; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">31 December</td><td style="white-space: nowrap; text-align: right; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right"> </td> <td colspan="2" style="white-space: nowrap; text-align: right">31 December</td><td style="white-space: nowrap; text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right; font-weight: bold">2021 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">2020 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic">Basic loss per share</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share:</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">(6,583,559</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(8,561,862</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic">Diluted loss per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share:</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,583,559</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,561,862</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 Number</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">31 December 2020 Number</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,405,110,327</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,323,432,372</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> -0.27 -0.65 -0.27 -0.65 -6583559 -8561862 -6583559 -8561862 2405110327 1323432372 <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in">6</td><td>Interest and other income</td></tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">31 December</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: right">31 December</td><td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: right">2021 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">2020 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic">Interest and other income</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 76%; text-align: left">Interest income</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">1,350</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">6,553</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,350</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,553</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; text-align: left">Other Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">R&D tax incentive</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">2,133,452</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,883,325</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>COVID-19 relief</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,064</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left">Other grant (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">225,746</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,359,198</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,924,389</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">1</td><td style="text-align: justify">Other grants relates to the receipt of grant funding awarded by Michael J. Fox Foundation during the period ended 31 December 2021.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">31 December</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: right">31 December</td><td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: right">2021 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">2020 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic">Interest and other income</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 76%; text-align: left">Interest income</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">1,350</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">6,553</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,350</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,553</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; text-align: left">Other Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">R&D tax incentive</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">2,133,452</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,883,325</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>COVID-19 relief</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,064</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left">Other grant (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">225,746</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,359,198</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,924,389</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">1</td><td style="text-align: justify">Other grants relates to the receipt of grant funding awarded by Michael J. Fox Foundation during the period ended 31 December 2021.</td> </tr></table> 1350 6553 1350 6553 2133452 1883325 41064 225746 2359198 1924389 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">7</td><td style="text-align: justify">Loss for the period</td> </tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; text-align: right; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">31 December</td><td style="white-space: nowrap; text-align: right; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right"> </td> <td colspan="2" style="white-space: nowrap; text-align: right">31 December</td><td style="white-space: nowrap; text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2021 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">2020 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Loss before income tax has been determined after:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">General and administration expenses</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Depreciation on fixed assets</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">6,602</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">12,417</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Depreciation on leased assets</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">24,934</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,215</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employee expenses (non R&D related)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">370,564</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">376,220</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Consultant and director expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">242,563</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">387,310</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Audit, internal control and other assurance expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">109,398</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115,798</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Corporate compliance expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">217,776</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">372,697</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office rental</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">30,458</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66,664</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Other administrative and office expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">503,885</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">332,784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Insurance expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">324,798</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">258,582</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Share-based payment expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">875,304</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,577,720</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Corporate advisory</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">488,508</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">150,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,194,790</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,673,407</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Employee expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">1,192,238</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,072,468</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other research and development expenses1</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,569,304</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,734,373</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,761,542</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,806,841</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Other gains and losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange (gain)/ loss</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,218,745</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">852,232</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,218,745</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">852,232</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Other research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; text-align: right; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">31 December</td><td style="white-space: nowrap; text-align: right; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right"> </td> <td colspan="2" style="white-space: nowrap; text-align: right">31 December</td><td style="white-space: nowrap; text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: right"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2021 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">2020 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Loss before income tax has been determined after:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">General and administration expenses</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Depreciation on fixed assets</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">6,602</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">12,417</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Depreciation on leased assets</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">24,934</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,215</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employee expenses (non R&D related)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">370,564</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">376,220</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Consultant and director expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">242,563</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">387,310</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Audit, internal control and other assurance expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">109,398</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115,798</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Corporate compliance expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">217,776</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">372,697</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office rental</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">30,458</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66,664</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Other administrative and office expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">503,885</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">332,784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Insurance expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">324,798</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">258,582</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Share-based payment expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">875,304</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,577,720</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Corporate advisory</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">488,508</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">150,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,194,790</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,673,407</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Employee expenses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">1,192,238</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,072,468</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other research and development expenses1</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,569,304</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,734,373</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,761,542</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,806,841</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Other gains and losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange (gain)/ loss</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,218,745</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">852,232</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,218,745</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">852,232</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 6602 12417 24934 23215 370564 376220 242563 387310 109398 115798 217776 372697 30458 66664 503885 332784 324798 258582 875304 1577720 488508 150000 3194790 3673407 1192238 1072468 5569304 4734373 6761542 5806841 -1218745 852232 -1218745 852232 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.25in">8</td><td>Financial assets and financial liabilities</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.25in">(a)</td><td style="text-align: left">Trade and other receivables</td></tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 December 2021 </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">30 June 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="text-align: right; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right">Current</td><td style="text-align: right; font-weight: bold"> </td><td style="text-align: right; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right">Non- current</td><td style="text-align: right; font-weight: bold"> </td><td style="text-align: right; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right">Total</td><td style="text-align: right; font-weight: bold"> </td><td style="text-align: right"> </td> <td colspan="2" style="text-align: right">Current</td><td style="text-align: right"> </td><td style="text-align: right"> </td> <td colspan="2" style="text-align: right">Non- current</td><td style="text-align: right"> </td><td style="text-align: right"> </td> <td colspan="2" style="text-align: right">Total</td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">A$</td><td style="padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">A$</td><td style="padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">A$</td><td style="padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">A$</td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">A$</td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">A$</td><td style="padding-bottom: 1.5pt; text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left">R&D tax incentive receivable</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">6,259,819</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31"> -</div></td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">6,259,819</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,126,364</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32"> -</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,126,364</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued interest income</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">267</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">267</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">269</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">269</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Goods and services tax receivable</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">491</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">491</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,706</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,706</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left">Other receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,338</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,338</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,260,577</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,260,577</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,277,677</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,277,677</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> R&D tax incentive receivable represents the amount of R&D tax incentive the Group expects to recover. For further details, see note 13(a). A 43.5% R&D Tax incentive refundable tax offset is available to eligible small companies with an annual aggregate turnover of less than $20 million. For the year ended 30 June 2021 and half-year ended 31 December 2021, the Group recorded $4,126,364 and $2,133,722 respectively in other income and receivables. (i) Classification as trade and other receivables Trade receivables and other receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. If collection of the amounts is expected in one year or less they are classified as current assets. If not, they are presented as non-current assets. Trade and other receivables are generally due for settlement within one year and therefore are all classified as current. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.25in">(b)</td><td style="text-align: left">Recognised fair value measurements</td></tr></table> The financial instruments recognised at fair value in the statement of financial position have been analysed and classified using a fair value hierarchy reflecting the significance of the inputs used in making the measurements. The fair value hierarchy consists of the following levels: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">quoted prices in active markets for identical assets or liabilities (Level 1);</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices) (Level 2); and</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">inputs for the asset or liability that are not based on observable market data (unobservable inputs) (Level3).</td> </tr></table> During the period, none of the Group’s assets and liabilities had their fair value determined using the fair value hierarchy. No transfers between the levels of the fair value hierarchy occurred during the current or previous periods. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">31 December 2021 </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">30 June 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="text-align: right; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right">Current</td><td style="text-align: right; font-weight: bold"> </td><td style="text-align: right; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right">Non- current</td><td style="text-align: right; font-weight: bold"> </td><td style="text-align: right; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right">Total</td><td style="text-align: right; font-weight: bold"> </td><td style="text-align: right"> </td> <td colspan="2" style="text-align: right">Current</td><td style="text-align: right"> </td><td style="text-align: right"> </td> <td colspan="2" style="text-align: right">Non- current</td><td style="text-align: right"> </td><td style="text-align: right"> </td> <td colspan="2" style="text-align: right">Total</td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">A$</td><td style="padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">A$</td><td style="padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">A$</td><td style="padding-bottom: 1.5pt; text-align: right; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">A$</td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">A$</td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">A$</td><td style="padding-bottom: 1.5pt; text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left">R&D tax incentive receivable</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">6,259,819</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31"> -</div></td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">6,259,819</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,126,364</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32"> -</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,126,364</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued interest income</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">267</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">267</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">269</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">269</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Goods and services tax receivable</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">491</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">491</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,706</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,706</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left">Other receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,338</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,338</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,260,577</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,260,577</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,277,677</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,277,677</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 6259819 6259819 4126364 4126364 267 267 269 269 491 491 47706 47706 103338 103338 6260577 6260577 4277677 4277677 0.435 20000000 4126364 2133722 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">9</td><td style="text-align: justify">Equity</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify">Contributed equity</td> </tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 Shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">30 June 2021 Shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">30 June 2021 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Ordinary shares - fully paid</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">2,406,874,578</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,084,016,678</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">213,814,776</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">197,447,990</td><td style="width: 1%; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; "> <td style="width: 100%">Movements in ordinary share:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold">Details</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">Number of shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Opening balance 1 July 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,084,016,678</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">197,447,990</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Shares issued during the year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">322,857,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,176,040</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Transaction costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(809,254</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Balance 31 December 2021</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,406,874,578</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">213,814,776</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> Details of shares issued during the current period: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right">Issue price </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right">Amount</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: left">Details</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">Number</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 11%; text-align: left">2-Jul-2021</td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="padding-bottom: 1.5pt; width: 52%; text-align: left">Issue of shares under ATM facility</td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">322,857,900</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.0532</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">17,176,040</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">322,857,900</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 4pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">17,176,040</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in">(b)</td><td>Accumulated losses</td></tr></table> Movements in accumulated losses were as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; text-align: right; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">31 December 2020 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Balance at the beginning of the period</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">169,728,414</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">154,419,061</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left">Net loss for the period</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,583,559</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,561,862</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Balance at the end of the period</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">176,311,973</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">162,980,923</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in">(c)</td><td style="text-align: left">Reserves</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify">Options</td> </tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 Options</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">30 June 2021 Options</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">30 June 2021 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Options over fully paid ordinary shares</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">205,692,720</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">160,542,720</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">3,626,188</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,750,884</td><td style="width: 1%; text-align: left"> </td></tr> </table> The table below presents the movements in options granted and issued during the half-year ended 31 December 2021. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Details</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; font-weight: bold">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; font-weight: bold">Amount A$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 11%">8-Dec-2021</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 64%; text-align: left">Unlisted options issued to consultant</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">12,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">326,544</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>8-Dec-2021</td><td> </td> <td style="text-align: left; padding-left: 2.1pt">Unlisted options issued to employees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,900,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,326</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">8-Dec-2021</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 2.1pt">Unlisted options issued to employees</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,816</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; padding-left: 2.1pt"> </td><td style="padding-bottom: 4pt; font-weight: bold"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">45,150,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 4pt; font-weight: bold"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">358,686</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td colspan="2" style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td colspan="2" style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td colspan="2" style="text-align: right; white-space: nowrap"> Fair value at grant</td> <td style="text-align: right; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; white-space: nowrap">Date issued</td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">Quantity</td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">Grant Date</td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">Expiry Date</td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; white-space: nowrap">Exercise price ($)</td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; white-space: nowrap">date per option ($) *</td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 16%">08-Dec-2021</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">12,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">31-Jul-2021</td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">31-Jul-2024</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.0700</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.0272</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td>08-Dec-2021</td> <td> </td> <td> </td> <td style="text-align: right">13,900,000</td> <td> </td> <td> </td> <td style="text-align: right">29-Nov-2021</td> <td> </td> <td style="text-align: right">29-Nov-2026</td> <td> </td> <td>$</td> <td style="text-align: right">0.0238</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0210</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>08-Dec-2021</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">19,250,000</td> <td> </td> <td> </td> <td style="text-align: right">29-Nov-2021</td> <td> </td> <td style="text-align: right">29-Nov-2026</td> <td> </td> <td>$</td> <td style="text-align: right">0.0375</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0214</td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td> </td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">45,150,000</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Rounded to the nearest four decimal points.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify">Free-attaching options</td> </tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 Options</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">30 June 2021 Options</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">30 June 2021 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Free-attaching options</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">674,694,939</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">674,694,939</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44"> -</div></td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45"> -</div></td><td style="width: 1%; text-align: left"> </td></tr> </table> There was no movement during the half-year ended 31 December 2021. There have been no other options over fully paid ordinary shares issued, exercised or forfeited during the current period. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify">Nature and purpose of reserves</td> </tr></table> The share-based payments reserve is used to recognise the fair value of options issued to employees and consultants but not exercised. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 Shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">30 June 2021 Shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">30 June 2021 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Ordinary shares - fully paid</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">2,406,874,578</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,084,016,678</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">213,814,776</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">197,447,990</td><td style="width: 1%; text-align: left"> </td></tr> </table> 2406874578 2084016678 213814776 197447990 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold">Details</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">Number of shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Opening balance 1 July 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,084,016,678</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">197,447,990</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Shares issued during the year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">322,857,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,176,040</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Transaction costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(809,254</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Balance 31 December 2021</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,406,874,578</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">213,814,776</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 2084016678 197447990 322857900 17176040 -809254 2406874578 213814776 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right">Issue price </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right">Amount</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: left">Details</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">Number</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; font-weight: bold">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 11%; text-align: left">2-Jul-2021</td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="padding-bottom: 1.5pt; width: 52%; text-align: left">Issue of shares under ATM facility</td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">322,857,900</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.0532</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">17,176,040</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">322,857,900</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 4pt; font-weight: bold; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">17,176,040</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 322857900 0.0532 17176040 322857900 17176040 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; text-align: right; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">31 December 2020 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Balance at the beginning of the period</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">169,728,414</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">154,419,061</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left">Net loss for the period</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,583,559</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,561,862</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Balance at the end of the period</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">176,311,973</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">162,980,923</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 169728414 154419061 6583559 8561862 176311973 162980923 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 Options</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">30 June 2021 Options</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">30 June 2021 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Options over fully paid ordinary shares</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">205,692,720</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">160,542,720</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">3,626,188</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,750,884</td><td style="width: 1%; text-align: left"> </td></tr> </table> 205692720 160542720 3626188 2750884 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Details</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; font-weight: bold">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; font-weight: bold">Amount A$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 11%">8-Dec-2021</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 64%; text-align: left">Unlisted options issued to consultant</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">12,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">326,544</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>8-Dec-2021</td><td> </td> <td style="text-align: left; padding-left: 2.1pt">Unlisted options issued to employees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,900,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,326</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">8-Dec-2021</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 2.1pt">Unlisted options issued to employees</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,816</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; padding-left: 2.1pt"> </td><td style="padding-bottom: 4pt; font-weight: bold"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">45,150,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 4pt; font-weight: bold"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">358,686</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 2021-12-08 12000000 326544 2021-12-08 13900000 13326 2021-12-08 19250000 18816 45150000 358686 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td colspan="2" style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td colspan="2" style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td style="text-align: right; white-space: nowrap"> </td> <td colspan="2" style="text-align: right; white-space: nowrap"> Fair value at grant</td> <td style="text-align: right; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; white-space: nowrap">Date issued</td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">Quantity</td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">Grant Date</td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">Expiry Date</td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; white-space: nowrap">Exercise price ($)</td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; white-space: nowrap">date per option ($) *</td> <td style="padding-bottom: 1.5pt; text-align: right; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 16%">08-Dec-2021</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">12,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">31-Jul-2021</td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">31-Jul-2024</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.0700</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.0272</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td>08-Dec-2021</td> <td> </td> <td> </td> <td style="text-align: right">13,900,000</td> <td> </td> <td> </td> <td style="text-align: right">29-Nov-2021</td> <td> </td> <td style="text-align: right">29-Nov-2026</td> <td> </td> <td>$</td> <td style="text-align: right">0.0238</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0210</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>08-Dec-2021</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">19,250,000</td> <td> </td> <td> </td> <td style="text-align: right">29-Nov-2021</td> <td> </td> <td style="text-align: right">29-Nov-2026</td> <td> </td> <td>$</td> <td style="text-align: right">0.0375</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0214</td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td> </td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right">45,150,000</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table> 2021-12-08 12000000 31-Jul-2021 31-Jul-2024 0.07 0.0272 2021-12-08 13900000 29-Nov-2021 29-Nov-2026 0.0238 0.021 2021-12-08 19250000 29-Nov-2021 29-Nov-2026 0.0375 0.0214 45150000 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 Options</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">30 June 2021 Options</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">31 December 2021 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">30 June 2021 A$</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Free-attaching options</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">674,694,939</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">674,694,939</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44"> -</div></td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45"> -</div></td><td style="width: 1%; text-align: left"> </td></tr> </table> 674694939 674694939 <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in">10</td><td>Reconciliation of profit after income tax to net cash flow from operating activities</td></tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: right">31 December 2021 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">31 December 2020 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Loss for the period</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">6,583,559</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,561,862</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Depreciation on fixed assets</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(6,602</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(12,417</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation on leased assets</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(24,934</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(23,215</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Non-cash employee benefits expense - share-based payments</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(875,304</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,577,720</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net foreign exchange differences</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">1,218,745</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(987,215</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">(Increase)/decrease in provisions</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(78,869</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(62,547</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Increase/(decrease) in trade and other receivables</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">1,982,900</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,916,120</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Increase/(decrease) in other current assets</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">504,210</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(229,445</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">(Increase)/decrease in trade and other payables</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(631,651</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(255,505</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left">(Increase)/decrease in other current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,672,054</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,330,306</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: right">31 December 2021 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: right">31 December 2020 A$</td><td style="white-space: nowrap; text-align: right; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Loss for the period</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 9%; font-weight: bold; text-align: right">6,583,559</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,561,862</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Depreciation on fixed assets</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(6,602</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(12,417</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation on leased assets</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(24,934</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(23,215</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Non-cash employee benefits expense - share-based payments</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(875,304</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,577,720</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net foreign exchange differences</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">1,218,745</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(987,215</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">(Increase)/decrease in provisions</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(78,869</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(62,547</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Increase/(decrease) in trade and other receivables</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">1,982,900</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,916,120</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Increase/(decrease) in other current assets</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">504,210</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(229,445</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">(Increase)/decrease in trade and other payables</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(631,651</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(255,505</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left">(Increase)/decrease in other current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">388</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,672,054</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,330,306</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 6583559 8561862 -6602 -12417 -24934 -23215 -875304 -1577720 1218745 -987215 -78869 -62547 1982900 1916120 504210 -229445 -631651 -255505 388 8672054 7330306 <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in">11</td><td>Related party transactions</td></tr></table> During the half-year ended 31 December 2021 the Group paid a total of A$37,500 (excl. GST) in corporate advisory fees to Montoya Pty Ltd, an associated entity of Mr. Lawrence Gozlan, a director of the Group and A$101,400 (excl. GST) in corporate advisory fees to Kemdev Pty Ltd, an associated entity of Mr. Geoffrey Kempler. A$75,000 (excl. GST) is payable to Kemdev Pty Ltd at the end of the period. There were no other related party transactions other than those related to director and key management personnel remuneration and equity and transactions by the Group and its subsidiaries. 37500 101400 75000 <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in">12</td><td>Events occurring after the reporting period</td></tr></table> Resignation of Non-Executive Directors On 4 January 2022 Dr. David Sinclair and Mr. Tristan Edwards resigned as Non-Executive Directors of the Group. Options issued under the ESOP Plan to Dr. Sinclair (7,000,000) and Mr. Edwards (7,000,000) as approved in September 2020 were forfeited and cancelled upon resignation. No other matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group or economic entity in subsequent financial periods. -7000000 -7000000 <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in">13</td><td>Significant estimates and assumptions</td></tr></table> Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances. The Company and its two wholly-owned subsidiaries (the “Group”) makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial period are discussed below. The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify">R&D tax incentives</td> </tr></table> The Australian Government replaced the research and development tax concession with the research and development tax incentive from 1 July 2011. The provisions provide refundable or non-refundable tax offsets. The research and development tax incentive applies to expenditure incurred and the use of depreciating assets in an income year commencing on or after 1 July 2011. A 43.5% refundable tax offset will be available to eligible small companies with an annual aggregate turnover of less than $20 million. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. For the period to 31 December 2021 the Group has recorded an item in other income of $A2,133,452 (31 Dec 2020:$1,883,325) to recognise this amount which relates to this period. On 7 October 2020, the Treasury Laws Amendment (A Tax Plan for the Covid-19 Economic Recovery Bill 2020) was introduced to the Parliament. This legislation supersedes the Treasury Laws Amendment (Research and Development Incentive) Bill 2019. Under the amendments, commencing 1 July 2021, the refundable tax offset rate for companies with aggregated turnover below $20 million would become 18.5% above the companies tax rate and the R&D expenditure threshold would be increased from $100 million to $150 million. Management does not consider the rate reduction or the refund cap has material impact towards the Group’s R&D tax incentive claim for the next financial year going forward. The rate reduction has no material impact on the R&D tax incentive estimate reported in financial statements for the half-year ended 31 December 2021. The research and development tax incentive applies to expenditure incurred and the use of depreciating assets in an income year commencing on or after 1 July 2011. A 43.5% refundable tax offset will be available to eligible small companies with an annual aggregate turnover of less than $20 million. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. the Group has recorded an item in other income of $A2,133,452 1883325 20000000 0.185 100000000 150000000 <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in">14</td><td>COVID-19 impact on business</td></tr></table> The COVID-19 pandemic has caused uncertainty in global markets and its impact is unable to be reliably measured. However, COVID-19 has had limited effect thus far on the Group’s operation. Development activities have continued with minimal disruption. false --06-30 Q2 2022 2021-12-31 6-K 0001131343 000-49843 ALTERITY THERAPEUTICS LTD Other grants relates to the receipt of grant funding awarded by Michael J. Fox Foundation during the period ended 31 December 2021. Other research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group. Rounded to the nearest four decimal points. EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 45 292 1 true 15 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://pranabio.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited) Sheet http://pranabio.com/role/ConsolidatedIncomeStatement Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Statement of Financial Position (Unaudited) Sheet http://pranabio.com/role/ConsolidatedBalanceSheet Consolidated Statement of Financial Position (Unaudited) Statements 3 false false R4.htm 003 - Statement - Consolidated Statement of Changes in Equity (Unaudited) Sheet http://pranabio.com/role/ShareholdersEquityType2or3 Consolidated Statement of Changes in Equity (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statement of Cash Flows (Unaudited) Sheet http://pranabio.com/role/ConsolidatedCashFlow Consolidated Statement of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Disclosure - Basis of Preparation of Half-Year Report Sheet http://pranabio.com/role/BasisofPreparationofHalfYearReport Basis of Preparation of Half-Year Report Notes 6 false false R7.htm 006 - Disclosure - Significant Changes in The Current Reporting Period Sheet http://pranabio.com/role/SignificantChangesinTheCurrentReportingPeriod Significant Changes in The Current Reporting Period Notes 7 false false R8.htm 007 - Disclosure - Segment Information Sheet http://pranabio.com/role/SegmentInformation Segment Information Notes 8 false false R9.htm 008 - Disclosure - Dividends Sheet http://pranabio.com/role/Dividends Dividends Notes 9 false false R10.htm 009 - Disclosure - Loss Per Share Sheet http://pranabio.com/role/LossPerShare Loss Per Share Notes 10 false false R11.htm 010 - Disclosure - Interest and Other Income Sheet http://pranabio.com/role/InterestandOtherIncome Interest and Other Income Notes 11 false false R12.htm 011 - Disclosure - Loss for the Period Sheet http://pranabio.com/role/LossforthePeriod Loss for the Period Notes 12 false false R13.htm 012 - Disclosure - Financial Assets and Financial Liabilities Sheet http://pranabio.com/role/FinancialAssetsandFinancialLiabilities Financial Assets and Financial Liabilities Notes 13 false false R14.htm 013 - Disclosure - Equity Sheet http://pranabio.com/role/Equity Equity Notes 14 false false R15.htm 014 - Disclosure - Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities Sheet http://pranabio.com/role/ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivities Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities Notes 15 false false R16.htm 015 - Disclosure - Related Party Transactions Sheet http://pranabio.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 016 - Disclosure - Events Occurring After the Reporting Period Sheet http://pranabio.com/role/EventsOccurringAftertheReportingPeriod Events Occurring After the Reporting Period Notes 17 false false R18.htm 017 - Disclosure - Significant Estimates and Assumptions Sheet http://pranabio.com/role/SignificantEstimatesandAssumptions Significant Estimates and Assumptions Notes 18 false false R19.htm 018 - Disclosure - Covid-19 Impact on Business Sheet http://pranabio.com/role/Covid19ImpactonBusiness Covid-19 Impact on Business Notes 19 false false R20.htm 019 - Disclosure - Loss Per Share (Tables) Sheet http://pranabio.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://pranabio.com/role/LossPerShare 20 false false R21.htm 020 - Disclosure - Interest and Other Income (Tables) Sheet http://pranabio.com/role/InterestandOtherIncomeTables Interest and Other Income (Tables) Tables http://pranabio.com/role/InterestandOtherIncome 21 false false R22.htm 021 - Disclosure - Loss for the Period (Tables) Sheet http://pranabio.com/role/LossforthePeriodTables Loss for the Period (Tables) Tables http://pranabio.com/role/LossforthePeriod 22 false false R23.htm 022 - Disclosure - Financial Assets and Financial Liabilities (Tables) Sheet http://pranabio.com/role/FinancialAssetsandFinancialLiabilitiesTables Financial Assets and Financial Liabilities (Tables) Tables http://pranabio.com/role/FinancialAssetsandFinancialLiabilities 23 false false R24.htm 023 - Disclosure - Equity (Tables) Sheet http://pranabio.com/role/EquityTables Equity (Tables) Tables http://pranabio.com/role/Equity 24 false false R25.htm 024 - Disclosure - Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Tables) Sheet http://pranabio.com/role/ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivitiesTables Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Tables) Tables http://pranabio.com/role/ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivities 25 false false R26.htm 025 - Disclosure - Significant Changes in The Current Reporting Period (Details) Sheet http://pranabio.com/role/SignificantChangesinTheCurrentReportingPeriodDetails Significant Changes in The Current Reporting Period (Details) Details http://pranabio.com/role/SignificantChangesinTheCurrentReportingPeriod 26 false false R27.htm 026 - Disclosure - Dividends (Details) Sheet http://pranabio.com/role/DividendsDetails Dividends (Details) Details http://pranabio.com/role/Dividends 27 false false R28.htm 027 - Disclosure - Loss Per Share (Details) - Schedule of earning loss per share Sheet http://pranabio.com/role/ScheduleofearninglosspershareTable Loss Per Share (Details) - Schedule of earning loss per share Details http://pranabio.com/role/LossPerShareTables 28 false false R29.htm 028 - Disclosure - Interest and Other Income (Details) - Schedule of interest and other income Sheet http://pranabio.com/role/ScheduleofinterestandotherincomeTable Interest and Other Income (Details) - Schedule of interest and other income Details http://pranabio.com/role/InterestandOtherIncomeTables 29 false false R30.htm 029 - Disclosure - Loss for the Period (Details) - Schedule of loss for the period Sheet http://pranabio.com/role/ScheduleoflossfortheperiodTable Loss for the Period (Details) - Schedule of loss for the period Details http://pranabio.com/role/LossforthePeriodTables 30 false false R31.htm 030 - Disclosure - Financial Assets and Financial Liabilities (Details) Sheet http://pranabio.com/role/FinancialAssetsandFinancialLiabilitiesDetails Financial Assets and Financial Liabilities (Details) Details http://pranabio.com/role/FinancialAssetsandFinancialLiabilitiesTables 31 false false R32.htm 031 - Disclosure - Financial Assets and Financial Liabilities (Details) - Schedule of trade and other receivables Sheet http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable Financial Assets and Financial Liabilities (Details) - Schedule of trade and other receivables Details http://pranabio.com/role/FinancialAssetsandFinancialLiabilitiesTables 32 false false R33.htm 032 - Disclosure - Equity (Details) - Schedule of contributed equity Sheet http://pranabio.com/role/ScheduleofcontributedequityTable Equity (Details) - Schedule of contributed equity Details http://pranabio.com/role/EquityTables 33 false false R34.htm 033 - Disclosure - Equity (Details) - Schedule of movements in ordinary share Sheet http://pranabio.com/role/ScheduleofmovementsinordinaryshareTable Equity (Details) - Schedule of movements in ordinary share Details http://pranabio.com/role/EquityTables 34 false false R35.htm 034 - Disclosure - Equity (Details) - Schedule of details of shares issued during the current period Sheet http://pranabio.com/role/ScheduleofdetailsofsharesissuedduringthecurrentperiodTable Equity (Details) - Schedule of details of shares issued during the current period Details http://pranabio.com/role/EquityTables 35 false false R36.htm 035 - Disclosure - Equity (Details) - Schedule of movements in accumulated losses Sheet http://pranabio.com/role/ScheduleofmovementsinaccumulatedlossesTable Equity (Details) - Schedule of movements in accumulated losses Details http://pranabio.com/role/EquityTables 36 false false R37.htm 036 - Disclosure - Equity (Details) - Schedule of options Sheet http://pranabio.com/role/ScheduleofoptionsTable Equity (Details) - Schedule of options Details http://pranabio.com/role/EquityTables 37 false false R38.htm 037 - Disclosure - Equity (Details) - Schedule of presents the movements in options granted and issued Sheet http://pranabio.com/role/ScheduleofpresentsthemovementsinoptionsgrantedandissuedTable Equity (Details) - Schedule of presents the movements in options granted and issued Details http://pranabio.com/role/EquityTables 38 false false R39.htm 038 - Disclosure - Equity (Details) - Schedule of fair value at grant date per option Sheet http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable Equity (Details) - Schedule of fair value at grant date per option Details http://pranabio.com/role/EquityTables 39 false false R40.htm 039 - Disclosure - Equity (Details) - Schedule of options free-attaching options Sheet http://pranabio.com/role/ScheduleofoptionsfreeattachingoptionsTable Equity (Details) - Schedule of options free-attaching options Details http://pranabio.com/role/EquityTables 40 false false R41.htm 040 - Disclosure - Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Details) - Schedule of profit after income tax to net cash flow from operating activities Sheet http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Details) - Schedule of profit after income tax to net cash flow from operating activities Details http://pranabio.com/role/ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivitiesTables 41 false false R42.htm 041 - Disclosure - Related Party Transactions (Details) Sheet http://pranabio.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://pranabio.com/role/RelatedPartyTransactions 42 false false R43.htm 042 - Disclosure - Events Occurring After the Reporting Period (Details) Sheet http://pranabio.com/role/EventsOccurringAftertheReportingPeriodDetails Events Occurring After the Reporting Period (Details) Details http://pranabio.com/role/EventsOccurringAftertheReportingPeriod 43 false false R44.htm 043 - Disclosure - Significant Estimates and Assumptions (Details) Sheet http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails Significant Estimates and Assumptions (Details) Details http://pranabio.com/role/SignificantEstimatesandAssumptions 44 false false All Reports Book All Reports ea156195-6k_alterity.htm ea156195ex99-1_alterity.htm athe-20211231.xsd athe-20211231_cal.xml athe-20211231_def.xml athe-20211231_lab.xml athe-20211231_pre.xml ea156195ex99-2_alterity.htm ea156195ex99-3_alterity.htm ea156195ex99-4_alterity.htm ex99-1_001.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full http://xbrl.sec.gov/dei/2021 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea156195-6k_alterity.htm ea156195ex99-1_alterity.htm": { "axisCustom": 0, "axisStandard": 5, "contextCount": 45, "dts": { "calculationLink": { "local": [ "athe-20211231_cal.xml" ] }, "definitionLink": { "local": [ "athe-20211231_def.xml" ] }, "inline": { "local": [ "ea156195-6k_alterity.htm", "ea156195ex99-1_alterity.htm" ] }, "labelLink": { "local": [ "athe-20211231_lab.xml" ] }, "presentationLink": { "local": [ "athe-20211231_pre.xml" ] }, "schema": { "local": [ "athe-20211231.xsd", "reference-2009-12-16.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd" ] } }, "elementCount": 288, "entityCount": 1, "hidden": { "http://pranabio.com/20211231": 16, "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 31, "http://xbrl.sec.gov/dei/2021": 16, "total": 63 }, "keyCustom": 76, "keyStandard": 216, "memberCustom": 10, "memberStandard": 5, "nsprefix": "athe", "nsuri": "http://pranabio.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "ea156195-6k_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://pranabio.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "ea156195-6k_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Loss Per Share", "role": "http://pranabio.com/role/LossPerShare", "shortName": "Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Interest and Other Income", "role": "http://pranabio.com/role/InterestandOtherIncome", "shortName": "Interest and Other Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:LossForThePeriodTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Loss for the Period", "role": "http://pranabio.com/role/LossforthePeriod", "shortName": "Loss for the Period", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:LossForThePeriodTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Financial Assets and Financial Liabilities", "role": "http://pranabio.com/role/FinancialAssetsandFinancialLiabilities", "shortName": "Financial Assets and Financial Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Equity", "role": "http://pranabio.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities", "role": "http://pranabio.com/role/ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivities", "shortName": "Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Related Party Transactions", "role": "http://pranabio.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Events Occurring After the Reporting Period", "role": "http://pranabio.com/role/EventsOccurringAftertheReportingPeriod", "shortName": "Events Occurring After the Reporting Period", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Significant Estimates and Assumptions", "role": "http://pranabio.com/role/SignificantEstimatesandAssumptions", "shortName": "Significant Estimates and Assumptions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:Covid19ImpactOnBusinessTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Covid-19 Impact on Business", "role": "http://pranabio.com/role/Covid19ImpactonBusiness", "shortName": "Covid-19 Impact on Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:Covid19ImpactOnBusinessTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:RevenueFromInterest", "reportCount": 1, "unitRef": "aud", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited)", "role": "http://pranabio.com/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:OtherIncome", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:EarningsPerSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Loss Per Share (Tables)", "role": "http://pranabio.com/role/LossPerShareTables", "shortName": "Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:EarningsPerSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:DisclosureOfOtherOperatingIncomeExpenseExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Interest and Other Income (Tables)", "role": "http://pranabio.com/role/InterestandOtherIncomeTables", "shortName": "Interest and Other Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:DisclosureOfOtherOperatingIncomeExpenseExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:ScheduleOfLossForThePeriodTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Loss for the Period (Tables)", "role": "http://pranabio.com/role/LossforthePeriodTables", "shortName": "Loss for the Period (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:ScheduleOfLossForThePeriodTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:DisclosureOfTradeAndOtherReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Financial Assets and Financial Liabilities (Tables)", "role": "http://pranabio.com/role/FinancialAssetsandFinancialLiabilitiesTables", "shortName": "Financial Assets and Financial Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:DisclosureOfTradeAndOtherReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:ScheduleOfContributedEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Equity (Tables)", "role": "http://pranabio.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:ScheduleOfContributedEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:ScheduleOfProfitLossFromOperatingActivitiesExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Tables)", "role": "http://pranabio.com/role/ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivitiesTables", "shortName": "Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:ScheduleOfProfitLossFromOperatingActivitiesExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c28", "decimals": "0", "first": true, "lang": null, "name": "athe:CompanyIssuedAmount", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Significant Changes in The Current Reporting Period (Details)", "role": "http://pranabio.com/role/SignificantChangesinTheCurrentReportingPeriodDetails", "shortName": "Significant Changes in The Current Reporting Period (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c28", "decimals": "0", "first": true, "lang": null, "name": "athe:CompanyIssuedAmount", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" } }, "R27": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Dividends (Details)", "role": "http://pranabio.com/role/DividendsDetails", "shortName": "Dividends (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:BasicEarningsLossPerShare", "reportCount": 1, "unitRef": "audPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Loss Per Share (Details) - Schedule of earning loss per share", "role": "http://pranabio.com/role/ScheduleofearninglosspershareTable", "shortName": "Loss Per Share (Details) - Schedule of earning loss per share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "INF", "lang": null, "name": "athe:LossAttributableToOrdinaryEquityHoldersOfGroupUsedInCalculatingBasicLoss", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:RevenueFromInterest", "reportCount": 1, "unitRef": "aud", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Interest and Other Income (Details) - Schedule of interest and other income", "role": "http://pranabio.com/role/ScheduleofinterestandotherincomeTable", "shortName": "Interest and Other Income (Details) - Schedule of interest and other income", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:DisclosureOfOtherOperatingIncomeExpenseExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "ifrs-full:OtherRevenue", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "aud", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Statement of Financial Position (Unaudited)", "role": "http://pranabio.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Statement of Financial Position (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c2", "decimals": "0", "lang": null, "name": "ifrs-full:OtherCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfLossForThePeriodTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:DepreciationRightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Loss for the Period (Details) - Schedule of loss for the period", "role": "http://pranabio.com/role/ScheduleoflossfortheperiodTable", "shortName": "Loss for the Period (Details) - Schedule of loss for the period", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfLossForThePeriodTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:DepreciationRightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "3", "first": true, "lang": null, "name": "athe:RDTaxIncentivePercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Financial Assets and Financial Liabilities (Details)", "role": "http://pranabio.com/role/FinancialAssetsandFinancialLiabilitiesDetails", "shortName": "Financial Assets and Financial Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "3", "first": true, "lang": null, "name": "athe:RDTaxIncentivePercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:DisclosureOfTradeAndOtherReceivablesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "athe:ResearchAndDevelopmentTaxIncentiveReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Financial Assets and Financial Liabilities (Details) - Schedule of trade and other receivables", "role": "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable", "shortName": "Financial Assets and Financial Liabilities (Details) - Schedule of trade and other receivables", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:DisclosureOfTradeAndOtherReceivablesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "athe:ResearchAndDevelopmentTaxIncentiveReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "athe:ScheduleOfContributedEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "athe:OrdinarySharesFullyPaidShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Equity (Details) - Schedule of contributed equity", "role": "http://pranabio.com/role/ScheduleofcontributedequityTable", "shortName": "Equity (Details) - Schedule of contributed equity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "athe:ScheduleOfContributedEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "athe:OrdinarySharesFullyPaidShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfMovementsInOrdinaryShareTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "athe:NumberOfShareIssuedAndFullyPaid", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Equity (Details) - Schedule of movements in ordinary share", "role": "http://pranabio.com/role/ScheduleofmovementsinordinaryshareTable", "shortName": "Equity (Details) - Schedule of movements in ordinary share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfMovementsInOrdinaryShareTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "athe:NumberOfShareIssuedAndFullyPaid", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfDetailsOfSharesIssuedDuringTheCurrentPeriodTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c30", "decimals": "INF", "first": true, "lang": null, "name": "athe:NumberIssueOfSharesUnderATMFacility", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Equity (Details) - Schedule of details of shares issued during the current period", "role": "http://pranabio.com/role/ScheduleofdetailsofsharesissuedduringthecurrentperiodTable", "shortName": "Equity (Details) - Schedule of details of shares issued during the current period", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfDetailsOfSharesIssuedDuringTheCurrentPeriodTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c30", "decimals": "INF", "first": true, "lang": null, "name": "athe:NumberIssueOfSharesUnderATMFacility", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfMovementsInAccumulatedLossesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "athe:RetainedEarning", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Equity (Details) - Schedule of movements in accumulated losses", "role": "http://pranabio.com/role/ScheduleofmovementsinaccumulatedlossesTable", "shortName": "Equity (Details) - Schedule of movements in accumulated losses", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfMovementsInAccumulatedLossesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "athe:RetainedEarning", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "athe:ScheduleOfOptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssuedAndFullyPaid", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Equity (Details) - Schedule of options", "role": "http://pranabio.com/role/ScheduleofoptionsTable", "shortName": "Equity (Details) - Schedule of options", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "athe:ScheduleOfOptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssuedAndFullyPaid", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfPresentsTheMovementsInOptionsGrantedAndIssuedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "athe:NumberOfStockOptionShareIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Equity (Details) - Schedule of presents the movements in options granted and issued", "role": "http://pranabio.com/role/ScheduleofpresentsthemovementsinoptionsgrantedandissuedTable", "shortName": "Equity (Details) - Schedule of presents the movements in options granted and issued", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfPresentsTheMovementsInOptionsGrantedAndIssuedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "athe:NumberOfStockOptionShareIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfFairValueAtGrantDatePerOptionTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "athe:NumberOfSharesQuantity", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Equity (Details) - Schedule of fair value at grant date per option", "role": "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable", "shortName": "Equity (Details) - Schedule of fair value at grant date per option", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfFairValueAtGrantDatePerOptionTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "athe:NumberOfSharesQuantity", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statement of Changes in Equity (Unaudited)", "role": "http://pranabio.com/role/ShareholdersEquityType2or3", "shortName": "Consolidated Statement of Changes in Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfOptionsFreeattachingOptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "athe:FreeattachingOptionsShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Equity (Details) - Schedule of options free-attaching options", "role": "http://pranabio.com/role/ScheduleofoptionsfreeattachingoptionsTable", "shortName": "Equity (Details) - Schedule of options free-attaching options", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfOptionsFreeattachingOptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "athe:FreeattachingOptionsShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfProfitLossFromOperatingActivitiesExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Details) - Schedule of profit after income tax to net cash flow from operating activities", "role": "http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable", "shortName": "Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Details) - Schedule of profit after income tax to net cash flow from operating activities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "athe:ScheduleOfProfitLossFromOperatingActivitiesExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:ProfessionalFeesExpense", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Related Party Transactions (Details)", "role": "http://pranabio.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:ProfessionalFeesExpense", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c40", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Events Occurring After the Reporting Period (Details)", "role": "http://pranabio.com/role/EventsOccurringAftertheReportingPeriodDetails", "shortName": "Events Occurring After the Reporting Period (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c40", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:DescriptionOfResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Significant Estimates and Assumptions (Details)", "role": "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails", "shortName": "Significant Estimates and Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:DescriptionOfResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statement of Cash Flows (Unaudited)", "role": "http://pranabio.com/role/ConsolidatedCashFlow", "shortName": "Consolidated Statement of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees", "reportCount": 1, "unique": true, "unitRef": "aud", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "005 - Disclosure - Basis of Preparation of Half-Year Report", "role": "http://pranabio.com/role/BasisofPreparationofHalfYearReport", "shortName": "Basis of Preparation of Half-Year Report", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:SignificantChangesInCurrentReportingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Significant Changes in The Current Reporting Period", "role": "http://pranabio.com/role/SignificantChangesinTheCurrentReportingPeriod", "shortName": "Significant Changes in The Current Reporting Period", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:SignificantChangesInCurrentReportingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Segment Information", "role": "http://pranabio.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:DividendsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Dividends", "role": "http://pranabio.com/role/Dividends", "shortName": "Dividends", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea156195ex99-1_alterity.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "athe:DividendsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 15, "tag": { "athe_AmountOfIssuedAndFullyPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Opening balance.", "label": "AmountOfIssuedAndFullyPaid", "periodEndLabel": "Ending balance", "periodStartLabel": "Opening balance" } } }, "localname": "AmountOfIssuedAndFullyPaid", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofmovementsinordinaryshareTable" ], "xbrltype": "monetaryItemType" }, "athe_AuditInternalControlAndOtherAssuranceExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of expenses related to audit internal control and other assurance.", "label": "AuditInternalControlAndOtherAssuranceExpenses", "terseLabel": "Audit, internal control and other assurance expenses" } } }, "localname": "AuditInternalControlAndOtherAssuranceExpenses", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "athe_BasisofPreparationofHalfYearReportLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of background and significant accounting policies [Abstract]" } } }, "localname": "BasisofPreparationofHalfYearReportLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/BasisofPreparationofHalfYearReport" ], "xbrltype": "stringItemType" }, "athe_BasisofPreparationofHalfYearReportTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Preparation of Half-Year Report [Table]" } } }, "localname": "BasisofPreparationofHalfYearReportTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/BasisofPreparationofHalfYearReport" ], "xbrltype": "stringItemType" }, "athe_COVID19GovernmentRelief": { "auth_ref": [], "calculation": { "http://pranabio.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "COVID-19 government relief.", "label": "COVID19GovernmentRelief", "terseLabel": "COVID-19 government relief" } } }, "localname": "COVID19GovernmentRelief", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "athe_COVID19Relief": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "COVID-19 relief.", "label": "COVID19Relief", "terseLabel": "COVID-19 relief" } } }, "localname": "COVID19Relief", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofinterestandotherincomeTable" ], "xbrltype": "monetaryItemType" }, "athe_CashFlowsFromFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CashFlowsFromFinancingActivitiesAbstract", "terseLabel": "Cash flows from financing activities" } } }, "localname": "CashFlowsFromFinancingActivitiesAbstract", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "athe_CashFlowsFromInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CashFlowsFromInvestingActivitiesAbstract", "terseLabel": "Cash flows from investing activities" } } }, "localname": "CashFlowsFromInvestingActivitiesAbstract", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "athe_CashFlowsFromOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CashFlowsFromOperatingActivitiesAbstract", "terseLabel": "Cash flows from operating activities" } } }, "localname": "CashFlowsFromOperatingActivitiesAbstract", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "athe_CompanyAnnualAggregateTurnover": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of company annual aggregate turnover.", "label": "CompanyAnnualAggregateTurnover", "terseLabel": "Company annual aggregate turnover" } } }, "localname": "CompanyAnnualAggregateTurnover", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/FinancialAssetsandFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "athe_CompanyIssuedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Company issued amount.", "label": "CompanyIssuedAmount", "terseLabel": "Company issued amount" } } }, "localname": "CompanyIssuedAmount", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SignificantChangesinTheCurrentReportingPeriodDetails" ], "xbrltype": "monetaryItemType" }, "athe_ConsolidatedStatementOfChangesInEquityUnauditedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statement of Changes in Equity (Unaudited) [Abstract]" } } }, "localname": "ConsolidatedStatementOfChangesInEquityUnauditedAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ConsultantAndDirectorExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consultant and director expenses.", "label": "ConsultantAndDirectorExpenses", "terseLabel": "Consultant and director expenses" } } }, "localname": "ConsultantAndDirectorExpenses", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "athe_CorporateAdvisory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Corporate advisory.", "label": "CorporateAdvisory", "terseLabel": "Corporate advisory" } } }, "localname": "CorporateAdvisory", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "athe_CorporateComplianceExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of corporate compliance expenses.", "label": "CorporateComplianceExpenses", "terseLabel": "Corporate compliance expenses" } } }, "localname": "CorporateComplianceExpenses", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "athe_Covid19ImpactOnBusinessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Covid 19 Impact On Business [Abstract]" } } }, "localname": "Covid19ImpactOnBusinessAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_Covid19ImpactOnBusinessTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Covid19ImpactOnBusinessTextBlock", "terseLabel": "COVID-19 impact on business" } } }, "localname": "Covid19ImpactOnBusinessTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/Covid19ImpactonBusiness" ], "xbrltype": "textBlockItemType" }, "athe_Covid19ImpactonBusinessLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Covid-19 Impact on Business [Abstract]" } } }, "localname": "Covid19ImpactonBusinessLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/Covid19ImpactonBusiness" ], "xbrltype": "stringItemType" }, "athe_Covid19ImpactonBusinessTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Covid-19 Impact on Business [Table]" } } }, "localname": "Covid19ImpactonBusinessTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/Covid19ImpactonBusiness" ], "xbrltype": "stringItemType" }, "athe_DateIssuedOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DateIssuedOneMember", "terseLabel": "Date Issued One [Member]" } } }, "localname": "DateIssuedOneMember", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable" ], "xbrltype": "domainItemType" }, "athe_DateIssuedThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DateIssuedThreeMember", "terseLabel": "Date Issued Three [Member]" } } }, "localname": "DateIssuedThreeMember", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable" ], "xbrltype": "domainItemType" }, "athe_DateIssuedTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DateIssuedTwoMember", "terseLabel": "Date Issued Two [Member]" } } }, "localname": "DateIssuedTwoMember", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable" ], "xbrltype": "domainItemType" }, "athe_DepreciationOnFixedAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of fixed assets lose value as they age because they provide long-term income, these assets are expensed differently than other items.", "label": "DepreciationOnFixedAssets", "terseLabel": "Depreciation on fixed assets" } } }, "localname": "DepreciationOnFixedAssets", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable" ], "xbrltype": "monetaryItemType" }, "athe_DepreciationOnLeasedAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation on leased assets.", "label": "DepreciationOnLeasedAssets", "terseLabel": "Depreciation on leased assets" } } }, "localname": "DepreciationOnLeasedAssets", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "athe_DepreciatonOnLeasedAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of capital leases can have an impact on companies' financial statements, influencing interest expense, depreciation expense, assets, and liabilities.", "label": "DepreciatonOnLeasedAssets", "terseLabel": "Depreciation on leased assets" } } }, "localname": "DepreciatonOnLeasedAssets", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable" ], "xbrltype": "monetaryItemType" }, "athe_DescriptionOfResearchAndDevelopment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of research and development.", "label": "DescriptionOfResearchAndDevelopment", "terseLabel": "Research and development, description" } } }, "localname": "DescriptionOfResearchAndDevelopment", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails" ], "xbrltype": "stringItemType" }, "athe_DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block] [Abstract]" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesTextBlockAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_DisclosureOfBasisOfPreparationOfFinancialStatementsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block] [Abstract]" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsTextBlockAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_DisclosureOfEarningsPerShareTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of earnings per share [text block] [Abstract]" } } }, "localname": "DisclosureOfEarningsPerShareTextBlockAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_DisclosureOfEntitysOperatingSegmentsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of entity's operating segments [text block] [Abstract]" } } }, "localname": "DisclosureOfEntitysOperatingSegmentsTextBlockAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_DisclosureOfFinancialInstrumentsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of financial instruments [text block] [Abstract]" } } }, "localname": "DisclosureOfFinancialInstrumentsTextBlockAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_DisclosureOfNonAdjustingEventsAfterReportingPeriodTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [text block] [Abstract]" } } }, "localname": "DisclosureOfNonAdjustingEventsAfterReportingPeriodTextBlockAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_DisclosureOfOtherOperatingIncomeExpenseExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureOfOtherOperatingIncomeExpenseExplanatoryTableTextBlock", "terseLabel": "Schedule of interest and other income" } } }, "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatoryTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/InterestandOtherIncomeTables" ], "xbrltype": "textBlockItemType" }, "athe_DisclosureOfProfitLossFromOperatingActivitiesTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of profit (loss) from operating activities [text block] [Abstract]" } } }, "localname": "DisclosureOfProfitLossFromOperatingActivitiesTextBlockAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_DisclosureOfTradeAndOtherReceivablesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureOfTradeAndOtherReceivablesTableTextBlock", "terseLabel": "Schedule of trade and other receivables" } } }, "localname": "DisclosureOfTradeAndOtherReceivablesTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/FinancialAssetsandFinancialLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "athe_DisclosureOfTransactionsBetweenRelatedPartiesTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block] [Abstract]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTextBlockAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_DiscriptionOfOtherIncome": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discription of other income.", "label": "DiscriptionOfOtherIncome", "terseLabel": "Description of other income" } } }, "localname": "DiscriptionOfOtherIncome", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails" ], "xbrltype": "stringItemType" }, "athe_DividendsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DividendsTextBlock", "terseLabel": "Dividends" } } }, "localname": "DividendsTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/Dividends" ], "xbrltype": "textBlockItemType" }, "athe_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_DrSinclairMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DrSinclairMember", "terseLabel": "Dr Sinclair [Member]" } } }, "localname": "DrSinclairMember", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EventsOccurringAftertheReportingPeriodDetails" ], "xbrltype": "domainItemType" }, "athe_EarningsPerSharesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EarningsPerSharesTableTextBlock", "terseLabel": "Schedule of earning loss per share" } } }, "localname": "EarningsPerSharesTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "athe_EmployeeBenefitsExpenseUnderResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of employee benefit expense under research and development.", "label": "EmployeeBenefitsExpenseUnderResearchAndDevelopment", "terseLabel": "Employee expenses" } } }, "localname": "EmployeeBenefitsExpenseUnderResearchAndDevelopment", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "athe_EquityDetailsScheduleoffairvalueatgrantdateperoptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) - Schedule of fair value at grant date per option [Line Items]" } } }, "localname": "EquityDetailsScheduleoffairvalueatgrantdateperoptionLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable" ], "xbrltype": "stringItemType" }, "athe_EquityDetailsScheduleoffairvalueatgrantdateperoptionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) - Schedule of fair value at grant date per option [Table]" } } }, "localname": "EquityDetailsScheduleoffairvalueatgrantdateperoptionTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable" ], "xbrltype": "stringItemType" }, "athe_EquityDetailsScheduleofpresentsthemovementsinoptionsgrantedandissuedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]" } } }, "localname": "EquityDetailsScheduleofpresentsthemovementsinoptionsgrantedandissuedLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofpresentsthemovementsinoptionsgrantedandissuedTable" ], "xbrltype": "stringItemType" }, "athe_EquityDetailsScheduleofpresentsthemovementsinoptionsgrantedandissuedTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) - Schedule of presents the movements in options granted and issued [Table]" } } }, "localname": "EquityDetailsScheduleofpresentsthemovementsinoptionsgrantedandissuedTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofpresentsthemovementsinoptionsgrantedandissuedTable" ], "xbrltype": "stringItemType" }, "athe_EventsOccurringAftertheReportingPeriodDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Events Occurring After the Reporting Period (Details) [Line Items]" } } }, "localname": "EventsOccurringAftertheReportingPeriodDetailsLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EventsOccurringAftertheReportingPeriodDetails" ], "xbrltype": "stringItemType" }, "athe_EventsOccurringAftertheReportingPeriodDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Events Occurring After the Reporting Period (Details) [Table]" } } }, "localname": "EventsOccurringAftertheReportingPeriodDetailsTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EventsOccurringAftertheReportingPeriodDetails" ], "xbrltype": "stringItemType" }, "athe_EventsOccurringAftertheReportingPeriodLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Events Occurring after the Reporting Period [Abstract]" } } }, "localname": "EventsOccurringAftertheReportingPeriodLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EventsOccurringAftertheReportingPeriod" ], "xbrltype": "stringItemType" }, "athe_EventsOccurringAftertheReportingPeriodTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Events Occurring After the Reporting Period [Table]" } } }, "localname": "EventsOccurringAftertheReportingPeriodTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EventsOccurringAftertheReportingPeriod" ], "xbrltype": "stringItemType" }, "athe_ExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price.", "label": "ExercisePrice", "terseLabel": "Exercise price" } } }, "localname": "ExercisePrice", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable" ], "xbrltype": "perShareItemType" }, "athe_ExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ExpensesAbstract", "terseLabel": "Expenses" } } }, "localname": "ExpensesAbstract", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "athe_ExpiryDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiry Date.", "label": "ExpiryDate", "terseLabel": "Expiry Date" } } }, "localname": "ExpiryDate", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable" ], "xbrltype": "stringItemType" }, "athe_FairValueAtGrantDatePerOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value at grant date per option.", "label": "FairValueAtGrantDatePerOption", "terseLabel": "Fair value at grant date per option" } } }, "localname": "FairValueAtGrantDatePerOption", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable" ], "xbrltype": "perShareItemType" }, "athe_FreeattachingOptionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Free-attaching options shares.", "label": "FreeattachingOptionsShares", "terseLabel": "Free-attaching options, shares" } } }, "localname": "FreeattachingOptionsShares", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofoptionsfreeattachingoptionsTable" ], "xbrltype": "sharesItemType" }, "athe_FreeattachingOptionsValues": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Free-attaching options value.", "label": "FreeattachingOptionsValues", "terseLabel": "Free-attaching options, value" } } }, "localname": "FreeattachingOptionsValues", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofoptionsfreeattachingoptionsTable" ], "xbrltype": "monetaryItemType" }, "athe_GeneralAndAdministrationExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GeneralAndAdministrationExpensesAbstract", "terseLabel": "General and administration expenses" } } }, "localname": "GeneralAndAdministrationExpensesAbstract", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "stringItemType" }, "athe_GeoffreyKemplerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GeoffreyKemplerMember", "terseLabel": "Geoffrey Kempler [Member]" } } }, "localname": "GeoffreyKemplerMember", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "athe_IncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IncomeAbstract", "terseLabel": "Income" } } }, "localname": "IncomeAbstract", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "athe_IntellectualPropertyExpenses": { "auth_ref": [], "calculation": { "http://pranabio.com/role/ConsolidatedIncomeStatement": { "order": 5.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intellectual property expenses.", "label": "IntellectualPropertyExpenses", "negatedLabel": "Intellectual property expenses" } } }, "localname": "IntellectualPropertyExpenses", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "athe_IssuanceOfSharesNetOfCostsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of shares net of costs value.", "label": "IssuanceOfSharesNetOfCostsValue", "terseLabel": "Issue of ordinary shares" } } }, "localname": "IssuanceOfSharesNetOfCostsValue", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "athe_IssueOfSharesUnderATMFacility": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issue of shares under ATM facility.", "label": "IssueOfSharesUnderATMFacility", "terseLabel": "Amount Issue of shares under ATM facility" } } }, "localname": "IssueOfSharesUnderATMFacility", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofdetailsofsharesissuedduringthecurrentperiodTable" ], "xbrltype": "monetaryItemType" }, "athe_IssuePriceOfShareUnderATMFacility": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issue price of shares under ATM facility.", "label": "IssuePriceOfShareUnderATMFacility", "terseLabel": "Issue price Issue of shares under ATM facility" } } }, "localname": "IssuePriceOfShareUnderATMFacility", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofdetailsofsharesissuedduringthecurrentperiodTable" ], "xbrltype": "perShareItemType" }, "athe_IssuedDated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued Date.", "label": "IssuedDated", "terseLabel": "Date issued" } } }, "localname": "IssuedDated", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable" ], "xbrltype": "dateItemType" }, "athe_IssuedDates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock option shares issued date.", "label": "IssuedDates", "terseLabel": "Issued Date" } } }, "localname": "IssuedDates", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofpresentsthemovementsinoptionsgrantedandissuedTable" ], "xbrltype": "dateItemType" }, "athe_LawrenceGozlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LawrenceGozlanMember", "terseLabel": "Lawrence Gozlan [Member]" } } }, "localname": "LawrenceGozlanMember", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "athe_LossAttributableToOrdinaryEquityHoldersOfGroupUsedInCalculatingBasicLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share.", "label": "LossAttributableToOrdinaryEquityHoldersOfGroupUsedInCalculatingBasicLoss", "terseLabel": "Loss attributable to the ordinary equity holders of the company used in calculating basic loss per share:" } } }, "localname": "LossAttributableToOrdinaryEquityHoldersOfGroupUsedInCalculatingBasicLoss", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofearninglosspershareTable" ], "xbrltype": "monetaryItemType" }, "athe_LossAttributableToOrdinaryEquityHoldersOfGroupUsedInCalculatingDilutedLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share.", "label": "LossAttributableToOrdinaryEquityHoldersOfGroupUsedInCalculatingDilutedLoss", "terseLabel": "Loss attributable to the ordinary equity holders of the company used in calculating diluted loss per share:" } } }, "localname": "LossAttributableToOrdinaryEquityHoldersOfGroupUsedInCalculatingDilutedLoss", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofearninglosspershareTable" ], "xbrltype": "monetaryItemType" }, "athe_LossForThePeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss for the period.", "label": "LossForThePeriod", "terseLabel": "Loss for the period" } } }, "localname": "LossForThePeriod", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "athe_LossForThePeriodTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LossForThePeriodTextBlock", "terseLabel": "Loss for the period" } } }, "localname": "LossForThePeriodTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/LossforthePeriod" ], "xbrltype": "textBlockItemType" }, "athe_LossPerShareForProfitAttributableToTheOrdinaryEquityHoldersOfTheGroupAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LossPerShareForProfitAttributableToTheOrdinaryEquityHoldersOfTheGroupAbstract", "terseLabel": "Loss per share for profit attributable to the ordinary equity holders of the Group:" } } }, "localname": "LossPerShareForProfitAttributableToTheOrdinaryEquityHoldersOfTheGroupAbstract", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "athe_LossPerShareForProfitAttributableToTheOrdinaryEquityHoldersOfTheGroupAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LossPerShareForProfitAttributableToTheOrdinaryEquityHoldersOfTheGroupAbstract0", "terseLabel": "Loss per share for profit attributable to the ordinary equity holders of the Group:" } } }, "localname": "LossPerShareForProfitAttributableToTheOrdinaryEquityHoldersOfTheGroupAbstract0", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofearninglosspershareTable" ], "xbrltype": "stringItemType" }, "athe_LossPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per share [abstract]" } } }, "localname": "LossPerShareLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/LossPerShare" ], "xbrltype": "stringItemType" }, "athe_LossPerShareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss Per Share [Table]" } } }, "localname": "LossPerShareTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/LossPerShare" ], "xbrltype": "stringItemType" }, "athe_MrEdwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MrEdwardsMember", "terseLabel": "Mr Edwards [Member]" } } }, "localname": "MrEdwardsMember", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EventsOccurringAftertheReportingPeriodDetails" ], "xbrltype": "domainItemType" }, "athe_NetCashFlowUsedInOperatingActivities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net cash flows used in operating activities.", "label": "NetCashFlowUsedInOperatingActivities", "terseLabel": "Net cash flows used in operating activities" } } }, "localname": "NetCashFlowUsedInOperatingActivities", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable" ], "xbrltype": "monetaryItemType" }, "athe_NoncashEmployeeBenefitsExpenseSharebasedPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of non-cash employee benefits expense share-based payments.", "label": "NoncashEmployeeBenefitsExpenseSharebasedPayments", "terseLabel": "Non-cash employee benefits expense - share-based payments" } } }, "localname": "NoncashEmployeeBenefitsExpenseSharebasedPayments", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable" ], "xbrltype": "monetaryItemType" }, "athe_NumberIssueOfSharesUnderATMFacility": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Issue of shares under ATM facility.", "label": "NumberIssueOfSharesUnderATMFacility", "terseLabel": "Number Issue of shares under ATM facility" } } }, "localname": "NumberIssueOfSharesUnderATMFacility", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofdetailsofsharesissuedduringthecurrentperiodTable" ], "xbrltype": "sharesItemType" }, "athe_NumberOfShareIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Shares Issued.", "label": "NumberOfShareIssued", "terseLabel": "Number Of Shares Issued" } } }, "localname": "NumberOfShareIssued", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SignificantChangesinTheCurrentReportingPeriodDetails" ], "xbrltype": "sharesItemType" }, "athe_NumberOfShareIssuedAndFullyPaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Opening balance, shares.", "label": "NumberOfShareIssuedAndFullyPaid", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Opening balance, shares" } } }, "localname": "NumberOfShareIssuedAndFullyPaid", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofmovementsinordinaryshareTable" ], "xbrltype": "sharesItemType" }, "athe_NumberOfSharesQuantity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares quantity.", "label": "NumberOfSharesQuantity", "terseLabel": "Quantity" } } }, "localname": "NumberOfSharesQuantity", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable" ], "xbrltype": "sharesItemType" }, "athe_NumberOfStockOptionShareIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock option shares issued.", "label": "NumberOfStockOptionShareIssued", "terseLabel": "Number of stock option shares issued" } } }, "localname": "NumberOfStockOptionShareIssued", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofpresentsthemovementsinoptionsgrantedandissuedTable" ], "xbrltype": "sharesItemType" }, "athe_OrdinarySharesFullyPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Ordinary shares - fully paid.", "label": "OrdinarySharesFullyPaid", "terseLabel": "Ordinary shares - fully paid value" } } }, "localname": "OrdinarySharesFullyPaid", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofcontributedequityTable" ], "xbrltype": "monetaryItemType" }, "athe_OrdinarySharesFullyPaidShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary shares - fully paid, shares.", "label": "OrdinarySharesFullyPaidShares", "terseLabel": "Ordinary shares - fully paid, shares" } } }, "localname": "OrdinarySharesFullyPaidShares", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofcontributedequityTable" ], "xbrltype": "sharesItemType" }, "athe_OtherComprehensiveLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OtherComprehensiveLossAbstract", "terseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveLossAbstract", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "athe_OtherGainsAndLossesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OtherGainsAndLossesAbstract", "terseLabel": "Other gains and losses" } } }, "localname": "OtherGainsAndLossesAbstract", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "stringItemType" }, "athe_OtherGrant1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "OtherGrant1", "terseLabel": "Other grant" } } }, "localname": "OtherGrant1", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofinterestandotherincomeTable" ], "xbrltype": "monetaryItemType" }, "athe_OtherReceivableTotal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The Amount of Other receivable Total.", "label": "OtherReceivableTotal", "terseLabel": "Other receivable, Total" } } }, "localname": "OtherReceivableTotal", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "athe_ProceedsFromIssuesOfSharesAndOtherEquitySecurities": { "auth_ref": [], "calculation": { "http://pranabio.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the exercise of options and issue of securities.", "label": "ProceedsFromIssuesOfSharesAndOtherEquitySecurities", "terseLabel": "Proceeds from issues of shares and other equity securities" } } }, "localname": "ProceedsFromIssuesOfSharesAndOtherEquitySecurities", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "athe_RDTaxIncentivePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "R&D Tax incentive Percentage.", "label": "RDTaxIncentivePercentage", "terseLabel": "R&D tax incentive percentage" } } }, "localname": "RDTaxIncentivePercentage", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/FinancialAssetsandFinancialLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "athe_ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of profit after income tax to net cash flow from operating activities [Abstract]" } } }, "localname": "ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivitiesLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivities" ], "xbrltype": "stringItemType" }, "athe_ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities [Table]" } } }, "localname": "ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivitiesTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivities" ], "xbrltype": "stringItemType" }, "athe_RefundableTaxOffsetRateValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Refundable tax offset rate value.", "label": "RefundableTaxOffsetRateValue", "terseLabel": "Refundable tax offset rate value" } } }, "localname": "RefundableTaxOffsetRateValue", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "athe_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "athe_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "athe_RelatedPartyTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related party transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/RelatedPartyTransactions" ], "xbrltype": "stringItemType" }, "athe_RelatedPartyTransactionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Table]" } } }, "localname": "RelatedPartyTransactionsTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/RelatedPartyTransactions" ], "xbrltype": "stringItemType" }, "athe_ResearchAndDevelopmentExpenditure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expenditure.", "label": "ResearchAndDevelopmentExpenditure", "terseLabel": "Research and development expenditure" } } }, "localname": "ResearchAndDevelopmentExpenditure", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "athe_ResearchAndDevelopmentExpenseOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of research and development that the entity does not separately disclose in the same statement or note.", "label": "ResearchAndDevelopmentExpenseOther", "terseLabel": "Other research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseOther", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "athe_ResearchAndDevelopmentExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ResearchAndDevelopmentExpensesAbstract", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpensesAbstract", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "stringItemType" }, "athe_ResearchAndDevelopmentTaxIncentive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development tax incentive.", "label": "ResearchAndDevelopmentTaxIncentive", "terseLabel": "Other income recognise amount" } } }, "localname": "ResearchAndDevelopmentTaxIncentive", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "athe_ResearchAndDevelopmentTaxIncentiveReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of research and development tax incentive receivable.", "label": "ResearchAndDevelopmentTaxIncentiveReceivable", "terseLabel": "R&D tax incentive receivable, Total" } } }, "localname": "ResearchAndDevelopmentTaxIncentiveReceivable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "athe_ResearchAndDevelopmentTaxIncentiveReceivableCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of research and development tax incentive receivable current.", "label": "ResearchAndDevelopmentTaxIncentiveReceivableCurrent", "terseLabel": "R&D tax incentive receivable, Current" } } }, "localname": "ResearchAndDevelopmentTaxIncentiveReceivableCurrent", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "athe_ResearchAndDevelopmentTaxIncentiveReceivableNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of research and development tax incentive receivable non-current.", "label": "ResearchAndDevelopmentTaxIncentiveReceivableNoncurrent", "terseLabel": "R&D tax incentive receivable, Non-current" } } }, "localname": "ResearchAndDevelopmentTaxIncentiveReceivableNoncurrent", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "athe_RetainedEarning": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Retained Earnings.", "label": "RetainedEarning", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period" } } }, "localname": "RetainedEarning", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofmovementsinaccumulatedlossesTable" ], "xbrltype": "monetaryItemType" }, "athe_ScheduleOfContributedEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of contributed equity [Abstract]" } } }, "localname": "ScheduleOfContributedEquityAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ScheduleOfContributedEquityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfContributedEquityTableTextBlock", "terseLabel": "Schedule of contributed equity" } } }, "localname": "ScheduleOfContributedEquityTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "athe_ScheduleOfDetailsOfSharesIssuedDuringTheCurrentPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of details of shares issued during the current period [Abstract]" } } }, "localname": "ScheduleOfDetailsOfSharesIssuedDuringTheCurrentPeriodAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ScheduleOfDetailsOfSharesIssuedDuringTheCurrentPeriodTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfDetailsOfSharesIssuedDuringTheCurrentPeriodTableTextBlock", "terseLabel": "Schedule of details of shares issued during the current period" } } }, "localname": "ScheduleOfDetailsOfSharesIssuedDuringTheCurrentPeriodTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "athe_ScheduleOfEarningLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of earning loss per share [Abstract]" } } }, "localname": "ScheduleOfEarningLossPerShareAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ScheduleOfFairValueAtGrantDatePerOptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of fair value at grant date per option [Abstract]" } } }, "localname": "ScheduleOfFairValueAtGrantDatePerOptionAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ScheduleOfFairValueAtGrantDatePerOptionTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfFairValueAtGrantDatePerOptionTableTextBlock", "terseLabel": "Schedule of fair value at grant date per option" } } }, "localname": "ScheduleOfFairValueAtGrantDatePerOptionTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "athe_ScheduleOfInterestAndOtherIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of interest and other income [Abstract]" } } }, "localname": "ScheduleOfInterestAndOtherIncomeAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ScheduleOfLossForThePeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of loss for the period [Abstract]" } } }, "localname": "ScheduleOfLossForThePeriodAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ScheduleOfLossForThePeriodTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfLossForThePeriodTableTextBlock", "terseLabel": "Schedule of loss for the period" } } }, "localname": "ScheduleOfLossForThePeriodTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/LossforthePeriodTables" ], "xbrltype": "textBlockItemType" }, "athe_ScheduleOfMovementsInAccumulatedLossesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of movements in accumulated losses [Abstract]" } } }, "localname": "ScheduleOfMovementsInAccumulatedLossesAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ScheduleOfMovementsInAccumulatedLossesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfMovementsInAccumulatedLossesTableTextBlock", "terseLabel": "Schedule of movements in accumulated losses" } } }, "localname": "ScheduleOfMovementsInAccumulatedLossesTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "athe_ScheduleOfMovementsInOrdinaryShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of movements in ordinary share [Abstract]" } } }, "localname": "ScheduleOfMovementsInOrdinaryShareAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ScheduleOfMovementsInOrdinaryShareTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfMovementsInOrdinaryShareTableTextBlock", "terseLabel": "Schedule of movements in ordinary share" } } }, "localname": "ScheduleOfMovementsInOrdinaryShareTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "athe_ScheduleOfOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of options [Abstract]" } } }, "localname": "ScheduleOfOptionsAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ScheduleOfOptionsFreeAttachingOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of options free-attaching options [Abstract]" } } }, "localname": "ScheduleOfOptionsFreeAttachingOptionsAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ScheduleOfOptionsFreeattachingOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfOptionsFreeattachingOptionsTableTextBlock", "terseLabel": "Schedule of options free-attaching options" } } }, "localname": "ScheduleOfOptionsFreeattachingOptionsTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "athe_ScheduleOfOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfOptionsTableTextBlock", "terseLabel": "Schedule of options" } } }, "localname": "ScheduleOfOptionsTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "athe_ScheduleOfPresentsTheMovementsInOptionsGrantedAndIssuedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of presents the movements in options granted and issued [Abstract]" } } }, "localname": "ScheduleOfPresentsTheMovementsInOptionsGrantedAndIssuedAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ScheduleOfPresentsTheMovementsInOptionsGrantedAndIssuedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfPresentsTheMovementsInOptionsGrantedAndIssuedTableTextBlock", "terseLabel": "Schedule of presents the movements in options granted and issued" } } }, "localname": "ScheduleOfPresentsTheMovementsInOptionsGrantedAndIssuedTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "athe_ScheduleOfProfitAfterIncomeTaxToNetCashFlowFromOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of profit after income tax to net cash flow from operating activities [Abstract]" } } }, "localname": "ScheduleOfProfitAfterIncomeTaxToNetCashFlowFromOperatingActivitiesAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_ScheduleOfProfitLossFromOperatingActivitiesExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfProfitLossFromOperatingActivitiesExplanatoryTableTextBlock", "terseLabel": "Schedule of profit after income tax to net cash flow from operating activities" } } }, "localname": "ScheduleOfProfitLossFromOperatingActivitiesExplanatoryTableTextBlock", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "athe_ScheduleOfTradeAndOtherReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of trade and other receivables [Abstract]" } } }, "localname": "ScheduleOfTradeAndOtherReceivablesAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_SegmentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentInformationLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SegmentInformation" ], "xbrltype": "stringItemType" }, "athe_SegmentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Information [Table]" } } }, "localname": "SegmentInformationTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SegmentInformation" ], "xbrltype": "stringItemType" }, "athe_SharebasedPaymentExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-based payment expenses.", "label": "SharebasedPaymentExpenses", "terseLabel": "Share-based payment expenses" } } }, "localname": "SharebasedPaymentExpenses", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "athe_SharesIssuedDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued during the year.", "label": "SharesIssuedDuringPeriod", "terseLabel": "Shares issued during the year" } } }, "localname": "SharesIssuedDuringPeriod", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofmovementsinordinaryshareTable" ], "xbrltype": "monetaryItemType" }, "athe_SharesIssuedDuringTheYearShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued during the year, shares.", "label": "SharesIssuedDuringTheYearShares", "terseLabel": "Shares issued during the year, shares" } } }, "localname": "SharesIssuedDuringTheYearShares", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofmovementsinordinaryshareTable" ], "xbrltype": "sharesItemType" }, "athe_SignificantChangesInCurrentReportingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SignificantChangesInCurrentReportingPeriod", "terseLabel": "Significant changes in the current reporting period" } } }, "localname": "SignificantChangesInCurrentReportingPeriod", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SignificantChangesinTheCurrentReportingPeriod" ], "xbrltype": "textBlockItemType" }, "athe_SignificantChangesInCurrentReportingPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Changes In Current Reporting Period [Abstract]" } } }, "localname": "SignificantChangesInCurrentReportingPeriodAbstract", "nsuri": "http://pranabio.com/20211231", "xbrltype": "stringItemType" }, "athe_SignificantEstimatesandAssumptionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Estimates and Assumptions (Details) [Line Items]" } } }, "localname": "SignificantEstimatesandAssumptionsDetailsLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails" ], "xbrltype": "stringItemType" }, "athe_SignificantEstimatesandAssumptionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Estimates and Assumptions (Details) [Table]" } } }, "localname": "SignificantEstimatesandAssumptionsDetailsTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails" ], "xbrltype": "stringItemType" }, "athe_SignificantEstimatesandAssumptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Estimates and Assumptions [Abstract]" } } }, "localname": "SignificantEstimatesandAssumptionsLineItems", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptions" ], "xbrltype": "stringItemType" }, "athe_SignificantEstimatesandAssumptionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Estimates and Assumptions [Table]" } } }, "localname": "SignificantEstimatesandAssumptionsTable", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptions" ], "xbrltype": "stringItemType" }, "athe_StockOptionSharesIssuedValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock option shares issued value.", "label": "StockOptionSharesIssuedValue", "terseLabel": "Stock option shares issued value" } } }, "localname": "StockOptionSharesIssuedValue", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofpresentsthemovementsinoptionsgrantedandissuedTable" ], "xbrltype": "monetaryItemType" }, "athe_TotalGeneralAndAdministrationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "TotalGeneralAndAdministrationExpense", "terseLabel": "Total general and administration expense" } } }, "localname": "TotalGeneralAndAdministrationExpense", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "athe_TotalResearchAndDevelopmentExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "TotalResearchAndDevelopmentExpenses", "terseLabel": "Total research and development expenses" } } }, "localname": "TotalResearchAndDevelopmentExpenses", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "athe_TotalValueOfSharesIssued": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total value of shares issued.", "label": "TotalValueOfSharesIssued", "terseLabel": "Total value of shares issued" } } }, "localname": "TotalValueOfSharesIssued", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofdetailsofsharesissuedduringthecurrentperiodTable" ], "xbrltype": "monetaryItemType" }, "athe_TransactionCostsRelatingToShareIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transaction costs.", "label": "TransactionCostsRelatingToShareIssues", "terseLabel": "Transaction costs | $" } } }, "localname": "TransactionCostsRelatingToShareIssues", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofmovementsinordinaryshareTable" ], "xbrltype": "monetaryItemType" }, "athe_TransactionCostsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction costs, shares.", "label": "TransactionCostsShares", "terseLabel": "Transaction costs, shares" } } }, "localname": "TransactionCostsShares", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofmovementsinordinaryshareTable" ], "xbrltype": "sharesItemType" }, "athe_UnlistedOptionsIssuedToConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UnlistedOptionsIssuedToConsultantMember", "terseLabel": "Unlisted options issued to consultant [Member]" } } }, "localname": "UnlistedOptionsIssuedToConsultantMember", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofpresentsthemovementsinoptionsgrantedandissuedTable" ], "xbrltype": "domainItemType" }, "athe_UnlistedOptionsIssuedToEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UnlistedOptionsIssuedToEmployeesMember", "terseLabel": "Unlisted options issued to employees [Member]" } } }, "localname": "UnlistedOptionsIssuedToEmployeesMember", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofpresentsthemovementsinoptionsgrantedandissuedTable" ], "xbrltype": "domainItemType" }, "athe_UnlistedOptionsIssuedToEmployeesOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UnlistedOptionsIssuedToEmployeesOneMember", "terseLabel": "Unlisted options issued to employees [Member[" } } }, "localname": "UnlistedOptionsIssuedToEmployeesOneMember", "nsuri": "http://pranabio.com/20211231", "presentation": [ "http://pranabio.com/role/ScheduleofpresentsthemovementsinoptionsgrantedandissuedTable" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pranabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pranabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pranabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pranabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pranabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pranabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pranabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pranabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pranabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pranabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pranabio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other current assets", "terseLabel": "Increase/(decrease) in other current assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Increase/(decrease) in trade and other receivables" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in other current liabilities", "terseLabel": "(Increase)/decrease in other current liabilities" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "terseLabel": "(Increase)/decrease in trade and other payables" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdministrativeExpense": { "auth_ref": [ "r2", "r35", "r46" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses that the entity classifies as being administrative." } }, "en-us": { "role": { "label": "Administrative expenses", "terseLabel": "Other administrative and office expenses" } } }, "localname": "AdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r19", "r89", "r90", "r91", "r105", "r108" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r51", "r52" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic loss per share (in Dollars per share)", "verboseLabel": "Basic loss per share" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement", "http://pranabio.com/role/ScheduleofearninglosspershareTable" ], "xbrltype": "perShareItemType" }, "ifrs-full_BasicEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss for the Period [Abstract]", "terseLabel": "Basic loss per share" } } }, "localname": "BasicEarningsPerShareAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofearninglosspershareTable" ], "xbrltype": "stringItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r92", "r93", "r94", "r97", "r100", "r116" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom of range [member]", "terseLabel": "Bottom of range [member]" } } }, "localname": "BottomOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BusinessCombinationsAxis": { "auth_ref": [ "r98" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Business combinations [axis]" } } }, "localname": "BusinessCombinationsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/EventsOccurringAftertheReportingPeriodDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r16", "r68", "r86" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at the beginning of the financial year", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet", "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r58", "r69" ], "calculation": { "http://pranabio.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash inflow from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r58", "r69" ], "calculation": { "http://pranabio.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash (outflow) from investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r58", "r69" ], "calculation": { "http://pranabio.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash (outflow) from operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in equity [abstract]", "terseLabel": "Transactions with owners in their capacity as owners:" } } }, "localname": "ChangesInEquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_ChangesInOtherProvisions": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in other provisions. [Refer: Other provisions]" } }, "en-us": { "role": { "label": "Increase (decrease) in other provisions", "terseLabel": "(Increase)/decrease in provisions" } } }, "localname": "ChangesInOtherProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ClassesOfCashPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest and Other Income [Abstract]" } } }, "localname": "ClassesOfCashPaymentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r26" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable", "http://pranabio.com/role/ScheduleofpresentsthemovementsinoptionsgrantedandissuedTable" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r26" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable", "http://pranabio.com/role/ScheduleofpresentsthemovementsinoptionsgrantedandissuedTable" ], "xbrltype": "domainItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r4", "r29", "r71", "r73", "r78", "r83" ], "calculation": { "http://pranabio.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income", "terseLabel": "Total comprehensive income for the period", "totalLabel": "Total comprehensive loss for the period" } } }, "localname": "ComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement", "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets": { "auth_ref": [ "r19", "r24" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]" } }, "en-us": { "role": { "label": "Current accrued income including current contract assets", "terseLabel": "Accrued interest income, Current" } } }, "localname": "CurrentAccruedIncomeIncludingCurrentContractAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r20", "r78", "r79" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r21", "r78", "r81" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentProvisions": { "auth_ref": [ "r18" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Current provisions", "terseLabel": "Provisions" } } }, "localname": "CurrentProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]" } }, "en-us": { "role": { "label": "Current receivables from taxes other than income tax", "terseLabel": "Goods and services tax receivable, Current" } } }, "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationRightofuseAssets": { "auth_ref": [ "r95" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } }, "en-us": { "role": { "label": "Depreciation, right-of-use assets", "terseLabel": "Depreciation on fixed assets" } } }, "localname": "DepreciationRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r51", "r52" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted loss per share (in Dollars per share)", "verboseLabel": "Diluted loss per share" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement", "http://pranabio.com/role/ScheduleofearninglosspershareTable" ], "xbrltype": "perShareItemType" }, "ifrs-full_DilutedEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Diluted earnings per share [abstract]", "terseLabel": "Diluted loss per share" } } }, "localname": "DilutedEarningsPerShareAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofearninglosspershareTable" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Significant estimates and assumptions" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } }, "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "terseLabel": "Basis of preparation of half-year report" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/BasisofPreparationofHalfYearReport" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r54" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "Loss per share" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/LossPerShare" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "auth_ref": [ "r114" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for operating segments." } }, "en-us": { "role": { "label": "Disclosure of entity's operating segments [text block]", "terseLabel": "Segment information" } } }, "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r101" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for financial instruments." } }, "en-us": { "role": { "label": "Disclosure of financial instruments [text block]", "terseLabel": "Financial assets and financial liabilities" } } }, "localname": "DisclosureOfFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/FinancialAssetsandFinancialLiabilities" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]" } }, "en-us": { "role": { "label": "Disclosure of investments accounted for using equity method [text block]", "terseLabel": "Equity" } } }, "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [member]]" } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [text block]", "terseLabel": "Events occurring after the reporting period" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/EventsOccurringAftertheReportingPeriod" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of profit (loss) from operating activities. [Refer: Profit (loss) from operating activities]" } }, "en-us": { "role": { "label": "Disclosure of profit (loss) from operating activities [text block]", "terseLabel": "Reconciliation of profit after income tax to net cash flow from operating activities" } } }, "localname": "DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ReconciliationofProfitAfterIncomeTaxtoNetCashFlowFromOperatingActivities" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Assets and Financial Liabilities [Abstract]" } } }, "localname": "DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory": { "auth_ref": [ "r77" ], "lang": { "en": { "role": { "documentation": "The disclosure of significant judgements and assumptions made in relation to interests in other entities." } }, "en-us": { "role": { "label": "Disclosure of significant judgements and assumptions made in relation to interests in other entities [text block]", "terseLabel": "Interest and other income" } } }, "localname": "DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/InterestandOtherIncome" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r45" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block]", "terseLabel": "Related party transactions" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DividendsPaid": { "auth_ref": [ "r10" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of dividends recognised as distributions to owners." } }, "en-us": { "role": { "label": "Dividends recognised as distributions to owners", "terseLabel": "Dividends" } } }, "localname": "DividendsPaid", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/DividendsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DividendsPaidOtherSharesPerShare": { "auth_ref": [ "r55" ], "lang": { "en": { "role": { "documentation": "The amount of dividends paid per other share." } }, "en-us": { "role": { "label": "Dividends paid, other shares per share", "terseLabel": "Price per share" } } }, "localname": "DividendsPaidOtherSharesPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/SignificantChangesinTheCurrentReportingPeriodDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r65", "r66" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Effects of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EmployeeBenefitsExpense": { "auth_ref": [ "r1", "r3", "r35" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee benefits expense", "terseLabel": "Employee expenses (non R&D related)" } } }, "localname": "EmployeeBenefitsExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r19", "r23", "r70", "r72", "r89", "r90", "r91" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total equity" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet", "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Gains (losses) on exchange differences on translation of foreign operations, net of tax", "terseLabel": "Net foreign exchange differences" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationNetOfTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "auth_ref": [ "r13", "r43" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Foreign exchange gain (loss)", "terseLabel": "Foreign exchange (gain)/ loss" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r12" ], "calculation": { "http://pranabio.com/role/ConsolidatedIncomeStatement": { "order": 6.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administration expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r32", "r38", "r39", "r40", "r47", "r88", "r104" ], "calculation": { "http://pranabio.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "auth_ref": [ "r68" ], "calculation": { "http://pranabio.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r7" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Transaction costs" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from transactions with owners." } }, "en-us": { "role": { "label": "Increase (decrease) through transactions with owners, equity", "terseLabel": "Total transactions with owners in their capacity as owners" } } }, "localname": "IncreaseDecreaseThroughTransactionsWithOwners", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InsuranceExpense": { "auth_ref": [ "r12" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from purchased insurance." } }, "en-us": { "role": { "label": "Insurance expense", "terseLabel": "Insurance expenses" } } }, "localname": "InsuranceExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "auth_ref": [ "r67" ], "calculation": { "http://pranabio.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } }, "en-us": { "role": { "label": "Interest received, classified as operating activities", "terseLabel": "Interest received" } } }, "localname": "InterestReceivedClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r23" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Contributed equity" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Contributed equity" } } }, "localname": "IssuedCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r19", "r89", "r90", "r91", "r105", "r109" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NameOfSubsidiary": { "auth_ref": [ "r48", "r49", "r75", "r76" ], "lang": { "en": { "role": { "documentation": "The name of a subsidiary. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Name of subsidiary", "terseLabel": "Grant Date" } } }, "localname": "NameOfSubsidiary", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoffairvalueatgrantdateperoptionTable" ], "xbrltype": "stringItemType" }, "ifrs-full_NetAssetsLiabilities": { "auth_ref": [ "r12", "r74" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } }, "en-us": { "role": { "label": "Assets (liabilities)", "totalLabel": "Net assets" } } }, "localname": "NetAssetsLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAccruedIncomeIncludingNoncurrentContractAssets": { "auth_ref": [ "r19", "r24" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current accrued income including non-current contract assets. [Refer: Accrued income including contract assets]" } }, "en-us": { "role": { "label": "Non-current accrued income including non-current contract assets", "terseLabel": "Accrued interest income, Non-current" } } }, "localname": "NoncurrentAccruedIncomeIncludingNoncurrentContractAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r20", "r78", "r80" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r21", "r78", "r82" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentProvisions": { "auth_ref": [ "r18" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Non-current provisions", "terseLabel": "Provisions" } } }, "localname": "NoncurrentProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentReceivables": { "auth_ref": [ "r15", "r22" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]" } }, "en-us": { "role": { "label": "Trade and other non-current receivables", "terseLabel": "Trade and other receivables, Non-current" } } }, "localname": "NoncurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentReceivablesFromTaxesOtherThanIncomeTax": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]" } }, "en-us": { "role": { "label": "Non-current receivables from taxes other than income tax", "terseLabel": "Goods and services tax receivable, Non-current" } } }, "localname": "NoncurrentReceivablesFromTaxesOtherThanIncomeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued", "terseLabel": "Total number of shares issued" } } }, "localname": "NumberOfSharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofdetailsofsharesissuedduringthecurrentperiodTable" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "auth_ref": [ "r25" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } }, "en-us": { "role": { "label": "Number of shares issued and fully paid", "terseLabel": "Options over fully paid ordinary shares, shares" } } }, "localname": "NumberOfSharesIssuedAndFullyPaid", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofoptionsTable" ], "xbrltype": "sharesItemType" }, "ifrs-full_OtherComprehensiveIncome": { "auth_ref": [ "r6", "r28", "r34", "r85" ], "calculation": { "http://pranabio.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Other comprehensive income for the period, net of tax" } } }, "localname": "OtherComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentAssets": { "auth_ref": [ "r19" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentLiabilities": { "auth_ref": [ "r19" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentReceivables": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } }, "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other receivable, Current" } } }, "localname": "OtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherGainsLosses": { "auth_ref": [ "r1", "r2" ], "calculation": { "http://pranabio.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other gains (losses)", "terseLabel": "Other gains/(losses)" } } }, "localname": "OtherGainsLosses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentLiabilities": { "auth_ref": [ "r19" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]" } }, "en-us": { "role": { "label": "Other non-current liabilities", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherNoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentReceivables": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current other receivables. [Refer: Other receivables]" } }, "en-us": { "role": { "label": "Other non-current receivables", "terseLabel": "Other receivable, Non-current" } } }, "localname": "OtherNoncurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherOperatingIncomeExpense": { "auth_ref": [ "r33" ], "calculation": { "http://pranabio.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other operating income (expense)", "terseLabel": "Other operating expenses" } } }, "localname": "OtherOperatingIncomeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherRevenue": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Other revenue", "terseLabel": "Total" } } }, "localname": "OtherRevenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofinterestandotherincomeTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsForShareIssueCosts": { "auth_ref": [ "r62" ], "calculation": { "http://pranabio.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for share issue costs." } }, "en-us": { "role": { "label": "Payments for share issue costs", "negatedLabel": "Transaction costs relating to issue of equity" } } }, "localname": "PaymentsForShareIssueCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r61" ], "calculation": { "http://pranabio.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Principle elements of lease payments" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees": { "auth_ref": [ "r59" ], "calculation": { "http://pranabio.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payments to suppliers for goods and services and to, and on behalf of, employees." } }, "en-us": { "role": { "label": "Payments to suppliers for goods and services and to and on behalf of employees", "negatedLabel": "Payments to suppliers and employees" } } }, "localname": "PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfessionalFeesExpense": { "auth_ref": [ "r12" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } }, "en-us": { "role": { "label": "Professional fees expense", "terseLabel": "Advisory fees paid" } } }, "localname": "ProfessionalFeesExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r5", "r27", "r63", "r71", "r73", "r78", "r105", "r107", "r115", "r117" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Loss for the period" } } }, "localname": "ProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss), attributable to owners of parent", "terseLabel": "Loss for the period" } } }, "localname": "ProfitLossAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofprofitafterincometaxtonetcashflowfromoperatingactivitiesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r1", "r2", "r99", "r105", "r107" ], "calculation": { "http://pranabio.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) before tax", "totalLabel": "Loss before income tax" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r33", "r50" ], "calculation": { "http://pranabio.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Loss for the period" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r14", "r41" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property, plant and equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://pranabio.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "Payments for property, plant and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r92", "r93", "r94", "r97", "r100", "r116" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r92", "r93", "r94", "r97", "r100", "r116" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity." } }, "en-us": { "role": { "label": "Receivables from taxes other than income tax", "terseLabel": "Goods and services tax receivable, Total" } } }, "localname": "ReceivablesFromTaxesOtherThanIncomeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RentalExpense": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense recognised on rental activities." } }, "en-us": { "role": { "label": "Rental expense", "terseLabel": "Office rental" } } }, "localname": "RentalExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r57" ], "calculation": { "http://pranabio.com/role/ConsolidatedIncomeStatement": { "order": 7.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "auth_ref": [ "r11", "r44" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]", "terseLabel": "Reserves" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_ReserveOfSharebasedPayments": { "auth_ref": [ "r23" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity resulting from share-based payments." } }, "en-us": { "role": { "label": "Reserve of share-based payments", "terseLabel": "Reserves", "verboseLabel": "Options over fully paid ordinary shares, value" } } }, "localname": "ReserveOfSharebasedPayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet", "http://pranabio.com/role/ScheduleofoptionsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r23", "r36" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated losses" } } }, "localname": "RetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r9", "r11" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings [member]", "terseLabel": "Accumulated losses" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r1", "r2", "r31", "r78", "r84", "r99", "r102", "r106", "r111", "r112", "r113" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "Revenue", "terseLabel": "Total" } } }, "localname": "Revenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofinterestandotherincomeTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromGovernmentGrants": { "auth_ref": [ "r42" ], "calculation": { "http://pranabio.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]" } }, "en-us": { "role": { "label": "Income from government grants", "terseLabel": "Other grant received" } } }, "localname": "RevenueFromGovernmentGrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromInterest": { "auth_ref": [ "r12", "r87", "r103", "r110" ], "calculation": { "http://pranabio.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income arising from interest." } }, "en-us": { "role": { "label": "Interest income", "terseLabel": "Interest income" } } }, "localname": "RevenueFromInterest", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement", "http://pranabio.com/role/ScheduleofinterestandotherincomeTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r96" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Right-of-use assets", "terseLabel": "Right-of-use assets" } } }, "localname": "RightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TaxRateEffectOfTaxLosses": { "auth_ref": [ "r40" ], "lang": { "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]" } }, "en-us": { "role": { "label": "Tax rate effect of tax losses", "terseLabel": "Refundable tax offset rate" } } }, "localname": "TaxRateEffectOfTaxLosses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r92", "r93", "r94", "r97", "r100", "r116" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range [member]", "terseLabel": "Top of range [member]" } } }, "localname": "TopOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/SignificantEstimatesandAssumptionsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayables": { "auth_ref": [ "r17" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } }, "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Trade and other payables" } } }, "localname": "TradeAndOtherCurrentPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentReceivables": { "auth_ref": [ "r15", "r22" ], "calculation": { "http://pranabio.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } }, "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Trade and other receivables", "verboseLabel": "Trade and other receivables, Current" } } }, "localname": "TradeAndOtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ConsolidatedBalanceSheet", "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherReceivables": { "auth_ref": [ "r15", "r22" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]" } }, "en-us": { "role": { "label": "Trade and other receivables", "terseLabel": "Trade and other receivables, Total" } } }, "localname": "TradeAndOtherReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r53" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share" } } }, "localname": "WeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://pranabio.com/role/ScheduleofearninglosspershareTable" ], "xbrltype": "sharesItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://pranabio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://pranabio.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccruedIncomeTaxes": { "auth_ref": [ "r119", "r120", "r152", "r160", "r162" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.", "label": "Accrued Income Taxes", "terseLabel": "Accrued interest income, Total" } } }, "localname": "AccruedIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pranabio.com/role/ScheduleoftradeandotherreceivablesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividends [Abstract]" } } }, "localname": "DividendsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Share-based payment expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pranabio.com/role/ScheduleoflossfortheperiodTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest and Other Income [Abstract] [Standard Label]", "terseLabel": "Interest and other income" } } }, "localname": "InterestAndOtherIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pranabio.com/role/ScheduleofinterestandotherincomeTable" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r163" ], "calculation": { "http://pranabio.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pranabio.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Component of Operating Income [Abstract]", "terseLabel": "Other Income" } } }, "localname": "OtherIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pranabio.com/role/ScheduleofinterestandotherincomeTable" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashIncome": { "auth_ref": [ "r129" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income or gain included in net income that result in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income", "terseLabel": "Other income" } } }, "localname": "OtherNoncashIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pranabio.com/role/FinancialAssetsandFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pranabio.com/role/FinancialAssetsandFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r118", "r124", "r125", "r126", "r128", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r161" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss for the period" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pranabio.com/role/ScheduleofmovementsinaccumulatedlossesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost": { "auth_ref": [ "r164" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.", "label": "Research and Development Expense, Software (Excluding Acquired in Process Cost)", "terseLabel": "R&D tax incentive" } } }, "localname": "ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pranabio.com/role/ScheduleofinterestandotherincomeTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r121", "r122", "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "terseLabel": "Forfeited and cancelled" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pranabio.com/role/EventsOccurringAftertheReportingPeriodDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24" }, "r1": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "107", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_107&doctype=Standard", "URIDate": "2021-03-24" }, "r100": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r101": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Scope", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2021-03-24" }, "r102": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2021-03-24" }, "r103": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2021-03-24" }, "r104": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2021-03-24" }, "r105": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24" }, "r106": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2021-03-24" }, "r107": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r108": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24" }, "r109": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2021-03-24" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24" }, "r110": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2021-03-24" }, "r111": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r112": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2021-03-24" }, "r113": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r114": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2021-03-24" }, "r115": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2021-03-24" }, "r116": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard", "URIDate": "2021-03-24" }, "r117": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2021-03-24" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2021-03-24" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2021-03-24" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r165": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r17": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "k", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2021-03-24" }, "r18": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "l", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2021-03-24" }, "r19": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24" }, "r2": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard", "URIDate": "2021-03-24" }, "r20": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r21": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard", "URIDate": "2021-03-24" }, "r22": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24" }, "r23": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24" }, "r24": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard", "URIDate": "2021-03-24" }, "r25": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24" }, "r27": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24" }, "r28": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2021-03-24" }, "r29": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2021-03-24" }, "r3": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard", "URIDate": "2021-03-24" }, "r30": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r31": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2021-03-24" }, "r32": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2021-03-24" }, "r33": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24" }, "r34": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2021-03-24" }, "r35": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard", "URIDate": "2021-03-24" }, "r36": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r37": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard", "URIDate": "2021-03-24" }, "r38": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r39": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2021-03-24" }, "r4": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2021-03-24" }, "r40": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r41": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2021-03-24" }, "r42": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "20", "Paragraph": "39", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2021-03-24" }, "r43": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2021-03-24" }, "r44": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2021-03-24" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard", "URIDate": "2021-03-24" }, "r46": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_vi&doctype=Standard", "URIDate": "2021-03-24" }, "r47": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2021-03-24" }, "r48": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r49": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r5": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2021-03-24" }, "r50": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r51": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r52": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard", "URIDate": "2021-03-24" }, "r53": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2021-03-24" }, "r54": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2021-03-24" }, "r55": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "34", "Paragraph": "16A", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=34&code=ifrs-tx-2021-en-r&anchor=para_16A_f&doctype=Standard", "URIDate": "2021-03-24" }, "r56": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Paragraph": "84", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84&doctype=Standard", "URIDate": "2021-03-24" }, "r57": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r58": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r59": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "14", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_14&doctype=Standard", "URIDate": "2021-03-24" }, "r6": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r60": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2021-03-24" }, "r61": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r62": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r63": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r64": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r65": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r66": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r67": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r68": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r69": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24" }, "r7": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r70": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r71": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24" }, "r72": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r73": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r74": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "IG63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r75": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_a&doctype=Standard", "URIDate": "2021-03-24" }, "r76": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "19B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r77": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r78": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r79": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r8": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24" }, "r80": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r81": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r82": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r83": { "Clause": "ix", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r84": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r85": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r86": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r87": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r88": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r89": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24" }, "r90": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24" }, "r91": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24" }, "r92": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r93": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r94": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24" }, "r95": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2021-03-24" }, "r96": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2021-03-24" }, "r97": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2021-03-24" }, "r98": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r99": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2021-03-24" } }, "version": "2.1" } ZIP 68 0001213900-22-009569-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-009569-xbrl.zip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

Document And Entity Information	6 Months Ended
Document And Entity Information	Dec. 31, 2021
Document Information Line Items
Entity Registrant Name	ALTERITY THERAPEUTICS LTD
Document Type	6-K
Current Fiscal Year End Date	--06-30
Amendment Flag	false
Entity Central Index Key	0001131343
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity File Number	000-49843

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited) - AUD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income
Interest income	$ 1,350	$ 6,553
Other income	2,359,198	1,924,389
Expenses
Intellectual property expenses	(205,896)	(160,304)
General and administration expenses	(3,194,790)	(3,673,407)
Research and development expenses	(6,761,542)	(5,806,841)
Other operating expenses	(624)	(20)
Other gains/(losses)	1,218,745	(852,232)
Loss for the period	(6,583,559)	(8,561,862)
Loss before income tax	(6,583,559)	(8,561,862)
Income tax expense
Other comprehensive loss
Other comprehensive income for the period, net of tax
Total comprehensive loss for the period	$ (6,583,559)	$ (8,561,862)
Loss per share for profit attributable to the ordinary equity holders of the Group:
Basic loss per share (in Dollars per share)	$ (0.27)	$ (0.65)
Diluted loss per share (in Dollars per share)	$ (0.27)	$ (0.65)

Consolidated Statement of Financial Position (Unaudited) - AUD ($)	Dec. 31, 2021	Jun. 30, 2021
Current assets
Cash and cash equivalents	$ 37,002,201	$ 28,115,516
Trade and other receivables	6,260,577	4,277,677
Other current assets	1,599,963	1,095,753
Total current assets	44,862,741	33,488,946
Non-current assets
Property, plant and equipment	27,270	31,313
Right-of-use assets	41,039	65,495
Total non-current assets	68,309	96,808
Total assets	44,931,050	33,585,754
Current liabilities
Trade and other payables	3,134,160	2,502,509
Provisions	613,098	537,368
Other current liabilities	15,167	27,746
Total current liabilities	3,762,425	3,067,623
Non-current liabilities
Provisions	12,907	9,768
Other non-current liabilities	26,727	37,903
Total non-current liabilities	39,634	47,671
Total liabilities	3,802,059	3,115,294
Net assets	41,128,991	30,470,460
EQUITY
Contributed equity	213,814,776	197,447,990
Reserves	3,626,188	2,750,884
Accumulated losses	(176,311,973)	(169,728,414)
Total equity	$ 41,128,991	$ 30,470,460

Consolidated Statement of Changes in Equity (Unaudited) - AUD ($)	Contributed equity	Reserves	Accumulated losses	Total
Balance at Jun. 30, 2020	$ 160,703,754	$ 866,121	$ (154,419,061)	$ 7,150,814
Loss for the period			(8,561,862)	(8,561,862)
Total comprehensive income for the period			(8,561,862)	(8,561,862)
Transactions with owners in their capacity as owners:
Issue of ordinary shares	36,562,055			36,562,055
Share-based payment expenses		1,577,720		1,577,720
Transaction costs	(2,372,505)			(2,372,505)
Total transactions with owners in their capacity as owners	34,189,550	1,577,720		35,767,270
Balance at Dec. 30, 2020	194,893,304	2,443,841	(162,980,923)	34,356,222
Balance at Jun. 30, 2021	197,447,990	2,750,884	(169,728,414)	30,470,460
Total comprehensive income for the period				(6,583,559)
Balance at Dec. 31, 2021				41,128,991
Balance at Jun. 30, 2021	197,447,990	2,750,884	(169,728,414)	30,470,460
Loss for the period			(6,583,559)	(6,583,559)
Total comprehensive income for the period			(6,583,559)	(6,583,559)
Transactions with owners in their capacity as owners:
Issue of ordinary shares	17,176,040			17,176,040
Share-based payment expenses		875,304		875,304
Transaction costs	(809,254)			(809,254)
Total transactions with owners in their capacity as owners	16,366,786	875,304		17,242,090
Balance at Dec. 30, 2021	$ 213,814,776	$ 3,626,188	$ (176,311,973)	$ 41,128,991

Consolidated Statement of Cash Flows (Unaudited) - AUD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Payments to suppliers and employees	$ (9,002,490)	$ (7,385,267)
COVID-19 government relief	103,338	53,564
Other grant received	225,746
Interest received	1,352	1,397
Net cash (outflow) from operating activities	(8,672,054)	(7,330,306)
Cash flows from investing activities
Payments for property, plant and equipment	(2,559)	(2,494)
Net cash (outflow) from investing activities	(2,559)	(2,494)
Cash flows from financing activities
Proceeds from issues of shares and other equity securities	17,176,040	36,562,055
Transaction costs relating to issue of equity	(809,254)	(2,372,505)
Principle elements of lease payments	(23,755)	(24,249)
Net cash inflow from financing activities	16,343,031	34,165,301
Net increase in cash and cash equivalents	7,668,418	26,832,501
Cash and cash equivalents at the beginning of the financial year	28,115,516	9,196,892
Effects of exchange rate changes on cash and cash equivalents	1,218,267	(987,215)
Cash and cash equivalents at end of period	$ 37,002,201	$ 35,042,178

Significant Changes in The Current Reporting Period (Details)	1 Months Ended
	Jul. 31, 2021 AUD ($) $ / shares shares
Significant Changes In Current Reporting Period [Abstract]
Company issued amount \| $	$ 17,176,040
Number Of Shares Issued \| shares	322,857,900
Price per share \| $ / shares	$ 0.0532

Dividends (Details) - USD ($)	6 Months Ended
Dividends (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Dividends [Abstract]
Dividends

Financial Assets and Financial Liabilities (Details)	6 Months Ended
Financial Assets and Financial Liabilities (Details)	Dec. 31, 2021 AUD ($)
Disclosure of financial instruments [text block] [Abstract]
R&D tax incentive percentage	43.50%
Company annual aggregate turnover	$ 20,000,000
Other income	4,126,364
Other receivables	$ 2,133,722

Financial Assets and Financial Liabilities (Details) - Schedule of trade and other receivables - AUD ($)	Dec. 31, 2021	Jun. 30, 2021
Schedule of trade and other receivables [Abstract]
R&D tax incentive receivable, Current	$ 6,259,819	$ 4,126,364
R&D tax incentive receivable, Non-current
R&D tax incentive receivable, Total	6,259,819	4,126,364
Accrued interest income, Current	267	269
Accrued interest income, Non-current
Accrued interest income, Total	267	269
Goods and services tax receivable, Current	491	47,706
Goods and services tax receivable, Non-current
Goods and services tax receivable, Total	491	47,706
Other receivable, Current		103,338
Other receivable, Non-current
Other receivable, Total		103,338
Trade and other receivables, Current	6,260,577	4,277,677
Trade and other receivables, Non-current
Trade and other receivables, Total	$ 6,260,577	$ 4,277,677

Equity (Details) - Schedule of contributed equity - AUD ($)	Dec. 31, 2021	Jun. 30, 2021
Schedule of contributed equity [Abstract]
Ordinary shares - fully paid, shares	2,406,874,578	2,084,016,678
Ordinary shares - fully paid value	$ 213,814,776	$ 197,447,990

Equity (Details) - Schedule of movements in ordinary share	6 Months Ended
	Dec. 31, 2021 AUD ($) shares
Schedule of movements in ordinary share [Abstract]
Opening balance, shares \| shares	2,084,016,678
Opening balance \| $	$ 197,447,990
Shares issued during the year, shares \| shares	322,857,900
Shares issued during the year \| $	$ 17,176,040
Transaction costs, shares \| shares
Transaction costs \| $ \| $	$ (809,254)
Ending balance, shares \| shares	2,406,874,578
Ending balance \| $	$ 213,814,776

Equity (Details) - Schedule of details of shares issued during the current period	Jul. 02, 2021 AUD ($) $ / shares shares
Schedule of details of shares issued during the current period [Abstract]
Number Issue of shares under ATM facility \| shares	322,857,900
Issue price Issue of shares under ATM facility \| $ / shares	$ 0.0532
Amount Issue of shares under ATM facility \| $	$ 17,176,040
Total number of shares issued \| shares	322,857,900
Total value of shares issued \| $	$ 17,176,040

Equity (Details) - Schedule of movements in accumulated losses - AUD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of movements in accumulated losses [Abstract]
Balance at the beginning of the period	$ 169,728,414	$ 154,419,061
Net loss for the period	6,583,559	8,561,862
Balance at the end of the period	$ 176,311,973	$ 162,980,923

Equity (Details) - Schedule of options - AUD ($)	Dec. 31, 2021	Jun. 30, 2021
Schedule of options [Abstract]
Options over fully paid ordinary shares, shares	205,692,720	160,542,720
Options over fully paid ordinary shares, value	$ 3,626,188	$ 2,750,884

Equity (Details) - Schedule of presents the movements in options granted and issued	6 Months Ended
	Dec. 31, 2021 AUD ($) shares
Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]
Number of stock option shares issued \| shares	45,150,000
Stock option shares issued value \| $	$ 358,686
Unlisted options issued to consultant [Member]
Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]
Issued Date	Dec. 08, 2021
Number of stock option shares issued \| shares	12,000,000
Stock option shares issued value \| $	$ 326,544
Unlisted options issued to employees [Member]
Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]
Issued Date	Dec. 08, 2021
Number of stock option shares issued \| shares	13,900,000
Stock option shares issued value \| $	$ 13,326
Unlisted options issued to employees [Member[
Equity (Details) - Schedule of presents the movements in options granted and issued [Line Items]
Issued Date	Dec. 08, 2021
Number of stock option shares issued \| shares	19,250,000
Stock option shares issued value \| $	$ 18,816

Equity (Details) - Schedule of options free-attaching options - AUD ($)	Dec. 31, 2021	Jun. 30, 2021
Schedule of options free-attaching options [Abstract]
Free-attaching options, shares	674,694,939	674,694,939
Free-attaching options, value

Reconciliation of Profit After Income Tax to Net Cash Flow From Operating Activities (Details) - Schedule of profit after income tax to net cash flow from operating activities - AUD ($)	6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of profit after income tax to net cash flow from operating activities [Abstract]
Loss for the period	$ 6,583,559	$ 8,561,862
Depreciation on fixed assets	(6,602)	(12,417)
Depreciation on leased assets	(24,934)	(23,215)
Non-cash employee benefits expense - share-based payments	(875,304)	(1,577,720)
Net foreign exchange differences	1,218,745	(987,215)
(Increase)/decrease in provisions	(78,869)	(62,547)
Increase/(decrease) in trade and other receivables	1,982,900	1,916,120
Increase/(decrease) in other current assets	504,210	(229,445)
(Increase)/decrease in trade and other payables	(631,651)	(255,505)
(Increase)/decrease in other current liabilities		388
Net cash flows used in operating activities	$ 8,672,054	$ 7,330,306

Related Party Transactions (Details)	6 Months Ended
Related Party Transactions (Details)	Dec. 31, 2021 AUD ($)
Related Party Transactions (Details) [Line Items]
Advisory fees paid	$ 37,500
Lawrence Gozlan [Member]
Related Party Transactions (Details) [Line Items]
Advisory fees paid	101,400
Geoffrey Kempler [Member]
Related Party Transactions (Details) [Line Items]
Advisory fees paid	$ 75,000

Events Occurring After the Reporting Period (Details)	1 Months Ended
Events Occurring After the Reporting Period (Details)	Sep. 30, 2020 shares
Dr Sinclair [Member]
Events Occurring After the Reporting Period (Details) [Line Items]
Forfeited and cancelled	(7,000,000)
Mr Edwards [Member]
Events Occurring After the Reporting Period (Details) [Line Items]
Forfeited and cancelled	(7,000,000)

Significant Estimates and Assumptions (Details) - AUD ($)		6 Months Ended
	Jul. 02, 2021	Dec. 31, 2021	Dec. 31, 2020
Significant Estimates and Assumptions (Details) [Line Items]
Research and development, description		The research and development tax incentive applies to expenditure incurred and the use of depreciating assets in an income year commencing on or after 1 July 2011. A 43.5% refundable tax offset will be available to eligible small companies with an annual aggregate turnover of less than $20 million. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme.
Description of other income		the Group has recorded an item in other income of $A2,133,452
Other income recognise amount			$ 1,883,325
Refundable tax offset rate value	$ 20,000,000
Refundable tax offset rate	18.50%
Bottom of range [member]
Significant Estimates and Assumptions (Details) [Line Items]
Research and development expenditure	$ 100,000,000
Top of range [member]
Significant Estimates and Assumptions (Details) [Line Items]
Research and development expenditure	$ 150,000,000